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ABSTRACT 
 
One of the fundamental questions in mucosal immunology is how the intestine 
maintains tolerance to food antigens and commensal flora, and yet it is capable of 
mounting immune responses to pathogens. Peyer’s patches (PP) are lymphoid 
aggregates that are found in the small intestine and are the primary sites where adaptive 
immune responses are initiated in the intestine. An understanding of how PP cells 
regulate innate immune responses may provide information on how immune responses 
are regulated in the intestine. The toll-like receptors (TLRs) are a family of pattern 
recognition receptors (PRR) which provide a sensory mechanism for the detection of 
infectious threats. TLR9 recognizes bacterial DNA or synthetic CpG 
oligodeoxynucleotides (ODN). Cells that express TLR9 when stimulated with CpG 
ODN proliferate and produce Th1-like pro-inflammatory cytokines and upregulate co-
stimulatory molecules. Because the intestine is constantly exposed to bacterial DNA 
from commensal flora, immune cells from the gut must have evolved mechanisms to 
modulate responses to TLR9 stimulation to prevent responses to harmless bacteria. Our 
hypothesis is that innate immune responses to the TLR9 agonist CpG ODN in Peyer’s 
patches (PP) are attenuated compared to other tissues such as blood or lymph nodes. 
This is due to local regulatory mechanisms unique to the intestinal microenvironment.  
We conducted a number of experiments to test this hypothesis. We initially 
assessed the immunostimulatory activity of three available classes of CpG ODN in 
lymph nodes (LN), peripheral blood mononuclear cells (PBMC) and PP since this had 
not been done in ruminants. We found that CpG ODN induced strong IFNα, IFNγ, IL-
12, lymphocyte proliferation and NK-like activity in LN and PBMC. In contrast, these 
responses were significantly less in PP stimulated with CpG ODN. We wondered 
whether the reduced responses of PP cells to CpG ODN were unique to the TLR9 
agonist. For this reason we tested responses of cells from these tissues to poly (I:C), 
LPS, and single-stranded RNA, which are agonists for TLR3, TLR4, and TLR7/8 
respectively. Additionally, we tested combinations of TLRs since others have reported 
that multiple TLR agonists may induce synergistic responses. All TLR agonists or their 
combinations either failed to induce detectable responses or the responses were 
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significantly less in PP compared to other tissues. Thus we concluded that PP cells 
responses to TLR stimulation were attenuated. In all tissues tested, there were no 
synergistic responses (IFNα, IFNγ and lymphocyte proliferation) following stimulation 
with combinations of agonists. However, there was inhibition of PBMC responses 
when TLR7/8 agonists were combined with CpG ODN (TLR9 agonist). Importantly, 
TLR7/8 agonists reduced the CpG-induced proliferative responses in purified blood B 
cells. Interestingly, ovine B cells constitutively expressed TLR7/8 and TLR9 mRNA, 
suggesting the potential for cross-talk between the receptors.  
Interestingly, cell from all isolated tissues [ileal PP (IPP), jejunal PP (JPP), 
mesenteric LN (mLN) and PBMC] expressed similar levels of TLR9 mRNA, 
suggesting that the reduced responsiveness to CpG ODN stimulation in PP was not due 
to a lack of TLR9 expression.  
Surprisingly, we observed that PP cells spontaneously secreted significant 
amounts of the immunoregulatory cytokine IL-10. Furthermore, we confirmed that 
CD21+ B cells were the source of the IL-10. We then examined the role of IL-10 in 
regulating IFN and IL-12 responses in PP. Neutralization of IL-10 resulted in a 
significant increase in the numbers of CpG-induced IFNα-secreting cells detected and 
in IFNγ and IL-12 production by PP cells (both follicular and interfollicular 
lymphocytes). Similarly, depletion of the CD21+ B cells resulted in significant increases 
in IFNα, IFNγ and IL-12 responses. These observations support the conclusion that IL-
10-secreting PP CD21+ B cells suppress innate immune responses in PP. Further 
characterization by flow cytometry revealed that these cells were CD1b-CD5-CD11c-
CD72+CD21+ IgM+ B cells. We have proposed that these IL-10-secreting PP CD21+ B 
cells are a novel subset of regulatory B cells (Bregs). 
Finally, we examined the capacity of IL-10 secreting B cells (Bregs) to respond 
to CpG ODN. To achieve this, we compared CD21+ B cells from blood and JPP. Unlike 
blood CD21+ B cells, CD21+ B cells from JPP proliferated poorly in response to CpG 
ODN. Moreover, PP CD21+ B cells, unlike blood CD21+ B cells, do not secrete IgM or 
IL-12 in response to CpG stimulation, although both PP and blood CD21+ B cells 
express similar level of TLR9 mRNA. Neutralization of IL-10 did not enhance CpG-
induced proliferative responses in PP CD21+ B cells.  Thus IL-10 does not play a direct 
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role in the hyporesponsiveness of PP CD21+ B cells to CpG ODN. To further explore 
the mechanism by which PP Bregs fail to respond to CpG ODN stimulation, we used a 
kinome analysis to determine whether the TLR9 pathway was functional in PP Bregs 
compared to blood CD21+ B cells. We observed that peptides representing critical 
adaptor molecules downstream of TLR9 such as IRAK1, TAK1, Casp8, p-38 MAPK, 
JNK, FOS, IKKα, NFκB-p65 were not phosphorylated in JPP CD21+ B cells following 
CpG ODN stimulation. However, in blood CD21+ B cells stimulated with CpG ODN, 
the same peptides on the array were all highly phosphorylated leading to a functional 
TLR9 signaling pathway. Thus PP Bregs have evolved mechanisms by which the TLR9 
signaling pathway is not activated following exposure to the TLR9 agonist, CpG ODN. 
In conclusion, we clearly demonstrated that TLR9-induced responses in cells 
from PP are significantly attenuated. This is a consequence of PP CD21+ B cells (Bregs) 
that spontaneously secrete IL-10, which in turn “conditions” an anti-inflammatory 
environment in this tissue leading to poor cytokine responses to the TLR9 agonist, CpG 
ODN. Additionally, we show that Bregs are unresponsiveness to TLR9 stimulation. This 
unresponsiveness is due to regulatory mechanisms in Bregs leading to a dysfunctional 
TLR9 signaling pathway. These may represent strategies by which PP dampen innate 
responses to pathogen-associated molecular patterns (PAMPs) in intestinal immune 
tissues to maintain intestinal immune homeostasis. These conclusions are consistent 
with our hypothesis that TLR responses in PP cells are attenuated, and this is due to B 
cell-mediated regulatory mechanisms that are unique to the intestinal 
microenvironment.  
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CHAPTER 1: LITERATURE REVIEW 
 
1.1 Innate Immune System 
  
Vertebrate immune defenses consist of two complementary systems, namely the 
innate immune system (IIS) and adaptive immune system (AIS). Though 
complementary, the two immune systems have distinct attributes including recognition 
of microbial molecules, the cells involved and their mechanisms of action. The AIS has 
two main effector cell populations, B and T lymphocytes, which can recognize single 
epitopes expressed on foreign antigens when presented in the context of MHC-antigen 
complexes. The hallmarks of the AIS are specificity, repertoire diversity and memory 
[1].  
Innate immunity is the focus of the work described in this thesis. The IIS has 
been described as the first line of immune defense against pathogens. Originally, it was 
thought that IIS were completely non-specific but it is now known that the IIS can 
indeed discriminate between self-antigens and a variety of pathogens. For example, the 
innate immune system can recognize lipopolysaccharide (LPS) as foreign by using 
innate sensors such as Toll like receptor 4 (TLR4). Thus it plays a critical role in the 
detection of pathogens [2]. The IIS utilizes limited germ-line-encoded receptors called 
pattern recognition receptors (PRR) [3, 4]. There are various families of PRR such as 
the Toll-like receptors (TLRs), Retinoic acid-induced gene (RIG)-like receptors (RLR), 
Nucleotide-binding oligomerization domain (NOD)-like receptors (NLR), mannose 
receptors, scavenger receptors, and natural killer (NK)-activating receptors (CD16, 
NKG2D). The cells that are involved in IIS include dendritic cells (DC), natural killer 
cells (NK), macrophages (Mφ), neutrophils, basophils, eosinophils, epithelial cells and 
mast cells although each of these are involved in the AIS response. For a long time, the 
IIS has been described as an evolutionarily ancient system that helps in the rapid 
clearance of pathogens during the early phase of infection. There is now overwhelming 
evidence that IIS is not only involved in the early clearance of pathogens but it also 
initiates and shapes the development of the adaptive responses [2, 5]. In turn, the AIS 
 2
has been shown to influence the innate responses [6]. Thus, for pathogen clearance, 
coorperation between the IIS and AIS is necessary.  
 
1.1.1 Pattern recognition receptors (PRR) 
 
PRR are conserved among species from plants and fruit flies to mammals. PRR 
recognize a plethora of conserved molecular structures usually termed PAMPs which 
are present on a large group of microbes (including pathogens and commensals) [7]. 
These conserved structures are essential for the survival of the microorganism and in 
addition, PAMPs are not expressed by the host. PRR are usually constitutively 
expressed in the host, detect the pathogens regardless of their life cycle, and are present 
in serum, intracellularly, extracellularly and on the cell surface. When pathogens are 
present in blood, serum PRR opsonize them, leading to enhanced clearance by 
phagocytic action of neutrophils and macrophages [8]. TLRs, one of the most studied 
families of PRR, upon stimulation, initiate common nuclear factor kappa B (NF-
κB)/activator protein-1(AP-1) and distinct interferon regulatory factor (IRF) pathways 
[9]. These in turn lead to transcription of immune response genes that coordinate innate 
immunity and initiate adaptive immunity against pathogens. Recently, TLR-
independent pathways have been identified. The cytoplasmic caspase-recruiting domain 
(CARD) helicase, such as RIG-1/melanoma differentiation-associated gene 5 (MDA5) 
initiates antiviral immunity by stimulating the production of interferons (type I) via 
adaptor interferon-β promoter stimulator 1 (IPS-1) [10, 11]. Also, NLR activate NFκB 
or inflammasomes when induced by bacterial molecules [12]. An important mannose 
receptor, Dectin-1, is involved in detection of antifungal antigens and promotes 
phagocytosis and activates NFκB [13]. In vivo, upon encounter with a pathogen, the IIS 
will recognize various PAMPs associated with the particular organism. Different 
signaling pathways are activated, some of which are dependent on the adaptor molecule 
myeloid differentiation 88 (MyD88). Interestingly enough, most of the PRR receptor 
signaling pathways activate the NFκB pathway.  
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1.1.2 TLR 
 
Toll was first identified as a developmental gene product essential for the 
development of embryonic dorsoventral polarity in Drosophila [14]. Later, it was 
observed that Toll plays a critical role in the antifungal response of these flies [15]. 
Subsequently, other homologous receptors were found in vertebrates and denoted as 
TLRs [16, 17]. The TLRs family currently consists of 13 known members in mammals 
which recognize a whole array of PAMPs [18]. TLR are type I transmembrane 
glycoproteins and consist of an extracellular domain containing leucine-rich repeat 
(LRR) motifs and a cytoplasmic signaling, Toll/IL-1R (TIR) interacting domain [17]. 
These receptors are found both intracellularly and on the cell surface. TLR 1, 2, 4, 5 and 
6 are expressed on the cell surface while TLR 3, 7, 8 and 9 are found exclusively in 
intracellular compartments such as endosomes [19]. The TLR family can be further 
divided into subfamilies based on the primary sequences they recognize, for example 
TLR1, 2 and 6 recognize lipids whereas TLR 3, 7, 8, and 9 recognize nucleic acids 
(Table 1.1). However TLR4 can recognize a very divergent collection of ligands such as 
lipopolysaccharide (LPS), the plant diterpene paclitaxel, the fusion protein of 
respiratory syncytial virus (RSV), fibronectin and heat shock proteins [20-23]. TLR are 
expressed on immune such as Mφ, DC, B cells, specific types of T cells, and non-
immune cells such as fibroblasts and epithelial cells. Although the expression of TLR is 
constitutive, they can also be modulated rapidly during infection and are differentially 
expressed on different subsets of cells [7]. Another important aspect is the distribution 
of the PRR, such as TLR, on immune system cells. All TLR are not distributed equally 
on all cell types suggesting that particular cell types are more specialized to recognize 
particular PAMPs and deal with the subsequent threat.  
For example, human myeloid DC (mDC) express TLR1, 2, 4, 6, but not TLR7 
and 9, whereas plasmacytoid DC (pDC) express only TLR7 and 9 [24, 25]. Upon 
engagement of these distinct subsets of DCs by TLR agonists, a different innate 
immune profile is obtained. pDC are known for their potent type I IFN secretion 
following stimulation with TLR9 agonist whereas myeloid DC produce limited amounts 
of IFN [26]. Upon engagement of any of the TLR, the TIR domain recruits adaptor 
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molecules leading to the activation NFκB/AP-1 and IRF pathways. There are five main 
adaptor molecules in the TLR signaling pathway that have been identified as crucial. 
These are myeloid differentiation factor 88 (MyD88), MyD88-adaptor-like (MAL, also 
known as TIRAP), TIR domain-containing adaptor protein-inducing IFNβ (TRIF, also 
known as TICAM1), TRIF-related adaptor molecule (TRAM, also known as TICAM2) 
and sterile α- and armadillo motif-containing protein (SARM) [27].  
 
 
TLR  Agonist Organism Major Cell type  Reference 
1 Triacyl lipopeptides  Mycobacteria 
Mφ, cDC, neutrophils, 
mast cells  [28] 
2 
LTA, Zymosan, 
PamCSK4, MALP2, 
lipoarabinomanna 
G+ve bacteria, yeast, 
mycobacteria 
Mφ, cDC, neutrophils, 
mast cells  [29] 
3 dsRNA, poly(I:C) Virus 
cDC, Mφ (mouse), 
endo/epithelial cells  [30] 
4 
LPS, mannan, GIPLs, 
envelope proteins, Heat 
shock proteins 
G-ve bacteria, 
Candida albicans, 
Trypanosoma, RSV 
and MMTV 
Mφ, cDC, neutrophils, 
mast cells, eosinophils  [31] 
5 Flagellin Bacteria Monocytes, cDC, iEC  [32] 
6 
Diacyl lipopetides, 
LTA, Zymosan 
Mycoplasma, G+ve 
bacteria, yeast 
Monocytes, mast cells, 
cDC, neutrophils  [33] 
7 
ssRNA, 
Imiquimod,Resiquimod 
(R848), synthetic 
polyU RNA, siRNAs Virus 
pDC, neutrophils, 
eosinophils  [34] 
8 
Resiquimod (R848), 
ssRNA Virus 
Monocytes, cDC, mast 
cells, neutrophils  [35] 
9 CpG DNA, hemozoin Bacteria, plasmodium 
pDC, B cells, NK cells, 
eosinophils, 
neutrophils  [36] 
10 Not known   pDC, B cells   
11 Profillin-like molecule 
Toxoplasma gondii, 
uropathogenic 
bacteria Mφ, epithelial cells  [37] 
12 Not known       
13 Not Known       
Mφ -Macrophages: pDC-plasmacytoid dendritic cells: cDC-conventional DC: IEC-
intestinal epithelial cells: NK-Natural Killer cells. 
Table 1.1: TLR members each recognizing unique features (PAMPs) from pathogens and  
are expressed on some major cell types.  
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The first four adaptor molecules have been shown to be involved in TLR 
signaling pathways. The last one is a negative regulator of the pathway.  The TLR 
signaling can be sub-divided into 2 pathways: MyD88-dependent and MyD88-
independent pathways. All known TLRs activate MyD88-dependent pathways except 
for TLR3. In addition, TLR4 signals through both MyD88-dependent and independent 
pathways [38]. All TLR pathways lead to the activation of NFκB, mitogen-activated 
protein kinase (MAPK), AP-1 and IRF pathway.  TIR domain of the TLR receptor 
directly recruits MyD88. First, this complex recruits IL-1R-associated kinase 4 
(IRAK4) and then IRAK1, and TRAF6 (tumour necrosis factor receptor-associated 
factor 6) interacts with the TLR-MyD88-IRAK4 complex. Subsequently TAK1 
(transforming growth factor β-activated kinase) is actively recruited by the five adaptor 
complex. The ubiquitinylating factors UEV1A (ubiquitin-conjugating enzyme E2 
variant1) and UBC13 (ubiquitin-conjugating enzyme 13) modify and activate TRAF6 
and TAK1 on the complex. This leads to the activation of the inhibitor of NFκB kinase 
(IKK) complex and NFκB, and the upstream kinases for p38 and  JUN N-terminal 
kinase (JNK) (Fig. 1.1) [39]. MyD88 is an important molecule and is subjected to 
negative regulation because TLR need to be tightly controlled as they activate potent 
immunostimulatory responses [27].  
 6
 
Fig. 1.1: General TLR pathway showing various adaptor molecules with negative regulators (adapted 
from Cell Signaling Technology (www.cellsignal.com). 
 
One of the negative regulators of MyD88 termed MyD88s interferes with 
IRAK4 recruitment and FAS-associated via death domain (FADD). MyD88s also 
couples to IRF5 and IRF1 [39], and thus interfere with the induction of IFN 
transcription. Interleukin-1 receptor-associated kinase M (IRAK-M) also inhibits 
signaling by the release of IRAK1 and IRAK4 from MyD88. Both TLR2 and TLR4 
signaling involve a bridging adaptor molecule, MAL, which is needed for the 
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recruitment of MyD88. BTK (Bruton’s tyrosine Kinase) and SOCS1 (Suppressor of 
cytokine signaling 1) promote MAL degradation and thereby regulate the recruitment of 
MyD88. TLR7, 8, and 9 activate the MyD88-IRAK4 pathway and through TRAF6 and 
TRAF3 also lead to the activation of IRF7. Mice deficient in MyD88 show profound 
unresponsiveness to ligands for TLR 2, 5, 7 and 9 [38], while mice deficient in TRIF 
show unresponsiveness to agonists for TLR3 [40]. 
 
1.1.3 TLR9 and CpG motif recognition 
 
Bacterial and viral DNA is the natural ligand for TLR9 but synthetic CpG 
oligodeoxynucleotides (ODN) are commonly used as TLR agonists because they were 
shown to be present in higher frequency in bacterial and viral genomes. CpG ODN bind 
to TLR9 [41], leading to stimulation of innate and adaptive immune responses. The 
distinct compartmentalization of the TLR9 receptor is believed to be an important factor 
in its ability to trigger specific responses to a variety of harmful intra- and extracellular 
microorganisms [42]. An important aspect of TLR9 recognition is the discrimination 
between self and foreign DNA, which is achieved through structural differences 
between vertebrate and microbial DNA. Bacterial and viral DNA has a frequency (1/16 
instead of 1/64) of unmethylated CpG dinucleotides compared to vertebrate DNA [43]. 
Therefore, it is thought that the vertebrate IIS has evolved to detect unmethylated CpG 
dinucleotides as a way of sensing the presence of infection. However, in certain 
pathogenic situations, such as in systemic lupus erythematosis, TLR9 can recognize 
mammalian DNA within immune complexes, leading to autoimmunity [44]. Recent 
reports suggest that most of the observed immune effects of CpG ODN are an artifact of 
modification of the ODN backbone [45] but this remains unresolved.  
In this regard, normal phosphodiester (PO) CpG ODN are rapidly degraded 
inside cells such that their ability to stimulate CpG-induced responses is reduced. Thus 
the synthetic ODN backbone has been modified to a phosphorothioate (PS) and this 
provides a high degree of nuclease resistance, greatly stabilizing the ODN against 
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degradation [46]. In addition, the PS ODN generally binds more avidly to cell 
membranes leading to a higher cellular uptake [47].  
There are three known classes of CpG ODN which are classified according to 
unique structural and biological characteristics. A-class CpG ODN contains poly G 
motifs with PS linkages at the 5’ and 3’ ends and a PO palindromic CpG-containing 
sequence in the ODN center [24]. A-class CpG ODN has the ability to strongly activate 
plasmacytoid DC to secrete IFNα and is also effective in activating natural killer (NK) 
cells [48, 49]. However A-class is a poor inducer of B cell proliferation. In contrast, B-
class CpG ODN has a fully PS-modified backbone with one or more CpG motifs but no 
poly G motif [49]. They induce strong B cells proliferation and pDC maturation but are 
poor inducers of IFNα secretion in pDC. The biological characteristics of C-class CpG 
ODN are intermediate between A- and B-classes; these ODNs induce both B cell-
activation and IFNα secretion [50, 51].   This classification is largely based on effects of 
various CpG ODN on human PBMC. However, it has become evident that the 
classification may not hold true in immune cells from other tissues, such as lymph 
nodes (LN) (See chapter 3). 
The immune stimulatory effects of an ODN depend mainly on the precise bases 
flanking the CpG dinucleotide. It was observed that the optimal CpG motifs for 
different species vary according to the flanking bases. The best motifs for activating 
mouse or rabbit immune system cells have the general formula, purine-purine-CG-
pyrimidine-pyrimidine, GACGTT [52-54]. For human cells, the optimal motif is 
GTCGTT [55]. This latter motif has also been found to be optimal for many other 
vertebrates including sheep, cows, cats, dogs, goats, horses, pigs and chickens [53, 56].   
 
1.2 Innate Immune responses induced by CpG ODN 
 
TLR9 activation with CpG ODN results in induction of the IIS and shapes the 
adaptive immune responses. In general the innate immune responses induced by CpG 
ODN involve the secretion of IFNα, IFN-inducible chemokines and cytokines, pro-
inflammatory cytokines such as IL-6, TNFα, IL−12 and anti-inflammatory cytokines 
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such as IL-10 and IL-1RA. CpG ODN also induces NK cell lytic activity, monocyte 
expression of TNF-related apoptosis-inducing ligand (TRAIL) [57] and neutrophil 
activation, migration and bacterial uptake [58-60]. On the adaptive end, CpG ODN 
induces B cells to undergo isotype switch and secrete antibody, but also IL-6, IL-10 and 
IL-12. CpG ODN indirectly induces Th1 cells to differentiate. A few studies have found 
that T cells highly express TLR after activation via the T cell receptor (TCR). These 
activated T cells respond to TLR agonists which can then modulate T cell function [61, 
62].  Responses to CpG ODN have been found to vary according to the range of cells 
expressing the TLR9 receptor [43]. In mice, most cell types, including B cells, pDC, 
cDC, monocytes, NK cells, T cells, Mφ, and neutrophils, express TLR9 and therefore 
CpG ODN is highly potent in mice [9].   
 
1.2.1 Dendritic cell responses to CpG ODN 
 
There are various distinct subsets of murine and human DC and they express 
different subsets of TLR which allow them to modulate different patterns of immune 
responses to different pathogens. In humans, one of the DC subsets that expresses high 
level of TLR9 is pDC (B220+, Ly6C+) while myeloid CD11c+ pre-DC do not express 
TLR9, but do express TLR4. Thus, in humans, CpG ODN directly activate pDC to 
secrete cytokines [IFNα, TNFα, IL-6 and granulocyte macrophage colony stimulating 
factor (GM-CSF)], and chemokines (IL-8, IP-10), and to increase surface expression of 
major histocompatibility complex (MHC) class II, inter-cellular adhesion molecule 1 
(ICAM-1) and co-stimulatory molecules (CD40, CD54, CD80 and CD86) [25, 26, 63, 
64]. pDC also mature and become CD83bright leading to increased activation of 
allogeneic T cells [65] and resistance to IL-4-induced apoptosis. pDC are known for 
their role as the primary source of IFNα, which is rapidly produced during CpG 
stimulation. The functional properties of DC vary according to their location. Murine 
Peyer’s patch DC produce higher levels of IL-10 and lower IFNα than spleen DC upon 
stimulation with CD40L or microbial stimuli [66]. Further PP DC, but not spleen DC, 
can induce the differentiation of naïve T cells into T regulatory cells upon stimulation 
with CpG ODN [67]. Thus the anatomical location of cells plays a role in their 
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responses to stimulation. However, the local factors in the PP that modulate the 
behavior of pDC are not known. 
 
 1.2.2 B cell responses to CpG ODN  
B cells are the other main cell type that express TLR9 in humans and hence can 
be stimulated directly by CpG ODN. Upon stimulation with CpG ODN, B cells enter 
the G1 phase of the cell cycle and secrete IL-6 within hours, a requirement for B cell 
secretion of IgM [68]. IL-10 is produced by B cells as a counter-regulatory mechanism 
to reduce the effects of proinflammatory cytokines such as IL-12 [69]. Further, CpG 
ODN induce B cells to increase their expression of the Fcγ receptor and costimulatory 
molecules (MHC II, CD80 and CD86) [54, 70, 71] and, in humans, CD40 and CD54 are 
also upregulated [55].  It has been reported that low concentrations of CpG ODN 
strongly synergize with B cell receptor (BCR) signals leading to increased B cell 
proliferation and antigen-specific antibody and IL-6 secretion [54]. CpG ODN has also 
been reported to have anti-apoptotic activity on isolated primary B cells [52] and to 
protect B cells against Fas-mediated apoptosis [72]. Moreover, TLR9 mRNA 
expression has been found to vary in B cell subtypes. In humans, it has been reported 
that only activated and memory B cells express high levels of TLR9 and therefore 
respond directly to CpG ODN [73, 74]. However, recent evidence suggests that naïve 
human B cells also respond directly to CpG ODN [75]. However, these studies were 
done using peripheral blood B cells and whether B cells from other immune tissues 
respond similarly has not been explored in details. The few studies that have addressed 
this issue found that all subsets of B cell populations in tonsils respond directly to TLR 
stimulation, including CpG ODN [76, 77]. B cells from tonsils upregulate CD80, CD86, 
CD40, CD23 and MHC class II following stimulation by CpG ODN. However, their 
proliferative responses, and antibody (IgM and IgG) and cytokine (IL-6 and IL-10) 
secretion were not significantly induced by CpG ODN. These tonsillar B cells required 
costimulation with CD40L and CpG ODN for significant proliferation and cytokine and 
antibody secretion [78]. Again, these results suggest that the anatomical 
microenvironment can influence the profile of CpG ODN responses. 
 11
1.2.3 Immune cells stimulated by CpG ODN  
  
Other immune cells such as macrophages (Mφ) and NK cells have been reported 
to be directly or indirectly activated by CpG ODN. In humans, Mφ and natural killer 
cells do not constitutively express TLR9 but can modulate its expression [25, 79]. In 
mice, CpG induces the secretion of cytokines such as TNFα by TLR9-expressing Mφ 
[80]. However, expression of inducible nitric oxide synthase and production of nitric 
oxide in Mφ is not due to direct CpG activation but rather requires IFNγ priming [81]. 
Initially, upon CpG stimulation, Mφ increase their ability for antigen processing and 
presentation but after 18 hours, these processes are downregulated [82, 83]. It has been 
shown that purified monocytes do not express TLR9 and thus are not activated directly 
by CpG ODN in humans [25].  Recently it has been proposed that while monocytes are 
not directly activated by CpG ODN in bovine species, they are required for B cells 
proliferative responses to CpG ODN (Arsenault et al., 2009, in press).  
Murine NK cells are not directly activated by CpG ODN but are affected by 
cytokines such as type I interferon secreted as a consequence of CpG ODN stimulation. 
Thus CpG ODN seems to perform as a costimulatory signal for murine NK cells. In 
humans, ODN containing CpG palindromes reportedly can activate human NK cells 
directly [84]. However, this report did not use highly purified NK cells and it may be 
that the NK cells could have been activated indirectly via contaminating cells.  
Similar to NK cells, there are conflicting reports on whether T cells are directly 
activated by CpG ODN. It has been shown that human peripheral blood T cells 
expressed TLR 1, 2, 3, 4, 5, 7 and 9 mRNA to varing degrees [85-87]. It seems that 
purified T cells in humans can be induced to proliferate by CpG ODN as long as the 
TCR is strongly cross-linked [84]. Selective expression of TLR appears to occur on 
specific subsets of T cells. Human regulatory T cells (Tregs) (CD4+ CD25+Foxp3+) were 
found to express TLR5 and 8, whereas CD25- CD4+ T cells do not express these two 
TLR [88]. Stimulation of Tregs with TLR5 agonist, enhances the suppressive capacity 
and induces higher expression of forkhead box P3 (Foxp3) [89] whereas stimulation 
with TLR8 reverses the suppressive nature of Tregs [90]. There are only a few reports on 
the effect of CpG on neutrophils and it appears that CpG ODN does not directly activate 
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these cells but it may improve their ability to phagocytose and increase their production 
of reactive oxygen species [91]. Thus, in humans and possibly in ruminants, the main 
cells that are activated directly by CpG are B cells and pDC [92, 93].  
 
1.3 Simultaneous multiple TLR stimulation 
 
1.3.1 Multiple TLR stimulation 
 
Most studies on TLR activation have explored the effects of exposure to a single 
TLR agonist. However, during the course of an infection, the host immune system is 
usually presented with multiple TLR and non-TLR agonists and therefore the responses 
observed are a net effect of these signals, which are possibly synergistic or inhibitory to 
each other. For this reason, recent studies have explored multiple TLR stimulation, 
which can profoundly alter the effects of each other. Therefore the order in which the 
cells are exposed to TLR agonists may have a significant impact on the ensuing immune 
responses.  For example, Napolitani and colleagues reported that in mice and human 
DC, TLR3 and 4 synergize with TLR7, 8 and 9 stimulation [94] to increase levels of IL-
12, and IL-23 and the Delta-4/Jagged ratio, which enhanced and sustained T helper 1 
(Th1) polarization. It is known that all TLRs, except for TLR3, use the MyD88-
dependent pathway and that TLR4 uses both pathways. Recently, Bagchi and colleagues 
showed that a combination of TLR agonists that employed MyD88-dependent and -
independent pathways have synergistic outcomes as indicated by increased cytokine 
levels and NF-κB translocation in both in vivo and in vitro experiments [95]. They also 
showed that when used simultaneously or sequentially, all MyD88-dependent TLR 
agonists are inhibitory to one another. Thus they concluded that simultaneous and 
sequential activation of both MyD88-dependent and MyD88-independent pathways 
resulted in synergistic TLR responses, whereas activation with multiple agonists using 
the same pathway resulted in inhibition [95].  
TLR agonists have been shown to induce the secretion of both inflammatory 
(TNFα, IL-12) and anti-inflammatory cytokines (IL-10). In one recent study, Hirata and 
colleagues showed that TLR2 agonist (Pam3CSK4) alone does not induce the secretion 
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of IL-10 and that TLR4 agonist (ultra pure LPS) alone induces the secretion of 
proinflammatory cytokines such as IL-12 and TNFα in conventional murine DC. Co-
stimulation with both TLR2 and TLR4 agonists lead to high level of IL-10 but not of 
IL-12 and TNFα [96]. Therefore, TLRs can also cross-regulate their effects, resulting in 
either an inflammatory or anti-inflammatory state.  
 
1.4 Overview of the Mucosal Immune system 
 
The mucosal immune system is at the interface between the internal and external 
environment and interacts with air, water, microbes and food antigens. The intestine, 
respiratory and urogenital mucosal tissues have a surface area that is larger than the skin 
by 200-fold. The mucosal tissues constitute efficient barriers, preventing pathogens 
from gaining access to the host milieu but they are also a major route of invasion by 
pathogenic microorganisms [97]. The microenviroment of the immune tissues at these 
mucosal barriers dictate the ensuing immune responses. 
The mucosal surfaces such as intestine are constantly exposed to food antigens 
and harmless commensal bacteria as well as many dangerous pathogens. Strong 
immune responses are needed to protect this tissue from pathogens. However immune 
response against food antigens and non-pathogenic organisms would not only be 
wasteful but would also lead to constant inflammation and pathology. This type of 
inflammatory disorder has been found in humans such as coeliac disease, which is a 
chronic inflammation of the upper small intestine in humans caused by immunological 
hypersensitivity to the α-gliadin component of wheat gluten [98]. Thus, active 
regulatory mechanisms are required to prevent responses to such harmless microbial 
molecules and dietary antigens both at the systemic and mucosal levels [99]. The 
mucosal tissues have special features, including unique ontogeny, specialized cells and 
organs (M cell and Peyer’s patches) for antigen uptake, unique subsets of antigen-
presenting cells (APC), unique B and T cell populations, and high level production of 
non-pathogenic immunoglobulin A (IgA) antibodies [100]. Moreover the levels of 
mucus and antimicrobial peptides secreted not only protect the epithelial cells but 
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influence colonization by microorganisms [101]. More recently, the involvement of 
TLR receptors has been implicated in gut homeostasis [102, 103]. Thus the mucosal 
immune system must have the ability to discriminate between pathogens and 
commensals and food antigens. 
 
1.4.1 Gut-associated lymphoid tissues 
 
In humans, Peyer’s patches (PP), small intestinal isolated lymphoid follicles, 
appendix and colonic lymphoid follicles constitute the gut-associated lymphoid tissues 
(GALT). Although many studies have been performed in rodents, there are large 
phenotypic and structural differences in the GALT of mice, humans and other species 
such as sheep. These differences are: (i) mice do not have fully developed PP at birth 
while, in humans and sheep, PP are fully developed and functional at birth; (ii) the 
number of PP in humans and sheep are higher than in mice; (iii) there are more 
cryptopatches in mice than in human and sheep; and (iv) finally, there are more γδ T 
cells in the gut epithelium of mice than in humans [100]. These differences suggest that 
the functions of the GALT between humans and mice would be different. GALT can be 
divided into (i) inductive sites consisting of Peyer’s patches and mesenteric lymph 
nodes (mLN) and (ii) effector sites which are a network of immune cells scattered 
throughout the epithelium and lamina propria of the intestine. 
 
1.4.2 Peyer’s patches 
  
PP named after the Swiss physician Johann Conrad Peyer, are secondary 
lymphoid tissues containing germinal centers, similar to lymph nodes.  PP develop in 
specific regions of the gut during fetal development and some persist in adult [104]. PP 
consist of a collection of large B cell follicles surrounded by T cell areas. The follicle-
associated epithelium (FAE) is comprised of the single columnar epithelial cells that 
separates the lymphoid tissues from the gut lumen whereas the subepithelial dome 
(SED) is the diffuse area just below the epithelium (Fig. 1.2) [105]. FAE differs from 
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other epithelia because it is infiltrated by large numbers of B cells, T cells, Mφ and DC 
and expresses lower levels of digestive enzymes [106]. An important feature of the FAE 
is the presence of microfold (M) cells that are specialized enterocytes which lack 
surface microvilli and the normal over-layer of mucus. The primary function of M cells 
is to sample antigens from the intestinal lumen (reviewed by Corr et al [107]). 
However, they can also bind invasive pathogens such as Salmonella, Shigella, Yersinia 
and reoviruses and particulate antigens [108]. B cells that are present near the epithelial 
cells secrete Notch 1 and LTα1β2, which regulate epithelial cell differentiation into M 
cells [109].  
                              
Fig. 1.2: Diagramatic representation of Peyer’s patch (Inductive site) showing M cell and the follicular 
region (adapted from Mowat, 2003). 
 
1.4.3 Distribution and function of PP in sheep 
 
PP can be found in two distinct locations in the small intestine, namely the ileum 
and jejunum. Jejunal and ileal PP have distinct developmental, structural and functional 
attributes as shown in Table 2.1. The JPP is an efficient site for the induction of both 
mucosal and systemic immunity  [110], whereas the IPP is a major source of cells for 
the total B cell pool and appears to play a role in the antigen-independent diversification 
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of the immunoglobulin repertoire [111]. Therefore the JPP but not the IPP is an immune 
induction site in the intestine.   
 
Table 2.1: Differences between sheep IPP and JPP (Adapted from [100]) 
IPP JPP 
Continuous single patch Discrete patches (25-40 patches) 
100,000 follicles 10,000 follicles 
Present at birth, involutes  6-15 months Present at birth and throughout life 
70% of total B cell pool 5% of total B cell  pool 
95% B cells 35-45% B cells 
Less than 0.5% T cells in follicle 10-15% T cells in follicle 
2-3% CD5+ B cells 30-40% CD5+ B cells 
No M cells Contains M cells 
Generation of primary antibody repertoire Induction of mucosal Immunity 
 
1.4.4 Sheep PP B cells 
 
Two phenotypic distinct populations of B cells have been reported in sheep 
[112-115]. One subpopulation expresses CD11b+, sIgMhi, and CD11c+ but not CD21 or 
L-selectin. These B cells populate the splenic marginal zone but are absent from splenic 
and ileal PP follicles. They do not recirculate but remain in blood and spleen. The 
second population of B cells are CD21+, L-selectin+ and IgMlo. These cells populate the 
PP and splenic follicles but are absent from the splenic marginal zone. They are the only 
B cells in afferent lymph, efferent lymph and all lymph nodes. CD21+ B cells are 
recirculating cells as they can be detected in efferent lymph by 16 hrs after cannulation 
and peaking at 24-30 hrs when using a fluorescent trace on that population.  
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1.4.5 Mucosal DC  
 
DC are professional APC that take up and process antigen for presentation to 
naïve T cells in lymph nodes. There is an extensive network of dendritic cells present in 
the GALT, including conventional DC (CD11chi) and pDC.  They are derived from 
hematopoetic cells that seed most tissues and thus DC control tolerance and immune 
response at those locations. Mucosal DC have been shown to have distinct functional 
properties. For example murine PP DC secrete higher levels of IL-10 than spleen DC in 
response to TLR stimulation [116]. These differences suggest that DCs at the mucosal 
sites are influenced by various local environment factors that affect their ability to 
respond. DC can be classified according to their cell surface receptor expression. In 
murine PP and mLN, there are three subsets of so-called conventional DC namely 
CD11chiCD11b+CD8α-, CD11chiCD11b-CD8 α+ and CD11chiCD11b-CD8α- cells [66, 
117]. Murine PP CD11chiCD11b-CD8α+ and CD11chiCD11b-CD8 α - DC have been 
shown to secrete IL-12 and subsequently induce IFNγ in T cells [66], but murine PP 
CD11chiCD11b+CD8α- DC produce IL-10 and prime Th2 cells. The expression of 
chemokine receptors have also been used to categorize DC. In the FAE of mice, 
CX3CR1+ DC were closely associated with the epithelial cell in the steady state while 
CX3CR1- DC were found to be mostly in the lamina propria [118]. The pDC subset has 
a surface marker CD11cmid and is present in both murine PP and mLN, but has not been 
found in the lymph [67, 119, 120].  
In sheep, the panel of antibodies that has been used to stain and identify DC in 
afferent lymph include CD1, mannose receptor, CD11c and CD21. Sheep DC have been 
described as CD1+, CD11c+,and  CD11b+, but CD21- [121]. Ovine prefemoral afferent 
lymph DC were found to express high levels of MHC I and II molecules, CD1 and 
CD58 (an adhesion molecule) [122]. In vitro-generated ovine DC were found to weakly 
express CD11c and mannose receptor [123]. Moreover DC obtained by cannulation of 
sheep were characterized and found to crossreact with human DC marker (CD83 and 
CMRF-56) monoclonal antibodies [124]. 
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1.4.6 Mechanisms leading to intestinal homeostasis 
 
The intestine is always exposed to PAMPs from commensal bacteria and food 
antigens but seldom mounts an inflammatory response to such molecules and antigens. 
However, the mucosal immune system can mount strong immune responses to 
pathogens. Therefore there must be mechanisms by which the mucosal immune system 
dampens responses to commensals and food antigens and thereby maintains intestinal 
homeostasis. TLR detect conserved microbial molecules that trigger innate and adaptive 
immune responses and have been reported to be expressed in a variety of cells in the 
intestine, including intestinal epithelial cells (IEC), Mφ, DC and B cells. It is thought 
that TLR signaling must be tightly regulated in the intestine to prevent unwanted or 
prolonged inflammation. How TLR responses are regulated in the intestine is not fully 
understood, but several mechanisms have been proposed. 
 
1.4.6.1 Downregulation of TLR and their adaptors on immune system cells 
 
The lamina propria and PP are rich with immune system cells such as DC, Mφ, 
B cells and T cells that express TLRs. One of the proposed mechanisms regulating TLR 
responses in intestine is downregulation of the expression of TLRs and their adaptors on 
immune cells. For example, lamina propria Mφ have low expression of TLR 2 and 4 in 
uninflamed intestinal tissue [125]. Furthermore intestinal Mφ lack both CD14 and CD89 
[126]. CD14 is a surface cell receptor that is required in TLR4 stimulation by LPS. 
Moreover, Smythies and colleagues showed that intestinal Mφ do not express a number 
of innate immune receptors such as CD14 (LPS), CD89 (Fcα), Fcγ (CD64, CD32, 
CD16), CR3, CR4, and receptors for growth factors (IL-2, IL-3) [127]. Interestingly, 
these cells have acquired profound inflammatory anergy but they retain their full 
phagocytic and bactericidal activity. Therefore the absence or low expression of TLRs 
and other innate immune receptors may contribute to low levels of inflammation in 
normal intestinal tissues. 
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1.4.6.2 Inhibitors in TLR signaling pathways 
 
Negative regulation of TLR signaling is one of the other mechanisms by which 
the intestine can maintain homeostasis. It has been suggested that initiation of TLR 
signaling is tightly regulated, as prolonged activation can lead to uncontrolled 
inflammation. Various mechanisms appear to control TLR activation in intestinal 
epithelial cells including several negative regulators, such as IRAK-M, Toll-interacting 
protein (TOLLIP), single immunoglobulin IL-1R-related molecule (SIGIRR), A20 (zinc 
finger protein with ubiquitin-modifying activity), NOD2, peroxisome proliferator-
activated receptor gamma (PPARγ) and suppressor of cytokine signaling (SOCS) [128]. 
TOLLIP has been shown to inhibit the TLR pathway by suppressing IRAK molecules 
and is upregulated in response to non-pathogenic bacteria [129, 130]. PPAR-γ is a 
member of a nuclear receptor family. It is involved in the repression of a distinct subset 
of TLR [131]. Kelly and colleagues demonstrated that PPAR-γ associates directly with 
the reticuloendotheliosis viral oncogene homolog A (relA) subunit of NFκB and limits 
the translocation of NFκB to the nucleus [132]. The other inhibitors also affect the 
association of adaptor molecules in the pathway. For example IRAK-M blocks the 
formation of IRAK1-TRAF6 complexes and prevents the dissociation of IRAK1-
IRAK4 from the TLR receptor complex, thereby inhibiting downstream activation of 
NFκB.  Therefore negative regulators could play a role in maintaining gut homeostasis. 
 
1.4.6.3 Cellular localization of TLR9 
 
Another mechanism for intestinal homeostasis that has been recently proposed 
involves the expression of bacteria DNA receptor TLR9, in intestinal epithelial cells 
(IEC). TLR9 is usually found in the endosomal compartment in immune cells. It has 
been recently reported that cell surface TLR9 has been observed in intestinal epithelial 
cells, paneth cells and tonsillar epithelial cells [133]. This is a peculiar location, as 
TLR9 could be readily engaged by commensal bacterial or viral DNA in the intestinal 
lumen and induces pro-inflammatory responses. However Lee and colleagues have 
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proposed a novel TLR9 signaling mechanism that may explain how IEC avoid 
inflammation in a microbe-rich environment under steady state [103, 134]. An 
important feature of IEC is the polarity of these cells. On one side, the apical surface 
faces the lumen which contains abundant antigens, while the basolateral side faces the 
lamina propria which contains vast amount of immune cells.  Lee and colleagues 
investigated whether this polarity affects the immune response to TLR ligands [103, 
134]. They showed that while the expression of TLR9 was on both apical and 
basolateral surfaces of IEC, only the latter responded to CpG ODN by activating NFκB. 
The authors infer that the differential response to CpG ODN was the result of different 
signaling pathways in response to apical and basolateral stimulation. They demonstrated 
that p105 (a precursor of NFκB) and IkBα (inhibitor of NFκB) degrade only during 
basolateral stimulation but not upon apical stimulation of TLR9. They further found that 
after apical stimulation, subsequent TLR re-stimulation whether it is apically or 
basolaterally, resulted in unresponsiveness. Therefore, the authors proposed that apical 
stimulation of TLR9 could induce a state of unresponsiveness to proinflammatory TLR 
signaling from both apical and basolateral IEC surfaces. This may be due to an 
increased threshold for NFκB activation.  
 
1.4.6.4 Th2 cytokine bias 
 
One of the special features of the intestine is that it is a Th2-biased 
microenvironment and thus it is usually under the influence of Th2 cytokines such as 
IL-4, IL-5, and IL-13. This skewed cytokine profile in the intestine is thought to 
influence the TLR expression profile. In 2006, Mueller and colleagues proposed that the 
Th2 cytokine environment of the gut plays an important role in balancing TLR 
signalling in human IEC. They showed that Th2 cytokines downregulate TLR 
expression and function (IL-8 secretion) in IEC, thereby preventing the host from 
mounting excessive responses to commensals [135]. The authors proposed that this may 
be an important mechanism by which the gut maintains homeostasis. 
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1.4.6.5 Immunoregulatory cytokines (IL-10, TGFβ) 
 
Interleukin-10 is a critical immunoregulatory cytokine and is produced mainly 
by DC, Mφ, B cells and Tregs. IL-10 has pleiotropic effects on various hemopoeitic cells. 
IL-10 has been reported as a stimulator of NK cells and B cells in mice and humans 
[136], but it was first shown to have the ability to suppress activation and effector 
function of T cells, monocytes and Mφ [137]. The role of IL-10 is to limit and terminate 
inflammatory responses. For example, IL-10 inhibits the production of IL-12, IL-18 and 
MHC II upregulation by APC [138]. This anti-inflammatory role is demonstrated in IL-
10-deficient mice, which spontaneously develop colitis [139]. This observation suggests 
an important role for IL-10 in the maintenance of intestinal homeostasis. IL-10 also 
plays a key role in autoimmune diseases, as shown in disease models such as 
experimental autoimmune encephalomyelitis (EAE) where it can downregulate the 
active inflammatory responses [140]. We have shown that IL-10 is secreted by PP 
CD21+ B cells in vitro and that it has suppressive effects on other immune cells, as 
indicated by downregulation of CpG-induced IFNα, IFNγ and IL-12 in the intestine. 
TGFβ has also been suggested to downregulate responses in the intestine, thereby 
contributing to gut homeostasis. It has been shown that TGFβ is constitutively 
expressed in the intestine [141] and contributes to PP B cells switching to IgA [142]. 
Moreover, TGFβ suppresses IFN responses by pDC, but maintains lower level of IL-12 
secretion [143]. Regulatory T and B cells (Tregs and Bregs) present in the gut are thought 
to be the major sources of IL-10 and TGFβ, and therefore to play a major role in 
preventing potentially tissue-damaging T cell responses.  
 
1.5 B lymphocytes  
 
1.5.1 TLR9 in B cell activation  
 
Krieg and colleagues reported that unmethylated CpG dinucleotides induced 
murine B cells to proliferate and secrete immunoglobulin in vitro and in vivo [54]. This 
was the first demonstration that bacterial or synthetic DNA triggers direct activation of 
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B cells. Thus they showed that purified B cells can be activated with microbial PAMPs.  
However, the B cells were purified by Krieg and colleagues on the basis of MHC class 
II expression, which suggests that other leucocytes such as Mφ and DC could have been 
present and thus could have confounded their results. Moreover, when TLR9 ligand was 
used alone, the level of proliferation was low (less that 2500 cpm) but on activation 
through BCR, the level of proliferation was high (above 15000 cpm). This suggests that 
BCR signaling is required for significant activation of B cells through TLR9. This is 
similar to the two signal model where signal 1 (BCR signal) and 2 (T cell signal) are 
needed for B cell activation. However signal 2 originates from innate immune receptors 
as proposed by Janeway [2]. Subsequently, it was shown by Leadbetter and colleagues 
[144], that DNA-containing chromatin-IgG complexes have the ability to activate 
autoreactive B cells to produce antibody against self IgG (rheumatoid factors) by 
engaging BCR and TLR9 in sequential fashion. Thus the dual BCR-TLR stimulation is 
well established [145-147]. Moreover, the induction of antigen-specific T-dependent B 
cells responses has been shown to also require TLR activation of B cells for optimal 
antibody production in mice and humans [73, 148]. More recently, a study was 
performed where subsets of murine naive B cells, namely B-1a, B-1b, marginal zone 
(MZ) and follicular B cells (FO) were stimulated with TLR agonists [149]. They 
showed that upon TLR stimulation, B-1 and MZ B cells differentiated primarily into 
mature plasma cells but not follicular B cells. Thus TLR9 may be required for T-
dependent B cell responses, which adds another layer of complexity to the system in 
terms of ‘signal 3’. Therefore the model for B cell activation has been suggested to 
consist of three signals, where signal 1 (BCR signal), signal 2 (T cell signal) and signal 
3 (innate immune receptors such as TLR) are each required [73, 74, 150]. 
However, the effect of CpG ODN is not clear in T-independent naïve B cell 
activation. There are studies that suggest that multiple signals (e.g BCR) are required 
for naïve B cell activation by CpG ODN [54], while others have shown that direct TLR 
stimulation is sufficient to stimulate the survival and effector functions of naive B cells, 
notably IgM secretion and cytokine secretion.  Recent studies show that purified human 
naïve B cells express TLR9 and respond significantly (proliferation, IL-6 and IL-10) to 
CpG ODN [75, 76, 151].   
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1.5.2 Cytokine secreting B cells 
 
The main known function of B cells is their ability to produce antibodies against 
specific antigens and their capacity to take up antigen through their BCR and present it 
via MHC class II, similar to APC. However, B cells also have the ability to secrete 
various cytokines and modulate the activities of other immune cells, thereby influencing 
immune responses. 
 
1.5.2.1 Effector B cells 
 
There is substantial evidence that B cells do not act solely through their antibody 
secretion but also influence the course of immune responses through antibody-
independent mechanisms. For example, B cells can be activated by TLR agonist alone 
and secrete pro-inflammatory or anti-inflammatory cytokines. It has been proposed that 
B cells can be subdivided on the basis of the cytokines they produce. B cells that have 
the ability to secrete IL-10 or TGFβ can be classified as regulatory B cells [152, 153] 
and these are analogous to regulatory T cells [154]. Similar to T cells, B cells can be 
classified as effector B (Be) cells [155], including Be-1 cells that secrete cytokines such 
as IFNγ, IL-12 and TNFα and Be-2 cells that secrete cytokines such as IL-2, IL-4, IL-6 
and TNFα [153]. Similar to T cells, B cells primed by Th1 cells and antigen produce 
type I cytokines such as IFNγ and IL-12, whereas B cells primed by Th2 cells and 
antigen produce IL-1, IL-13 and IL-4. These cytokine-secreting cells have been found 
in mice infected with specific pathogens. Mice infected with Th1 type pathogens have 
IFNγ- and IL-12-secreting B cells [156, 157] while mice infected with parasites 
inducing Th2 immunity have IL-4-secreting B cells [158]. These particular B cells 
subsets have also been found in human peripheral blood and tonsils [159-161].  
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1.5.2.2 Regulatory B cells 
 
Immune responses elicited by a pathogen, allergen or foreign antigen need to be 
controlled to prevent immunopathology. One of the proposed regulatory mechanisms 
that is currently a subject of intense investigation is a subset of T cells with regulatory 
functions, namely regulatory T cells (Tregs). Tregs are functionally distinct T cells and 
have the phenotype CD4+CD25+Foxp3+ cells (natural Tregs), or IL-10 producing T 
regulatory 1(Tr1), or TGFβ1 producing T regulatory 3 (Th3). They have been shown to 
have suppressive characteristics such that they down-modulate immune responses. 
Similar to Tregs, B cells with regulatory functions (Bregs) have been proposed. Bregs 
perform their suppressor role by secreting IL-10 and TGFβ, which suppresses 
inflammation and they can also interact with other immune cells. The first report about 
the existence of Bregs was by Janeway and colleagues in a murine model of EAE [162]. 
They found that genetically modified mice that were deficient in B cells developed 
more severe EAE, and that restoring the B cells in these mice allowed complete 
recovery from the disease. Since then there have been numerous reports in chronic 
inflammation models proposing that Bregs play a role in dampening immune 
inflammation and inducing immune tolerance, similar to their T cell counterpart [163]. 
In models of severe inflammatory bowel disease (IBD), using a B cell-deficient TCRα 
double KO (am DKO) mice, Bregs have been shown to contribute to the suppression of 
the ulcerative colitis like disease [164]. Bregs have also been shown to be involved in 
diseases such as lupus and experimental rheumatoid arthritis (RA), wherein pathogenic 
B cells secrete auto-antibodies that play a major role in the disease [162, 165, 166]. All 
available reports suggest that Bregs are induced during chronic inflammation but are not 
present in normal (healthy) tissues.  
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CHAPTER 2: RATIONALE, HYPOTHESIS AND OVERALL OBJECTIVE AND 
AIMS 
 
2.1 Rationale and hypothesis 
 
The IIS has a conserved network of receptors called PRR that have the ability to 
recognize PAMPs as danger signals. On recognition of their respective ligands, PRR are 
capable of inducing a variety of immune responses that range from production of 
cytokines to activation of a variety of cells and resulting in triggering of the AIS. The 
TLR constitute one family of PRR which provide a sensory mechanism for the detection 
of infectious threats [167]. Recognition of bacterial DNA or CpG DNA occurs through 
TLR9 [41]. Upon stimulation with CpG ODN, cells that express TLR9, including pDC 
and B cells produce Th1-like pro-inflammatory cytokines and upregulate co-stimulatory 
molecules. Most of these observations were made using cells from blood and spleen. 
Unlike blood and the LN, the intestinal tract is constantly exposed to microbes 
which express a variety of PAMPs, including TLR agonists.  We are interested in TLR9 
responses in PP, which are the major sites where induction of immune responses occurs 
in the intestine. In addition to constant exposure to microbial flora, several other factors 
in the intestinal microenvironment suggest that the response to CpG ODN of immune 
cells from PP may be different from immune cells in other tissues: (i) unlike peripheral 
blood and lymph nodes, B cells comprise a large proportion of follicular lymphoid cells 
(up to 80%) in the PP of sheep [114]; (ii) DC isolated from PP of mice prime Th2 
responses while those from spleen prime Th1/Th0 responses [168, 169]; (iii) the 
intestinal microenvironment may modulate receptor expression in cells, and 
consequently their capacity to respond to CpG. For example, human MΦ isolated from 
the lamina propria do not express CD14 and respond poorly to LPS [126], possibly 
because the intestine is constantly exposed to LPS. Based on these observations, my 
hypothesis is that: 
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 Innate immune responses to the TLR9 agonist, CpG ODN, in cells from PP 
are attenuated compared to cells from other tissues such as the blood or lymph 
nodes. This is due to regulatory mechanisms unique to the intestinal 
microenvironment, which downregulate TLR responses. 
 
2.2 Overall Objective 
 
Our overall objective was to define the mechanisms which regulate TLR-
induced responses in PP. To achieve this objective, we had the following aims.  
2.3 Aims 
 
1. Evaluate innate immune responses induced by various CpG ODN classes in 
immune cells from lymphoid tissues of sheep. 
 
2. Assess responses of PP cells to various TLR agonists alone and in combination. 
 
3. Assess TLR expression in PP.  
 
4. Determine the role of IL-10 and IL-10-secreting PP CD21+ B cells in regulating 
TLR9-induced responses in PP. 
 
5. Assess the capacity of PP CD21+ B cells to respond to CpG ODN stimulation. 
 
6. Investigate the TLR9 signaling in CD21+ B cells from PBMC and JPP by using 
the kinome analysis. 
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CHAPTER 3: INNATE IMMUNE RESPONSES INDUCED BY CLASSES OF 
CpG ODN IN OVINE LYMPH NODE AND BLOOD MONONUCLEAR CELLS 
 
3.1 Abstract  
 
CpG-ODN signal through Toll-like receptor 9 (TLR9) and trigger a cascade of 
events that lead to activation of innate and adaptive immune responses. Our current 
understanding of the immunobiology of host responses to CpG is based largely on 
studies on peripheral blood mononuclear cells (PBMC) and splenocytes. Little is known 
regarding CpG-induced responses in other lymphoid tissues. In the present study, we 
investigated responses induced by CpG in both PBMC and lymph nodes. Cells were 
isolated from the superficial cervical lymph node (LN) and blood and then stimulated 
with CpG ODN (either A-, or B- or C-Class ODN). Cytokine production was assayed 
by ELISA, and lymphocyte proliferation was determined by 3H-thymidine 
incorporation. NK-like cytotoxicity was analyzed by lysis of 51Cr-labelled target cells. 
All three classes of CpG induced IFNα and IFNγ in LN cells. In contrast, only A- and 
C-class ODN induced IFNα and IFNγ in PBMC. Moreover, the IFN levels in LN were 
20-40 fold higher than in PBMC. Furthermore, all classes of ODN induced higher IL-12 
levels in LN (5-6 fold) than in PBMC. Both B- and C-class ODN induced significant 
proliferative responses in PBMC and LN, but the A-class ODN did not induce 
proliferation of PBMC and only induced moderate proliferation of LN cells. A-class 
ODN induced significant NK-like activity in LN.  Thus, all three classes of CpG ODN 
induced similar responses in LN, and these responses were consistently higher than in 
PBMC. These observations indicate that CpG ODN-induced responses differ between 
blood and lymph nodes, and suggest that the functional classification of CpG ODN 
based on PBMC responses may not be applicable to cells from other immune tissues. 
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3.2 Introduction 
 
The innate immune system (IIS) has a conserved network of receptors called 
pathogen recognition receptors (PRR) that have the ability to recognize pathogen 
associated molecular patterns (PAMPs) as ‘danger’ signals [3]. On recognition of their 
respective ligands, PRR are capable of inducing a variety of immune responses. TLR 
constitute one family of PRR. Currently, thirteen TLR have been identified in mammals 
and they provide a sensory mechanism for the detection of infectious threats [167, 170]. 
For example, TLR3, TLR4, TLR7/8 and TLR9 recognize double-stranded RNA, 
lipopolysaccharides (LPS), single stranded RNA/imidazoquinolines and CpG or 
bacterial DNA respectively [41, 171-174].   
CpG dinucleotides are present at the expected frequency (1/16 base pair) in 
bacterial DNA. In contrast, the frequency of CpG is suppressed to about one quarter of 
the predicted value in vertebrate DNA and also the cytosine is often methylated [175]. 
Based on these differences, it has been proposed that vertebrates have evolved to 
recognize CpG DNA as a mechanism of detecting the presence of pathogens and 
stimulating the IIS. Bacterial DNA, but not vertebrate DNA can stimulate mammalian 
immune cells [54]. Synthetic oligonucleotides containing CpG motifs mimic the 
immunostimulatory effects of bacterial DNA [54]. 
Both in vitro and in vivo studies have demonstrated that CpG ODN are potent 
activators of the IIS in numerous species including humans, non-human primates, mice, 
cattle, sheep, pigs, horses, dogs, cats, chickens and fish [53, 56, 176-181]. CpG ODN 
have been shown to be protective against a variety of pathogens including bacteria, 
viruses and protozoa in numerous animal models [182-188].  When given with an 
antigen, CpG has the ability to enhance antigen specific immune responses and this has 
been shown in humans and numerous animal species [189-194].  
Numerous in vitro studies have revealed that in mice, a variety of cell types are 
activated directly or indirectly by CpG ODN. These include B lymphocytes, monocytes, 
macrophages, dendritic cells, NK cells and even mast cells and, depending on the cell 
type activated they proliferate, upregulate MHC class I and II, B7-1 and B7-2 co-
stimulatory molecules, or express a broad range of cytokines including IL-1, IL-6, IL-
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10, IL-12, IFNα, IFNγ and TNFα [24, 195-198]. In humans, plasmacytoid dendritic 
cells (pDCs) and B cells express TLR-9 and are directly stimulated by CpG ODN to 
proliferate, produce cytokines and upregulate co-stimulatory molecules [36, 85, 199]. 
There have been relatively few studies in ruminants, but those that have been reported 
indicate that CpG ODN induce IFNα and IFNγ secretion in bovine PBMC in vitro, but 
no NK-like cytotoxicity [200, 201]. It has also been reported that CpG ODN induced 
IL-6, IL-12 and IFNγ in bovine PBMC whereas B lymphocytes produced only IL-6 
[202]. However, CpG ODN stimulation of ovine PBMC induced IFNα and NK-like 
cytotoxicity but no IFNγ secretion [200, 201], whereas stimulation of ovine lymph node 
cells induced both IFNα as well as IFNγ [203]. However, in these studies, the capacity 
of CpG to induce IL-12, a cytokine that plays a key role in the development of Th-1 
type immune response, was not evaluated [200, 201]. 
Three distinct classes of CpG ODN have been characterized: (i) A-class ODN 
(phosphodiester/phosphorothioate backbone with a poly G tail) trigger maturation of 
antigen-presenting cells (APC) and directly induce the secretion of high levels of IFNα 
from pDCs but little or no B cells activation [24, 48, 204], (ii) B-class ODN (multiple 
CpG motifs on a phosphorothioate backbone) trigger B cells to proliferate and induce 
little or no IFNα  [199, 205, 206], and (iii) C-class ODN (Hexameric CpG motif [5’-
TCGTCGTT-3’] linked by a T spacer to GC-rich palindromic sequences) have the 
functional properties of both A- and B- class ODN [199, 207]. Most of these 
observations were made using human PBMC or mouse splenocytes. Little is known 
about the immunostimulatory effects of these ODN in other lymphoid tissues. A recent 
study indicated that the biodistribution of CpG is more dynamic than previously thought 
[208]. These investigators showed that following subcutaneous injection of CpG ODN, 
approximately 10-15% of the ODN were present in lymph node and organs after four 
hours whereas in serum, the level of the ODN was very low [208]. They also observed a 
significant increase in ODN concentration between 4 hrs and 24 hrs in the lymph nodes. 
The accumulation of ODN in lymph nodes suggests that this may be an important tissue 
in the development of CpG-induced effects in vivo. We recently reported that A-class 
CpG ODN (2216), but not B-class (2007) induced IFNα in PBMC of sheep but both 
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ODN induced IFNα in lymph node cells (LN) [203]. However, in these previous 
studies, the newly reported C-class ODN were not evaluated. Sheep provide a 
convenient model for such studies since an adequate number of cells can be obtained 
from a number of different immune compartments in the same animal. Furthermore 
sheep have been used extensively as a model for immunological and physiological 
studies as reviewed recently [209]. 
The objectives of this study were to investigate and understand the in vitro 
immunostimulatory effects of the C-class CpG ODN and compare these responses with 
the other two classes of CpG ODN in PBMC and LN using a variety of immune assays.  
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3.3 Materials and methods 
 
3.3.1 Oligodeoxynucleotides 
 
Both A-class CpG ODN 2216 and B-class CpG ODN 2007 have previously 
been shown to be biologically active in sheep in vitro and in vivo [210, 211]. However 
the immunostimulatory effects of C-class CpG ODN have not yet been evaluated in 
sheep. Table 3.1 shows the sequences of the ten ODN used in these studies. CpG ODN 
2007, 20620 and 2216 were obtained from Merial limited (Lyon, France), while CpG 
ODN 2006, 2429, 5482 and 8954 were provided by Coley Pharmaceutical group 
(Wellesley, MA, USA). Control non-CpG ODN 2137, 2243 and 2007GC were 
purchased from Operon (Alameda, CA, USA).  
 
Table 3.1: A, B and C-class CpG ODN sequences and backbone structure  
 
ODN name Class Sequence 
2007 B tcgtcgttgtcgttttgtcgtt 
2007GC B tgctgcttgtgcttttgtgctt 
2006 B tcgtcgttttgtcgttttgtcgtt 
2137 B tgctgcttttgtgcttttgtgctt 
2216 A ggGGGACGATCGTCggggg 
2243 A ggGGGAGCATGCTGggggg 
8954 A ggGGACGACGTCGTGgggggG 
2429 C tcgtcgttttcggcggccgccg 
5482 C tcgtcgtttttcgtgcgttttt 
20620 C tcgtcgttttaCGgcgccgtgccg 
 
Lower case – phosphorothioate backbone 
Upper case – phosphodiester backbone 
   
3.3.2 Animals 
  
Suffolk sheep of either sex (2-4 months of age) were obtained from the 
Department of Animal and Poultry Science (University of Saskatchewan, Saskatoon, 
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SK, Canada). The animals were housed at the Vaccine and Infectious Disease 
Organization (VIDO) animal facility and fed ad libitum on a ration of rolled barley and 
alfalfa hay. All experiments were carried out according to the Guide to the Care and 
Use of Experimental Animals, provided by the Canadian Council on Animal Care. 
Experimental protocols were approved by the University of Saskatchewan Animal Care 
Committee. All animals were housed in the same pen throughout each experiment. 
 
3.3.3 Isolation of peripheral blood mononuclear cells (PBMC) and lymph node cells    
(LN) 
 
Blood was collected from the jugular vein of sheep in EDTA-treated vacutainer 
tubes (BD Biosciences, Mountain View, CA, USA) and PBMC were isolated using 
54% isotonic PercollTM (Pharmacia Biotech AB, Uppsala, Sweden), as described 
previously [212]. Cells were counted using a cell counter (Dual Diluter III, Coulter 
electronics Ltd, Luton, England) and resuspended in AIM V medium (GibcoBRL, 
Burlington, ON, Canada) containing 2% fetal bovine serum (FBS; GibcoBRL).  
Sheep were euthanised and superficial cervical lymph nodes were removed and 
placed in ice-cold minimum essential medium (MEM, GibcoBRL) containing the 
antibiotics 100 IU/mL Penicillin, 100 µg/mL Streptomycin sulfate and 0.25 µg/mL 
Amphotericin B (Sigma-Aldrich, St Louis, Missouri, USA). Cells were isolated from 
lymph nodes by finely mincing tissue with a scalpel, filtering the cell suspension 
through a 40-µm nylon cell strainer (Becton Dickinson Labware, Franklin Lakes, NJ, 
USA) and washing cells with PBS (pH 7.2), as described previously [213]. Viable LN 
numbers were determined by trypan blue dye exclusion and counting in a 
hemocytometer with the aid of a light microscope. Cells were resuspended in AIM V 
medium containing 2% FBS. 
 3.3.4 Tissue culture conditions 
 
Stimulation of PBMC and LN cells was performed in 96-well, round bottom 
plates (Nunc, Naperville, IL, USA) using AIM V medium supplemented with 2% FBS, 
100 IU/mL Penicillin, 100 µg/mL Streptomycin sulfate, 0.25 µg/mL Amphotericin B, 2 
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mM L-glutamine, 50 µM 2-Mercaptoethanol and 10 µg/mL Polymyxin B Sulfate 
(Sigma-Aldrich). For measuring cytokines in culture supernatants, PBMC and LN were 
incubated with either 0.07, 0.22, 0.66, 2.0, 6.0 or 18.0 µg/mL of each of the ten ODN 
for 48 hrs at 37°C in an atmosphere of 5% CO2 and 95% humidity. Forty eight hours 
was previously shown to be the optimal time for detection of cytokine responses in 
ovine PBMC stimulated with CpG ODN [200]. For each treatment, 5x105 cells were 
cultured in triplicate wells in 200 µL total volume. Culture supernatants were harvested 
and stored at –20oC until assayed for IFNα, IFNγ and IL-12. 
 
3.3.5 Enzyme-linked immunosorbent assay (ELISA) for IFNα, IFNγ and IL-12 
 
The IFNα, IFNγ and IL-12 ELISA assays used during this study were previously 
shown to detect ovine and bovine IFNα, IFNγ and IL-12 cytokines as described 
elsewhere [210, 213, 214]. Briefly, polystyrene microtiter plates (Immulon 2; Dynex 
Technology INC, Chantilly, USA) were coated with capture antibody. For the IFNγ 
ELISA, mouse anti-bovine IFNγ antibody (clone 2-2-1A) [213] and for IFNα ELISA, 
two mouse anti-bovine IFNα antibodies (clones IFN-A2 and IFN-A4) were used in 
coating buffer [215]. For IL-12, mouse anti-recombinant bovine IL-12 antibody 
(Serotec MCA 1782Z, NC, USA) was diluted to 8 µg/mL in coating buffer. Plates were 
washed with Tris buffer saline/0.01% Tween 20 (Sigma-Aldrich) (TBST) at all steps. 
Recombinant bovine IFNγ (bIFN-γ), bovine IFNα (bIFN-α) (Ciba Giegy) and 
recombinant human IL-12 (rHuIL-12) (Serotec PHP 100) were used as standards. 
Standards and samples were diluted in TBST/0.5% gelatin (Sigma-Aldrich) (TBST-g) 
and added to the wells. To detect bound cytokine, rabbit anti-bovine IFNγ antisera  or 
rabbit anti-bovine IFNα anti-sera and mouse anti-bovine IL-12 CC326 biotin (Serotec 
MCA 2173B; biotinylated at VIDO) were added. Biotinylated goat anti-rabbit IgG 
(Zymed, South San Fransisco, CA, USA) and strepavidin-alkaline phosphatase 
(GibcoBRL) were used for detection. The assay was developed by using p-nitrophenyl 
phosphate (Sigma-Aldrich) substrate in 1 % diethanolamine (Sigma-Aldrich) and 0.5 
mg/mL magnesium chloride. The reaction was stopped by adding EDTA to each well. 
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Optical density of the reaction product was measured at 405 nm using a 490 nm 
reference on a Benchmark microplate reader (Bio-Rad Laboratories, Hercules, CA, 
USA). Sample concentrations were calculated using Microplate Manager 5.0.1 version 
software (Bio-Rad).  
 
3.3.6 Cytotoxicity assay 
 
A NK-sensitive target cell line (K562 cells), which was previously shown to be 
sensitive to cytotoxicity by ovine PBMC were prepared as described by Mena et al 
[200]. Briefly, NK-sensitive target cells were labeled, washed and resuspended in 
culture medium. Cells (1 x 104) were added to each well in a round bottom 96-well 
plate. All assays were performed in triplicate and six wells per plate were used to 
determine the mean spontaneous release (release of 51Cr from K562 cells in media 
alone) and total release (lysis of K562 cells with 5% Triton X-100). One million 
effector cells (PBMC) were added per well for a 100:1 effector to target ratio. LN or 
PBMC and K562 cells were co-cultured for 24 hrs at 37°C, either in medium alone, 
stimulated with 15 ng/mL of recombinant bovine IL-2 (bIL-2, Ciba Giegy, Basel, 
Switzerland), or incubated with 2 µg/mL of either of the three classes of ODN in a final 
volume of 200 µL. Supernatants were harvested using a supernatant collection system 
(Skatron, Virginia, USA) and counts per minute (c.p.m.) were determined using a 
gamma counter (Model 5500, Beckman Instruments). Spontaneous release was always 
less than 25% of total release. The percentage cytotoxicity was calculated using the 
formula {(experimental c.p.m.) – (spontaneous c.p.m.) / (total c.p.m.) – (spontaneous 
c.p.m.)} x 100. 
 
3.3.7 Lymphocyte Proliferative responses (LPR) 
 
PBMC and LN resuspended in culture medium for LPR assays were pulsed with 
0.4 µCi [3H] thymidine (Amersham Pharmacia, Piscataway, NJ) during the final 6 hrs of 
a 72-hrs incubation as previously described [200]. Cells were harvested using standard 
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liquid scintillation protocols and uptake of 3H-thymidine was assessed in a beta counter 
(Topcount, Packard Instrument Company, Meriden, CT). The LPR were calculated as 
the mean counts per minute (c.p.m) of triplicate cultures and expressed as a stimulation 
index (c.p.m in the presence of stimulus/c.p.m in the absence of stimulus). 
 
3.3.8 Statistical analysis 
 
Data were analyzed using the statistical software program SPSS 12 (SPSS Inc., 
Chigaco, IL, USA). Data that were not normally distributed were transformed by 
ranking. The differences among individual groups were examined by performing one-
way analysis of variance (ANOVA). If the results of ANOVA were significant (p< 
0.05), the means of the transformed data were compared using Tukey’s test. The 
residuals of each ANOVA were examined to determine that the assumptions of the 
analysis had not been violated.  Differences were considered significant when p<0.05.  
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3.4 Results 
 
3.4.1 Effect of CpG ODN class and concentration in PBMC and LN 
 
3.4.1.1 IFNα induction in LN and PBMC 
 
Both A-class (2216, 8954) and C-class (2429) CpG ODN induced 
IFNα  secretion in PBMC (Fig. 3.1 A) and in LN (Fig. 3.1 B). B-class ODN (2006, 
2007) also induced secretion of IFNα at 0.66, 2.0, and 6.0 µg/mL of ODN but only in 
LN and not in PBMC (Fig. 3.1 A-B). IFNα levels were 30-40 fold higher in LN than in 
PBMC (Fig. 3.1 A-B). Not only was the amount of IFNα higher in CpG-stimulated LN 
but also more ODN sequences induced the LN to produce IFNα (Fig. 3.1 A-B). There 
was an effect of CpG concentration on the IFNα response (Fig. 3.1 A). At low 
concentration (0.07 – 0.22 µg/mL), CpG ODN induced small amounts of IFNα. 
Production of IFNα continued to increase as the concentration of ODN increased (0.66- 
2.0 µg/mL), and reached a plateau (2.0 -18.0 µg/mL). Thus the optimal dose appears to 
be 2.0 µg/mL.  Control GpC ODN did not induce IFNα secretion in PBMC or LN, 
indicating that IFNα secretion by either PBMC or LN was ‘CpG- specific’.  
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3.4.1.2 IFNγ  induction in LN and PBMC  
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Fig. 3.1 A-B: IFNα secretion by ovine PBMC and LN following stimulation with varying concentration 
of CpG ODN. Data represent the mean of 8 animals (n=8) for each concentration of CpG ODN. Boxed 
ODN responses are similar but significantly different (p<0.05) from ODN responses outside the box. The 
letter in parenthesis in figure legend indicates the class of ODN. 
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Production of IFNγ in response to CpG ODN stimulation of PBMC and LN 
followed a similar pattern to that observed with IFNα. A-class (2216, 8954) and C-class 
CpG ODN (2429, 5482) stimulation resulted in significant production of IFNγ  in both 
PBMC and LN. However, the level of IFNγ was approximately 20-30 fold higher in 
LN. Also, it was observed that B-class ODN 2006 and 2007 induced IFNγ in the LN 
(Fig. 3.2 B) but not in the PBMC (Fig. 3.2 A). However, significant induction of IFNγ 
by B-class ODN required at least 2.0 µg/mL concentration of CpG ODN (Fig. 3.2 B). 
The responses were dependent on the concentration of CpG ODN (Fig. 3.2 A-B). At 
low concentrations of 0.07 to 0.22 µg/mL, CpG ODN induced low amounts of IFNγ but 
as the concentration increased from 0.66 to 2.0 µg/mL, responses continued to increase 
and then reached a plateau at 6.0 to 18.0 µg/mL (Fig. 3.2 A-B). Just as for IFNα, the 
IFNγ response was CpG specific as the non-CpG ODN controls did not stimulate any 
significant production of this cytokine (Fig. 3.2 A-B). 
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Fig. 3.2 A-B: IFNγ secretion by ovine PBMC and LN following stimulation with varying concentration 
of CpG ODN. Data represent the mean of 8 animals (n=8) for each concentration of CpG ODN. Boxed 
ODN responses are similar but significantly different (p<0.05) from ODN responses outside the box. The 
letter in parenthesis in figure legend indicates the class of ODN. 
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3.4.1.3 Proliferative responses in LN and PBMC  
 
In LN and PBMC, B-class (2007, 2006) and C-class (2429, 5482) ODN induced 
significant proliferation compared to the control GpC ODN (2007 GC, 2137, 2243) 
(Fig. 3.3 A-B). In contrast, A-class ODN (8954, 2216) induced significant proliferation 
in LN at concentration of 2.0 and 6.0 µg/mL of ODN (Fig. 3.3 B) but did not induce 
strong proliferation in PBMC (Fig. 3.3 A). The proliferation of PBMC and LN 
stimulated with CpG increased as the concentration of CpG ODN increased (Fig. 3.3 A-
B). The highest proliferative responses were seen with ODN in the range of 2.0 to 6.0 
µg/mL as was observed for IFNα and IFNγ responses. Also proliferative responses were 
CpG specific as the control GpC (non-CpG) ODN did not stimulate any proliferative 
effects in both PBMC and LN (Fig. 3.3 A-B). 
 41
  
3.4.2 IL-12 induction in LN and PBMC 
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Fig. 3.3 A-B: Proliferative responses by ovine PBMC and LN following stimulation with varying
concentration of CpG ODN. Data represent the mean of 8 animals (n=8) for each concentration of
CpG ODN. Boxed ODN responses are similar but significantly different (p<0.05) from ODN
responses outside the box. The letter in parenthesis in figure legend indicates the class of ODN.
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Since the optimal proliferative responses occurred at about 2 µg/mL of CpG 
ODN, the ability of eight ODN to induce IL-12 in both LN and PBMC was assessed at 
this concentration. All three classes of CpG ODN (A-class: 8954; B-class: 2006, 2007; 
C-class: 2429, 20620) induced significant IL-12 secretion in the LN (Fig. 3.4 B). In 
contrast only B-class (2006) and C-class ODN (2429, 20620) stimulated significant IL-
12 secretion in PBMC (Fig. 3.4 A). Induction of IL-12 was 5-6 fold higher in LN than 
in PBMC (Fig. 3.4 A-B). Again, this response was CpG specific as the GpC controls 
did not induce any IL-12 in LN and PBMC (Fig. 3.4 A-B). In LN, there was no 
significant distinction between the stimulatory effects of the three classes of CpG ODN 
in terms of IL-12 induction whereas in PBMC, only B- and C-class induced significant 
IL-12.    
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IL-12 secretion following CpG ODN stimulation in sheep PBMC
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IL-12 secretion following CpG ODN stimulation in sheep LN
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Fig. 3.4 A-B: IL-12 responses in ovine PBMC and LN following stimulation with either 2 µg/mL CpG 
ODN, 5 μg/mL concavalin A (ConA) or medium alone. Data for individual animals are presented with 
median value indicated by horizontal bar for each treatment group (n=8). Significant IL-12 secretion 
relative to GpC control is indicated by a boxed * (P<0.05). 
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3.4.3 NK-like cytotoxicity in LN and PBMC 
 
It is believed that an important characteristic of CpG ODN, especially of the A-
class, is the activation of NK cells [48]. Previously, it was shown that A-class and B-
class CpG ODN have the ability to stimulate cytolytic activity in ovine PBMC [200] but 
NK-like cytotoxicity has not been assayed in LN. In the present study, the ability of 
CpG ODN to stimulate cytolytic activity in ovine PBMC and LN was assessed. It was 
observed that A-class ODN (8954) induced significant NK-like cytotoxicity in LN (Fig. 
3.5 B). Although B (2006, 2007) and C-class (2429, 20620) ODN induced NK-like 
cytotoxicity in LN, this was not statistically different from the GpC control (Fig. 3.5 B). 
None of the three classes of ODN [A (8954), B (2006) or C-class (2429, 20620)] 
stimulated significant cytolytic activity in PBMC when compared to the GpC control 
(Fig. 3.5 A).     
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Natural killer like cytotoxicity following CpG ODN stimulation in sheep PBMC
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Natural killer like cytotoxicity following CpG ODN stimulation in sheep LN
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Fig. 3.5 A-B: NK-like cytotoxicity responses in ovine PBMC and LN following stimulation with either 2 
µg/mL CpG ODN, 15ng/mL IL-2, concavalin A (ConA) or medium alone. Data for individual animals 
are presented with median value indicated by horizontal bar for each treatment group (n=8).  The effector 
(PBMC, LN) to target (K562 cells) ratio was 100:1. Significant increases in specific 51Cr-release relative 
to GpC controls are indicated by boxed * (P<0.05). 
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3.5 Discussion 
 
The present investigation revealed for the first time that C-class CpG ODN are 
highly stimulatory in ovine PBMC and LN. Furthermore, we showed that while there 
were differences in ODN class responses in PBMC, all three classes of CpG ODN 
induced similarly high responses in LN. C-class ODN have the immunostimulatory 
effects of both A- and B-class ODN in ovine cells. These observations are consistent 
with studies in humans, mice and Rhesus monkeys where C-class ODN have been 
shown to have the combined stimulatory effects of A- and B-class ODN [199, 207, 216, 
217]. While we observed combined immunostimulatory effects of A- and B-class CpG 
ODN for the C-class ODN, similar to those reported by others [199, 207, 216, 217], our 
investigations revealed some new findings. First, CpG-induced responses (IFNα, IFNγ, 
IL-12 and proliferation) were much higher in LN than in PBMC. Second, while A- and 
C-class ODN induced significant IFNα and IFNγ in both PBMC and LN, B-Class ODN 
induced IFNα and IFNγ responses only in LN, but not in PBMC.  
The immune stimulatory activities of A- and B-class CpG ODN classes have 
been described in the sheep PBMC [200]. B-class ODN are potent at stimulating 
proliferative responses but do not induce significant IFNα in PBMC. In contrast, A-
class CpG ODN induce high levels of IFNα and stimulate NK-like cytotoxic activity 
[200]. In human PBMC and mouse splenocytes, a clear distinction has been 
demonstrated between A-, B- and C-class in terms of cytokine production (e.g. A-class 
induce mainly IFNα production) and proliferative responses [24, 199, 207].  
In LN, B-class ODN induced significant IFNα production and the levels were 
similar to those seen following stimulation with A- or C-class ODN. This was 
surprising since most studies have shown that B-class CpG ODN induce little or no 
IFNα production in PBMC. Thus, our data suggest that B-class ODN are equally 
efficient in inducing IFNα production in LN. Moreover, B-class ODN induced 
significant IFNγ similar to that of A and C-class ODN in the LN. These observations are 
consistent with the results of Nichani and colleagues [203] who observed increased 
levels of the IFN-induced enzyme 2’5’-A synthetase following subcutaneous injection 
of B-class CpG ODN 2007. In terms of proliferative effects, both LN and PBMC 
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showed strong proliferation in response to B- and C-class CpG ODN. However, A-class 
CpG ODN induced lower but significant proliferation at higher concentrations in LN 
but not in PBMC.  
The biodistribution and metabolism of immunostimulatory ODN 2006 in mice 
and rats was recently reported [208]. It was observed that upon injection of ODN, the 
maximal concentration of the CpG ODN in draining lymph node, kidney and liver were 
around 10-15% of that of the injection site, and that only very low, transient levels of 
CpG ODN were found in plasma [208]. The accumulation of CpG ODN in draining LN 
[208] and our observations that B-class ODN are highly stimulatory to LN may explain 
why B-class ODN have potent immunostimulatory effects in vivo [203, 218, 219]. 
Overall, the data presented here indicate that there are substantial differences in CpG-
induced responses between LN and PBMC. The differences for the responses to CpG in 
the two tissues are not known at the present time, but may be partly due to differences 
in cell populations that respond to CpG ODN. These differences may involve variations 
in frequency, and/or activation state of the responder cells.  Little is known about CpG 
ODN-induced responses in cells from other immune compartments like spleen, lung, 
gut-associated lymphoid tissues (GALT) and other mucosal-associated lymphoid tissues 
(MALT). Differences in responses between PBMC and LN suggest that cells from these 
other tissues might show different responses to various classes of CpG ODN. Such 
studies will be important in targeting CpG ODN to appropriate immune compartments 
in order to maximize the benefits of CpG treatment. 
IL-12 is a pro-inflammatory cytokine that is thought to link innate and adaptive 
immunity by favoring the differentiation of T helper 1 (Th1) cells and production of 
IFNγ [220]. In mice, CpG ODN directly activate monocytes, macrophages and dendritic 
cell which respond by secreting high levels of Th1 promoting cytokines such as IL-12 
[221]. In this study, significant IL-12 was induced in ovine PBMC by B- and C-class 
ODN while in LN all three classes of CpG ODN induced this cytokine. However, the 
difference between the levels of IL-12 produced by LN in response to different CpG 
classes was not as dramatic as that produced by PBMC.  
Given the importance of NK activation in innate immunity, the ability of all 
three classes of ODN to induce NK-like cytotoxic activity was assessed. Only A-class 
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ODN (8954) induced significant CpG specific non-MHC restricted NK-like 
cytotoxicity. The NK-like cytotoxicity responses were highly variable from animal to 
animal and likely contributed to the lack of statistical significance. Nonetheless our 
results are consistent with those reported previously by Mena et al [200] for A- and B-
class.        
The concentration of CpG ODN used can also have a significant impact on the 
responses observed. For example, highly stimulatory ODN will have activity at lower 
doses while ODN with low activity will require higher doses. Furthermore very high 
doses of ODN may result in poor responses. For these reasons, it was important to 
determine the optimal concentration of each ODN in PBMC and LN. Our observations 
indicated that the CpG concentrations that induced optimal responses were between 
0.66 to 2.0 µg/mL for IFNα, IFNγ and proliferative responses in vitro.  
Although the new C-class CpG ODN induced innate immunostimulatory 
responses comparable to A- and B-class CpG ODN, the C-class ODN may offer 
advantages over A- and B-class ODN. First, C-class ODN have broad 
immunostimulatory properties, as indicated by their capacity to stimulate potent 
interferon and B cells responses in PBMC and LN. Second, C-class CpG ODN have 
phosphorothioate backbone similar to B-class CpG ODN and therefore would not be 
rapidly degraded in vivo. Thus, this new class of CpG ODN has the potential to be used 
for stimulation of innate and adaptive immunity to protect against infections.  
 
3.6 Conclusion 
 
The immune responses induced by CpG can vary remarkably both quantitatively 
and qualitatively between cells from different immune tissues. Data from one tissue 
cannot be extrapolated to other tissues. Therefore, one must determine the effects of 
specific ODN in tissues of interest.   
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CHAPTER 4: SHEEP PEYER’S PATCHES RESPOND POORLY TO TLR 
AGONISTS AND TLR7/8 AGONISTS DOWNREGULATE CpG-INDUCED 
RESPONSES IN BLOOD MONONUCLEAR CELLS. 
 
4.1 Abstract 
 
Peyer’s patches (PP) are secondary lymphoid tissues and are the primary sites 
for immune induction in the intestine. In our previous study, we demonstrated that there 
were marked differences between CpG (TLR9 agonist)-induced responses in LN and 
blood. We wondered whether TLR agonists would stimulate PP cells in a similar 
manner. We found that cells from both ileal PP (IPP) and jejunal PP (JPP) responded 
poorly to all the TLR agonists poly(I:C) (agonist for TLR3), LPS (TLR4), single 
stranded RNA (ssRNA) (TLR7/8) and CpG ODN (TLR9). All the responses tested 
(IFNα, IFNγ, lymphocyte proliferation, and IgM secretion) were significantly lower in 
PP compared to LN. We also observed that the levels of mRNA expression for 
TLR7/8/9 in PP were similar to the levels in LN and PBMC. It has been proposed that 
simultaneous stimulation with multiple TLR agonists may result in complementary or 
inhibitory responses. We therefore tested whether simultaneous stimulation with 
multiple TLR agonists would trigger significant responses in PP and other tissues. We 
observed no significant increase in TLR-induced responses in PP cells and PBMC upon 
stimulation with combinations of TLR agonists. However, we observed significant 
inhibitory responses upon co-administration of TLR7/8 and TLR9 agonists in LN and 
PBMC. Therefore, we further investigated the effect of TLR7/8 agonists on the TLR9 
agonist-induced responses in ovine PBMC and purified blood B cells by simultaneous 
activation with CpG ODN 2429 and the TLR7/8 agonists; ssRNA oligoribonucleotides 
(ORN) or imiquimod.  Compared to responses induced by CpG alone, simultaneous 
activation with TLR9 and TLR7/8 agonists resulted in significantly reduced IFNα 
production, cell proliferation and IgM responses in PBMC.  Importantly, the TLR7/8 
agonists reduced the CpG-induced proliferative responses in purified blood B cells.  
Pre-incubation of cells with CpG for 2 or 4 hrs before addition of imiquimod (TLR7/8 
agonist) still resulted in reduced CpG-induced proliferation, indicating that the down-
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regulatory mechanisms are not associated with competition for cellular uptake or 
receptors for imiquimod and CpG ODN.  Imiquimod reduced the CpG-induced 
proliferation in a dose-dependent manner but this was not associated with an increase in 
caspase enzymes or IL-10, implying that the unresponsiveness was not due to 
activation-induced cell death or suppression by IL-10. Ovine B cells constitutively 
expressed TLR7, TLR8 and TLR9 mRNA suggesting a possible role of TLR cross-talk 
in the down-regulatory mechanisms. We conclude that while simultaneous activation 
with TLR7/8/9 agonists may influence responses in immune cells from blood and 
lymph nodes, these combinations of TLR agonists had no effect on responses in PP 
cells. 
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4.2 Introduction 
 
The innate immune system uses a set of germline-encoded pattern recognition 
receptors (PRR) to detect pathogen associated molecular patterns (PAMPS) present in 
microbial pathogens  [18].  PRR are strategically located in various cells and have been 
grouped into different families that include Toll-like receptors (TLRs), Caspase 
recruitment domain (CARD) helicases, retinoic acid induced gene (RIG)-like receptors 
(RLR), nucleotide oligomerization domains (NODs), C-type lectins, complement 
receptors and others [222].  TLRs, the main PRR family, are trans-membrane signaling 
molecules currently comprised of at least 13 members in mammals named TLR1-
TLR13 [18, 167, 222, 223].    
TLR3 recognizes viral double stranded dsRNA and poly(I:C) whereas TLR4 
detects lipopolysaccharide (LPS). Endosomal TLR7 and TLR8 recognize viral ssRNA 
and the small antiviral compounds, imidazoquinolines [224, 225], while TLR9 is the 
receptor for CpG-rich viral and bacterial DNA [226]. Agonists for TLR7/8 and TLR9 
are potent activators of innate and adaptive immunity, and have attracted a great deal of 
attention due to their potential as vaccine adjuvants and immunotherapeutic agents. 
Activation of TLR7/8 predominantly induces Th1 cytokine and chemokines including 
IFN-α, IP-10, IL-12, IL-6 and TNF-α [224, 227-230], increased expression of co-
stimulatory molecules and upregulation of the early activation marker CD69 [224, 231-
233].   Similarly, activation of TLR9 induces predominantly Th1 cytokines, 
chemokines and increased expression of costimulatory molecules, but also activates B 
cells to proliferate and secrete IgM and to produce cytokines such as IL-6 and IL-12, 
[234].  
PP have been shown to be the primary sites where immune responses are 
initiated in the intestine. However, PP are constantly exposed to PAMPs (TLR agonists) 
by the presence of commensals in the lumen. We reasoned that their response may be 
quite different from blood and LN. In sheep and many other species including humans, 
there are two distinct PP in the small intestine namely the jejunum PP (JPP) and ileal PP 
(IPP), each with their own characteristic development, structure and function [235].  
JPP) but IPP are the primary sites where active immunity is induced in the intestine 
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[110, 236, 237]. Unlike peripheral LN, the major proportion of lymphoid cells in the PP 
comprise of B cells (up to 80% in JPP and > 90% in IPP) [100, 114] whereas the B cells 
frequency in PBMC or LN is around 30-40% [238]. In our initial studies, we found that 
PP cells respond poorly to stimulation with single TLR agonists.   
However, experience with TLR9 agonist, CpG ODN suggests that individual 
TLR agonists in ruminants are not as potent immune activator as suggested in rodent 
models [239]. Given that viruses and bacteria express several TLR agonists and most 
likely pathogens stimulate multiple TLRs simultaneously, the consequences of 
activating multiple TLRs has generated a lot of interest.  Evidence is accumulating to 
support the notion that activation of multiple TLRs can result in complementary, 
synergistic or antagonistic effects. In this regard, simultaneous activation of dendritic 
cells (DC) with TLR9 and TLR4 agonists, CpG ODN and LPS resulted in additive 
effects on IL-12 production [240]. Similarly, costimulation of TLR3 and TLR8, or 
TLR4 and TLR8 resulted in a synergistic IL-12 response, but costimulation of TLR3 
and TLR4 had no effect on the IL-12 response [94]. In contrast, simultaneous activation 
with agonists for TLR7/8 and TLR9 resulted in inhibition of IFNα responses [241, 242]. 
An understanding of the cellular events triggered by combinations of TLRs will 
be valuable in the rational design of more successful TLR-based immunotherapies and 
vaccination strategies. TLR agonists can be grouped into two main categories based on 
their dependence or independence on the adaptor molecule MyD88. It has been 
proposed that co-stimulation with agonists sharing common pathway (MyD88 
dependent (D) or independent (I) agonists) do not induce synergistic, but rather may 
lead to inhibitory responses. In contrast, co-stimulation with a D agonist and I agonist 
lead to synergistic responses [95]. 
It is thought that most of the beneficial effects of TLR7/8 and TLR9 activation 
are mediated primarily through IFN-α produced by DC [43, 243]. Consequently, studies 
exploring costimulation of these TLRs have focused primarily on IFNα responses in 
DC, and relatively less is known about the effects of costimulation of other cells. B cells 
are one of the major cell populations which can be significantly influenced through TLR 
activation. Many B cells express TLR7/8/9 and, activation of TLR9 signal in B cells can 
synergize with the antigen-specific BCR signal resulting in enhanced antibody 
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production [43]. More recently, it was suggested that in addition to CD4+ T-cell help, 
generation of T-dependent antigen-specific antibody responses requires activation of 
TLRs in B cells [148]. Thus, TLR activation can have dramatic effects on the behavior 
of B cells, but not much is known about multiple TLR stimulation in these cells. One 
recent report suggested that simultaneous activation with TLR7 and TLR9 agonists had 
no effect on human B-cell responses [242].  
It has been suggested that the use of combinations of TLR agonists may be 
necessary to induce strong immune responses in large animal [239]. However, the 
consequences of multiple TLR stimulation have not been explored in ruminants. Given 
that TLR responses can differ dramatically from one species to another, we decided to 
investigate effects of co-stimulation of TLR3, TLR4, TLR7/8 and TLR9 in sheep.  
The objectives of the present studies were (i) to determine whether TLR agonists 
and their combinations can induce innate immune responses in ovine immune cells (PP, 
LN and PBMC), and (ii) to assess innate immune responses in ovine blood mononuclear 
and B cells following co-stimulation with TLR7/8 and TLR9 agonists.   
We report that co-stimulation of ovine blood mononuclear and B cells with 
TLR7/8 and TLR9 agonists results in significant reduction in ensuing innate immune 
responses.   
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4.3 Materials and methods 
 
4.3.1 TLR agonists and Animals 
 
The TLR7/8 agonists used included synthetic ssRNA oligonucleotide (ORN) R-
1075 [224] obtained from Coley Pharmaceutical Group (Ottawa, ON, Canada) and a 
synthetic imidazoquinoline compound imiquimod purchased from Invivogen (San 
Diego, CA, USA). CpG oligodeoxynucleotide (ODN) C-class ODN 2429; sequence; 
tcgtcgttttcggcggccgccg [244] or B-class CpG ODN 2007; sequence tcgtcgttgtcgttttgtcgtt 
were obtained from Merial Limited (Lyon, France). Suffolk sheep of either sex ( 2 to 4 
months of age) were obtained from the Department of Animal and Poultry Science 
(University of Saskatchewan, Saskatoon, SK, Canada). The animals were housed at the 
Vaccine and Infectious Disease Organization (VIDO) animal facility and fed ad libitum 
on a ration of rolled barley and alfalfa hay. All experiments were carried out according 
to the Guide to the Care and Use of Experimental Animals, provided by the Canadian 
Council on Animal Care. Experimental protocols were approved by the University of 
Saskatchewan Animal Care Committee. All animals were housed in the same pen 
throughout each experiment. 
 
4.3.2 Isolation of PBMC, JPP, IPP and LN cells 
 
Blood was collected from the jugular vein of sheep in ethylene di-amine tetra-
acetic acid (EDTA)-treated vacutainer tubes (BD Biosciences, Mountain View, CA, 
USA) and PBMC were isolated using 54% isotonic PercollTM (Pharmacia Biotech AB, 
Uppsala, Sweden), as described previously [201, 212]. Cells were counted using a cell 
counter (Dual Diluter III, Coulter electronics Ltd, Luton, England) and resuspended in 
AIM-V medium (GibcoBRL, Burlington, ON, Canada) containing 2% FBS 
(GibcoBRL). 
Sheep were euthanised and superficial cervical and mesenteric lymph nodes 
were removed and placed in ice-cold minimum essential medium (MEM, GibcoBRL) 
containing the antibiotics 100 IU/mL Penicillin, 100 µg/mL Streptomycin sulfate and 
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0.25 µg/mL Amphotericin B (Sigma-Aldrich, St Louis, Missouri, USA). Cells were 
isolated from lymph nodes by finely mincing tissue with a scalpel, filtering the cell 
suspension through a 40-µm nylon cell strainer (Becton Dickinson Labware, Franklin 
Lakes, NJ, USA) and washing cells with phosphate buffered saline calcium and 
magnesium free (PBSA) (pH 7.2), as described previously [213]. JPP and IPP tissues 
were also removed and placed in MEM (GibcoBRL) containing antibiotics (100 IU/mL 
Penicillin, 100 µg/mL Streptomycin sulfate, 0.25 µg/mL Amphotericin B) (Sigma-
Aldrich). The JPP and IPP cells were also isolated from the same sheep as described 
previously [110, 245]. The number of viable cells in all tissues was determined by 
trypan blue dye exclusion and counting with a hemocytometer under a light microscope. 
Cells were resuspended in AIM V medium containing 2% FBS. 
 
4.3.3 Magnetic activated cell sorting (MACS) 
 
The CD21+ B cell fraction of PBMC was isolated as previously described [246] 
with minor modifications.   Briefly PBMC were incubated with mouse anti-bovine 
CD21 antibody (IgG1, AbD Serotec, UK) for 15 min at 4 °C.  The cells were then 
washed twice with magnetic activated cell sorting (MACS) buffer (PBSA, 0.5M EDTA 
and 10% BSA) by spinning for 8 min at 440 ×g and incubated with goat anti-mouse 
IgG1 phycoerythrin (PE) conjugate (Southern Biotech, AL, USA) for 15 min at 4 °C. 
The cells were then labeled with anti-PE magnetic beads for 15 min at 4°C and eluted 
through the LC MACS column (Miltenyi Biotech, Bergisch Gladbach, Germany) 
according to manufacturer’s instructions.  The CD21+ fraction was flushed out, washed 
in PBS and re-suspended in AIM V media containing 2% FBS. The purity of the 
CD21+ cells were above 93%. 
 
 
4.3.4 Tissue culture conditions and stimulation with TLR agonists 
 
Cells were re-suspended in AIM V medium supplemented with 2% FBS, 100 
IU/mL penicillin, 100 µg/mL streptomycin sulfate, 0.25 µg/mL amphotericin B, 2mM 
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L-glutamine, 50 µM 2-mercaptoethanol and 10 µg/mL polymyxin B sulfate (Sigma-
Aldrich) and added to 96-well, round bottom plates (Nunc, Naperville, IL, USA).  For 
each treatment, 5x105 cells were cultured in triplicate wells in 200 µL total volume.  
Cells were incubated at 37°C in a 5% CO2 atmosphere and 95% humidity. Optimal cell 
stimulation concentrations for TLR3, TLR4, TLR7/8 or TLR9 agonists were established 
previously [200, 247].  Cells were stimulated with TLR7/8 agonists; ORN 1075 at 2.5 
μg/mL or imiquimod 5 μg/mL and TLR9 agonists; C-class CpG 2429 and B-class CpG 
2007 at 5 μg/mL.  ORN was used with DOTAP at ORN: DOTAP ratio of 1:2.  To 
further investigate the effect of imiquimod on CpG-induced responses, cells were co-
stimulated with CpG (5 μg/mL) with variable 10-fold concentrations of imiquimod 
ranging from 25 μg/mL to 0.25 µg/mL.  For optimal detection of cytokines, cells were 
stimulated for 48 hrs as previously described [200, 248].  Culture supernatants were 
stored at –20oC until assayed for cytokines.  
  
4.3.5 ELISA for IFNα, IFNγ, IL-10 and IL-12 
 
ELISA for quantifying cytokines in cell culture supernatants were performed as 
previously reported for IFNα and IFNγ [203], IL-12 [214] and IL-10 [249].  Briefly, 
polystyrene microtiter plates (Immulon 2 for Interferons; Nunc Maxisorp for IL-12 and 
IL-10; Dynex Technology INC, Chantilly, USA) were coated with capture monoclonal 
antibodies specific for targeted cytokines.  These included mouse anti-bovine 
recombinant IFNγ clone 2-21A [203], two mouse anti-recombinant bovine IFNα clone 
A2 and clone A4 [203], mouse anti-bovine IL-12 (MCA 1782EL, Serotec, North 
Carolina, USA) or mouse anti-recombinant bovine IL-10 clone CC318 (MCA 2110, 
Serotec). For every washing step, plates were washed with Tris buffer saline/0.05 % 
Tween 20.  Cell culture supernatants and ten serial two-fold dilutions of standard 
concentrations of recombinant bovine IFNγ or bovine IFNα (Ciba Giegy, Basel, 
Switzerland), recombinant (rHuIL-12) (Serotec PHP 100) and recombinant bovine IL-
10 (Kindly donated by J.C. Hope, Institute for Animal Health, Compton, UK) were then 
added to the plates.  For IFNγ and IFNα ELISA, the captured cyokines were detected in 
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two steps, first by addition of rabbit anti-bovine IFNγ antisera 92-131 [211] or rabbit 
anti-bovine IFNα antisera 92-133 [211] followed by addition of biotinylated goat-anti 
rabbit IgG (Zymed, California, USA).  For IL-12 and IL-10 ELISA, the captured 
cytokines were detected in one step by using biotinylated mouse anti-bovine IL-12 
clone CC326 (Serotec MCA 2173B) or biotinylated mouse anti-bovine IL-10 clone 
CC320 (Serotec MCA 2111B). The reaction was developed by addition of strepavidin-
alkaline phosphatase (Jackson ImmunoResearch Laboratories Inc, USA) and visualized 
by using p-nitrophenyl phosphate (10 mg/mL) (Sigma-Aldrich, Ontario, Canada) as 
substrate.  
 
4.3.6 Caspase assay 
 
Caspase-3/-7 enzyme activity was determined using Caspase-Glo 3/7 assay 
(Promega, Madison, USA) according to manufacturer’s instructions. Briefly cells were 
isolated as described above and stimulated with media, CpG (5 µg/mL), or CpG (5 
µg/mL) + imiquimod at various concentrations (0.25, 2.5, and 25 µg/mL). After 48 hrs 
of incubation, 100 µL of Caspase-Glo® 3/7 reagent was added to each well of a 96-well 
plate.  Luminescence in each sample was measured using the plate-reading 
Luminometer (Victor3V, Perkin Elmer, CA, USA).     
 
4.3.7 Lymphocyte Proliferative responses 
 
Cells were re-suspended in culture medium at 2.5 x 105 cells per well in a final 
volume of 200 µL. Triplicate cultures were stimulated and incubated as already 
described above. During the final 6 hrs of the 72 hrs incubation, cells were pulsed with 
0.4 µCi 3H-Thymidine (Amersham Pharmacia, Piscataway, NJ). Cells were harvested 
using standard liquid scintillation protocols and uptake of 3H-Thymidine was assessed 
in a beta counter (Topcount, Packard Instrument Company, Meriden, CT). Cell 
proliferation was calculated as the mean counts per minute (c.p.m) of triplicate cultures 
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and expressed as a stimulation index (c.p.m in the presence of stimulus/c.p.m in the 
absence of stimulus). 
 
4.3.8 Quantitative RT-PCR 
 
Total RNA was isolated from purified CD21+ B cell suspensions using Trizol 
reagent (Invitrogen, Carlsbad, CA) and RNA samples were treated with DNAse I Amp 
Grade (Invitrogen) (1 U/μg of RNA). The absence of genomic DNA contamination was 
confirmed by use of treated RNA as template directly in PCR.  RNA was quantified by 
determining optical density at 260 nm (OD260) and the OD260/OD280 ratio was calculated 
to assess purity. To obtain complementary DNA (cDNA), RNA (500 ng) was incubated 
in a final volume of 15 μl with dNTP (0.5 mM final each) (Invitrogen), 0.5 μg oligo dT 
(Invitrogen), RNAse out inhibitor (20 U) (Invitrogen), Superscript TM reverse 
transcriptase (RT) (8 U) (Invitrogen), and 1× buffer RT (Invitrogen). The reaction was 
allowed to proceed for 10 min at 25 °C, 30 min at 42 °C and then heat inactivated at 
93 °C for 5 min. The cDNA generated was either used immediately for qPCR or stored 
at −80 °C. The cDNA generated as above was used in the real-time PCR. cDNA was 
combined with primer/probe sets and IQ SYBR Green Supermix (Bio-Rad, Hercules, 
CA) according to the manufacturer's recommendations. The primers and amplification 
conditions were as previously reported [250].  TLR7, 8 and 9 forward and reverse 
primers were synthesized from Invitrogen.  The PCR conditions were 95 °C for 3 min, 
followed by 45 cycles with denaturation at 95 °C for 15 s, annealing temperature at 
59°C for 30 s, and elongation at 72 °C for 30 s. Real-time assays were run on a Bio-Rad 
iCycler iQ system (Bio-Rad, Hercules, CA). The specificity of the PCR reactions was 
assessed by the analysis of the melting curves of the products and size verification and 
sequencing of the amplicons. To normalize the amount of cDNA, we sampled equal 
number of cells, quantified RNA, assessed its quality prior to reverse transcription, and 
used a reference gene. Samples were normalized internally using the average cycle 
threshold (Ct) of beta-actin (β actin) as a reference. Values were expressed as delta Ct 
value per 500 ng of total input RNA. 
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4.3.9 Statistical analysis 
 
Data were analyzed using the statistical software GraphPad Prism 5 (Graphpad, 
San Diego, CA, USA).  One-way analysis of variance (ANOVA) test was used to 
determine statistical differences in mean values when more than two groups were 
compared Values of p<0.05 were considered significant.   
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4.4 Results 
 
4.4.1 Peyer’s patches respond poorly to TLR agonists compared to LN and PBMC 
 
  Previously we have tested CpG ODN as TLR9 agonists on LN and PBMC and 
observed differences in responses. We wondered whether PP will respond similarly to 
CpG ODN as LN since both tissues are secondary lymphoid tissues. As shown in Fig. 
4.1 A, mLN and PBMC responses in terms of IFNα were higher than JPP and IPP. 
Similarly, on stimulation with ssRNA, mLN produced higher amounts of IFNα than 
PBMC and PP cells (Fig. 4.1 B). 
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Fig. 4.1 A-D: IFNα responses in ovine IPP, JPP, mLN and PBMC following 48 hrs stimulation with TLR 
agonists [CpG ODN (5 µg/mL), LPS (100 ng/mL), ssRNA (2.5 µg/mL), P(I:C) (10 µg/mL)]. Data 
represent the mean of 7 animals (n=7).  ** Significantly different from IPP (p<0.05). 
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  In contrast, both LPS and P(I:C) (Fig. 4.1 C-D) did not induce IFNα from the 
tissues. Therefore, both CpG ODN and ssRNA induce significantly lower IFNα  in JPP 
and IPP than in mLN and PBMC.  
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Fig. 4.2 A-D: IFNγ responses in ovine IPP, JPP, mLN and PBMC following 48 hrs stimulation with TLR 
agonists [CpG ODN (5 µg/mL), LPS (100 ng/mL), ssRNA (2.5 µg/mL), P(I:C) (10 µg/mL)]. Data 
represent the mean of 7 animals (n=7).  ** Significantly different from IPP (p<0.05). 
 
Consistent with previous observation, CpG ODN induced significant IFNγ from 
mLN but not from PBMC, JPP and IPP (Fig. 4.2 A). Similarly, on stimulation with 
ssRNA, mLN induced higher levels of IFNγ than PBMC, JPP and IPP (Fig. 4.2 B). This 
pattern of response was similar to what was observed when stimulating with CpG ODN. 
However, ssRNA seemed to be more potent at inducing IFNγ than CpG ODN. Similar 
observations were made when stimulating with LPS (Fig. 4.2 C) and P(I:C) (Fig. 4.2 D), 
both induced IFNγ significantly in mLN but not in PBMC, JPP and IPP. However, both 
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LPS and P(I:C) induced lower levels of IFNγ in mLN as compared to CpG ODN and 
ssRNA. These results showed that PP responses were attenuated for the TLR ligands 
tested as compared to mLN and PBMC. 
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Fig. 4.3 A-D: Lymphocyte proliferative responses (c.p.m.) in ovine IPP, JPP, mLN and PBMC following 
72 hrs stimulation with TLR agonists [CpG ODN (5 µg/mL), LPS (100 ng/mL), ssRNA (2.5 µg/mL), 
P(I:C) (10 µg/mL)]. Data represent the mean of 7 animals (n=7). ** Significantly different from IPP 
(p<0.05). 
 
As observed previously, CpG ODN induced high level of proliferation in PBMC 
and mLN (Fig. 4.3 A). Upon stimulation by CpG ODN, significant proliferative 
responses were observed in IPP but it was reduced compared to mLN and PBMC (Fig. 
4.3 A). On stimulation with ssRNA, mLN showed higher proliferative response than 
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PBMC and PP (Fig. 4.3 B). In contrast, no proliferation response was observed in mLN, 
JPP and PBMC when all tissues were stimulated with LPS (Fig. 4.3 C) or poly(I:C) 
(Fig. 4.3 D). IPP proliferated moderately to both agonists. LPS or P(I:C) was not a 
stronger inducer of proliferation than CpG ODN.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
These results suggested that the PP proliferative response was reduced when 
using CpG ODN and ssRNA. Interestingly IPP proliferated significantly in response to 
CpG ODN, LPS and P(I:C) but not to ssRNA whereas mLN cells proliferated when 
stimulated by CpG ODN and ssRNA but not LPS or P(I:C). 
The IgM responses mirrored the lymphocyte proliferation data. PP cells secreted 
significantly lower levels of IgM than PBMC and mLN upon stimulation with CpG 
ODN (Fig. 4.4 A). Similarly, mLN produced higher level of IgM than IPP and JPP upon 
Fig.  
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Fig. 4.4 A-D: IgM responses (end point titer) in ovine IPP, JPP, mLN and PBMC following 48 hrs
stimulation with TLR agonists [CpG ODN (5 µg/mL), LPS (100 ng/mL), RNA (2.5 µg/mL), P(I:C) 
(10 µg/mL)]. Data represent the mean of 7 animals (n=7). ** Significantly different from IPP 
(p<0.05). 
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stimulation by ssRNA (Fig. 4.4 B). LPS and poly(I:C) induced higher level of IgM in 
PBMC and mLN than in JPP (Fig. 4.4 C-D). IPP secreted high level of IgM upon 
stimulation with both agonists.   
We wondered whether multiple stimulation of TLR agonist would trigger 
responses in PP cells. The lymphocyte proliferation responses were assessed on 
stimulation with different combinations of TLR agonists {CpG ODN (5 µg/mL), CpG + 
ssRNA (2.5 µg/mL), ssRNA + P(I:C) (10 µg/mL), ssRNA + LPS (100 ng/mL), P(I:C) + 
LPS, CpG + P(I:C)} on IPP, JPP, mLN and PBMC. As shown in Fig. 4.5 A-B, neither 
IPP nor JPP proliferated significantly following co-stimulation with different 
combinations of TLR agonists or with CpG ODN alone. PBMC and mLN proliferated 
significantly in response to CpG ODN stimulation (Fig. 4.5 C-D). However, stimulation 
with different combinations of TLR agonists did not induce cells from blood or LN to 
proliferate higher than with CpG ODN alone (Fig. 4.5 C-D). We noted that in PBMC 
and mLN, CpG-induced proliferative responses were reduced when costimulated with 
ssRNA. We decided to investigate this phenomenon further (See below). 
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Fig. 4.5 A-D: Lymphocyte proliferative responses in ovine IPP, JPP, mLN and PBMC following 48 hrs 
stimulation with combination of TLR agonists [CpG ODN (5 µg/mL), LPS (100 ng/mL), RNA (2.5 
µg/mL), P(I:C) (10 µg/mL)]. Data represent the mean of 7 animals (n=7). 
 
Finally, IFNα, IFNγ, and IgM responses were assessed after stimulation with 
different combinations of TLR ligands {CpG ODN (5 µg/mL), CpG + ssRNA (2.5 
µg/mL), ssRNA + P(I:C) (10 µg/mL), ssRNA + LPS (100 ng/mL), P(I:C) + LPS, CpG + 
P(I:C)} on IPP, JPP, mLN and PBMC.   The results showed that there was no 
synergistic responses for the combinations of agonists tested in IPP, JPP and PBMC for 
all the responses tested (Data not shown). Thus PP responses were attenuated compared 
to the lymph node even when stimulated with multiple TLR ligands.  
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4.4.2 PP express similar levels of TLR mRNA to mLN and PBMC 
 
Since TLR-induced responses were poor in PP, we wondered whether TLRs 
were expressed in sheep PP cells. Therefore the expression of TLR7, TLR8 and TLR9 
was determined in IPP, JPP, mLN and PBMC using real time PCR. As shown in Fig. 
4.6 A, the levels of TLR7 mRNA expression were similar in mLN, PP and PBMC. 
Similarly, the levels of TLR8 mRNA expression are similar in all tissues tested (Fig. 4.6 
B). Therefore the poor responses of TLR7/8 agonist were not due to a lack of TLR 
receptors. 
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Fig. 4.6 A-B: Expression of TLR7 and TLR8 in IPP, JPP, mLN and PBMC. Data represent the mean of 7 
animals (n=7). 
 
The level of TLR9 expression was also assessed in IPP, JPP, mLN and PBMC. 
As shown by Fig. 4.7, IPP, mLN and PBMC expressed equal amount of TLR9 copy 
number whereas the level of copy transcript in JPP was lower but not statistically 
different from the other tissues. Therefore the poor responses of PP cells to CpG ODN 
stimulation were not due to a lack of TLR9 receptor.  
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Fig. 4.7: Expression of TLR9 in IPP, JPP, mLN and PBMC. Data represent the mean of 7 animals (n=7). 
 
4.4.3 Oligoribonucleotides suppress the CpG-induced innate immune responses in 
peripheral blood, mesenteric lymph nodes and purified B cells. 
 
Since both ORN and CpG induce innate immune responses, we wondered 
whether simultaneous activation with both ORN and CpG will lead to additive or 
synergistic responses. However, results showed that co-stimulations with the two TLR 
agonists had a negative rather than a positive effect on the resulting innate immune 
responses. Compared to responses induced by CpG alone, the IFNα responses induced 
by ORN+CpG was lower (P<0.01) in PBMC (Fig. 4.8 A) as well as in mLN (p<0.001) 
(Fig. 4.8 B).   
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Fig. 15  
 
The suppression of CpG-induced responses by ORN was also reflected at the 
level of IgM responses as well.  CpG alone significantly (p<0.001) induced IgM 
responses in PBMC (Fig. 4.9 A) and mLN (Fig. 4.9 B).  But CpG+ORN caused a 
significant reduction in IgM (p<0.05) responses in PBMC (Fig. 4.9 A).  The IgM 
response in mLN (Fig. 4.9 B) was also reduced by CpG+ORN though not significantly.   
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Fig. 4.8 A-B: Simultaneous cell activation with RNA oligonucleotides (ORN) and CpG ODN reduce the 
CpG-induced IFNα response. Ovine mononuclear cells from peripheral blood (PBMC) (A) and 
mesenteric lymph nodes (mLN) (B) collected from 7 animals were stimulated with 5 μg/mL CpG 2429 
alone, 2.5 μg/mL ORN 1075 alone, or both for 48 hours and IFNα responses measured by ELISA. 
Significant difference between CpG alone and CpG + ORN (**P<0.05). 
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Fig. 4.9 A-B: ORN suppress the CpG-induced IgM response in cells simultaneously activated with the 
two TLR agonists.  Ovine mononuclear cells from peripheral blood (PBMC) (A) and mesenteric lymph 
nodes (mLN) (B) from 7 animals were stimulated with 5 μg/mL CpG 2429 alone, 2.5 μg/mL ORN 1075 
alone, or both for 48 hrs and IgM responses were measured by ELISA.  Significant difference between 
CpG alone and CpG + ORN (**P<0.05). 
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Fig. 4.10: Suppression of CpG-induced proliferative responses in purified ovine B cells following co-
stimulation with RNA oligoribonucleotides (ORN).   CD21+ B cells were purified from peripheral blood 
of 7 animals by magnetic activated cell sorting (MACS).  The cells were stimulated with 5 μg/mL CpG 
2429 alone, 2.5 μg/mL ORN 1075 alone, or both for 72 hours and the proliferative responses measured 
based on 3H-thymidine incorporation.  Significant difference between CpG alone and CpG + ORN 
(**P<0.05). 
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The suppression of CpG-induced responses by ORN was also observed at the 
level of purified B cells proliferative responses.  CpG induced significant B cells 
proliferation (p<0.001) which was significantly reduced (p<0.01) following co-
stimulation with ORN (Fig. 4.10). 
 
4.4.4 Imiquimod, another TLR7/8 agonist also suppresses CpG-induced responses in a 
dose dependent manner 
 
To confirm that the downregulation of CpG-induced responses was specific to 
the receptor, and not an artifact of the ORN molecule, we co-stimulated cells with CpG 
along with imiquimod (a synthetic small antiviral compound and a known TLR7/8 
agonist) at increasing ten-fold concentrations ranging from 0.25 μg/mL to 25 μg/mL.    
 
 
 
 
 
 
 
 
 
 
 
 
Fig. 4.11 A-B: The RNA oligoribonucleotides (ORN)-induced suppression of CpG-induced 
proliferative responses is dose-dependent.  Ovine PBMC (Fig. 17A) as well as purified CD21+ B cells 
(Fig. 17B) from 7 animals were stimulated with CpG along with increasing 10-fold concentrations of 
imiquimod (Imq) and the proliferative responses measured based on 3H-thymidine incorporation. Data 
is presented as proliferation relative to un-stimulated cells (stimulation index). Significant difference
between treatments (**p<0.05, ***p<0.001).
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The CpG-induced PBMC proliferative responses decreased progressively with 
increasing imiquimod concentrations and was significantly lower at imiquimod 
concentrations of 2.5 μg/mL (p<0.05) and 25 μg/mL (p<0.001) (Fig. 4.11 A).  Therefore 
the antagonistic effect to CpG responses is not specific to the nature of the TLR7/8 
agonist used but probably specific to the receptor (TLR7/8 activation).  A similar dose-
depended suppression of CpG-induced proliferation by imiquimod was seen for purified 
B cells (Fig. 4.11 B).  
 
4.4.5 Reduction of CpG-induced responses by TLR7/8 agonists is not associated with  
induction of cell  death or the anti-inflammatory cytokine  IL-10  
 
From this point, all subsequent experiments were done with imiquimod which is 
more convenient to handle (ORN requires prior conjugation to a carrier molecule, 
DOTAP, which enhances its stability and increases its uptake by cells).  
We then evaluated whether the inhibitory effects of the TLR7/8 and TLR9 
costimulation was due to production of the immunoregulatory molecule IL-10 or 
induction of programmed cell death (apoptosis). We measured the levels of the pro-
apoptotic caspase enzymes in the co-stimulated B-cells as well as the levels of the 
immunosuppressive IL-10 in culture supernatants of stimulated cells.   
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Fig. 4.12 A-B:  IL-10 responses by ovine peripheral blood mononuclear cells (PBMC) and purified B 
cells. PBMC and isolated B cells from 5 animals were stimulated with 5 μg/mL CpG 2429 or CpG 2429 + 
imiquimod (0.25, 2.5 and 25 µg/mL).   
 
 
   There was however no difference in pro-caspase enzyme activity or IL-10 levels 
between cells stimulated with CpG alone and those simultaneously activated with CpG 
plus with increasing imiquimod concentrations indicating that the reduced responses 
were not due to inhibition by IL-10 (Fig. 4.12 A-B) or induction of activation-induced 
cell death (Fig. 4.13). 
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Fig. 4.13:  Caspase 3/7 responses by ovine purified PBMC B cells stimulated with 5 μg/mL CpG2429 or 
CpG 2429 + imiquimod (0.25, 2.5 and 25 µg/mL) or imiquimod (Imq) (5 µg/mL) for 48hrs. Number of 
animals used is four (n=4).  
 
4.4.6 Suppression of CpG-induced responses was not due to preferential cellular uptake 
of the TLR7/TLR8 agonists 
 
  Since imiquimod is a rather small molecule, we wondered whether it was 
preferentially taken up by cells and therefore engage the receptors and/or the 
downstream signaling intermediates at the expense of CpG.  We therefore monitored the 
responses when cells were first exposed to CpG for variable time periods before 
addition of imiquimod.  We used two different CpG sequences; B-class CpG 2007 and 
C-class CpG 2429.  Surprisingly, addition of imiquimod 2 hours or even 4 hours after 
CpG treatment still resulted in a significant reduction (p<0.05) of the CpG-induced 
responses in PBMC (Fig. 4.14 A) indicating that preferential uptake of imiquimod 
cannot explain the reduction of the CpG-induced responses.  This suppression occurred 
when B-class CpG 2007 or when C-class CpG 2429 were used indicating that it is not 
associated with CpG class or sequence.  Similarly, addition of TLR7/8 agonists to 
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purified B-cells 2 or 4 hours after stimulation with CpG suppressed the CpG-induced 
proliferation (Fig. 4.14 B).   
 
 
 
 
 
 
 
 
 
 
Fig.  21  
 
4.5 Discussion 
 
4. 4 A-B:  Proliferative responses by ovine peripheral blood mononuclear cells (PBMC) (A) and 
purified B cells (B). PBMC and CD21+ B cells from 7 animals were stimulated with 5 μg/mL B-class 
CpG2007 or C-class CpG 2429 for 2 or 4 hours before addition of 5 μg/mL imiquimod (Imq). 
Proliferative responses were measured by 3H-thymidine incorporation. **Significant difference between 
treatments (**p<0.05). 
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4.5 Discussion 
In the present study, we investigated innate immune responses induced by TLR 
agonists or their combinations in immune cells from sheep.  The results demonstrated 
for the first time in ovine species that the PP immune responses were poor compared to 
LN and PBMC following stimulation with various TLR agonists despite the expression 
of TLR mRNA. Moreover, multiple stimulations with combinations of TLR agonists 
did not show any significant increase in responses in PP. Interestingly, we observed that 
TLR7/8 agonists in combination with CpG ODN downregulated the CpG-induced 
IFNα, proliferation and IgM responses in PBMC as well as proliferative responses in 
purified B cells.   
The responses in terms of proliferation following CpG stimulation represent 
mainly B cell responses in the tissues tested. Our results showed that PP responses in 
terms of proliferation were significantly less compared to PBMC. These proliferation 
responses were quite surprising as IPP and JPP consist of more than 90% and 70% of B 
cells, respectively, whereas in PBMC, the percent B cells composition varies around 30-
40%.  These results suggested that in PP, either the expression of TLR9 was 
downregulated or the cells were regulated differently. Given that the gut is always 
exposed to PAMPs from commensals, the PP may have evolved mechanisms to dampen 
the immune responses.   
The expression of TLR9 was determined using real-time RT-PCR and our 
results demonstrated that there was expression of TLR9 mRNA in both IPP and JPP 
comparable to the TLR9 expression in the LN and PBMC. These expression profiles of 
the PP and mLN correlate with the TLR profiles reported recently for sheep tissues 
[251, 252]. However none of those reports investigated further into the functional 
properties of the PP and mLN. Therefore our data demonstrated that PP innate 
responses to CpG ODN are poor despite expression of TLR9.   
Similarly, other TLR agonists such as poly(I:C), LPS, ssRNA did not induce any 
significant responses in PP cells. These results suggest that the poor responses of PP are 
not an artifact of CpG ODN or of the TLR9 receptor. Rather it seems that the PP cells 
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have evolved regulatory mechanisms to “ignore” TLR agonists and in this regard they 
respond differently from other sterile immune tissues such as blood and LN. There are 
similar studies that suggest that mucosal cells such as intestinal epithelial cells (IEC) or 
macrophages have adapted to their environment and do not respond directly to TLR 
stimulation [126, 127, 134]. It is worth noting that upon simultaneous stimulation of 
multiple TLR agonists, PP responses were still significantly less compared to PBMC 
and LN and no synergistic responses were observed.  
However in PBMC and mLN, we observed that the CpG-induced immune 
responses were inhibited upon simultaneous stimulation with multiple TLR agonists. 
Co-stimulation of PBMC with TLR7/8 and TLR9 results in reduction in CpG-induced 
IFNα responses and this is in agreement with previous reports using human PBMC or 
pDC [241, 242, 253]. However, our results differ with those of Marshall and colleagues 
[242] who reported that co-stimulation with these agonists did not have any effect on 
human B cells proliferation and IL-6 production. We observed that cell proliferation and 
IgM production were reduced in ovine B cells following co-stimulation of TLR7/8 and 
TLR9, but we were not able to assess IL-6 response by ELISA because reagents were 
not available. The reasons for the difference between responses to TLR co-stimulation 
in human and ovine B cells are not known but may involve cross-talk between the 
receptors. It was suggested that TLR7 agonists antagonized CpG through intracellular 
mechanisms because TLR7 and TLR9 are present on pDC [253].  Intracellular 
interactions or cross-talk between TLR7/8 and CpG mediated signaling may explain the 
down-regulation of B cell responses observed in this study because sheep B cells 
expressed TLR7, TLR8 and TLR9 mRNA.   Absence of cross-talk between TLR7 and 
TLR9 may explain the failure of the TLR7 agonist to antagonize CpG in human B cells 
[242] probably because naïve human B cells do not co-express TLR7 and TLR9.  
Further, we demonstrated the same effect in mLN and thus it was not tissue specific. 
By using a highly purified B cell population we were able to perform 
mechanistic studies which would otherwise be difficult to conduct in mixed cell 
population like PBMC. Two issues are worthy of consideration when co-stimulating 
cells with CpG and imiquimod.  The signaling pathways for TLR7/8 and TLR9 are 
similar in that they are both dependent on the adaptor molecule MyD88 and this may 
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lead to competition between the two agonists for downstream signaling intermediates.  
Secondly, because of its smaller size, imiquimod may be taken up more rapidly and 
engage the downstream signaling intermediate at the expense of CpG [241].  However, 
our results show that kinetic cellular uptake advantage or competition does not explain 
the antagonism mediated by TLR7/8 agonists because the suppression was not only 
observed when the TLR7/8 and CpG agonists were added simultaneously but also when 
cells were sequentially stimulated with CpG for 2-4 hours prior to stimulation with the 
TLR7/8 agonist.  CpG is internalized by cells and engage TLR9 within 30 minutes [254, 
255].  By 4 hours after exposure, CpG will most likely have initiated downstream 
signaling cascades before the TLR7/8 agonist was introduced.   
The interest in multiple TLR stimulation arises from the fact that pathogens 
express multiple PRRs and therefore simultaneous or sequential stimulation of more 
than one TLR (and non-TLR) is highly likely in vivo [241, 242, 253, 256]. Also, co-
infection with more than one pathogen would increase the likelihood of multiple TLR 
stimulation. It is thought that two complementary TLR agonists may induce stronger 
immune responses and better protection than a single TLR agonist.  The requirement for 
multiple signals to induce potent immune responses has been proposed as a mechanism 
by which the immune system exerts a stringent “combinatorial security code” whereby 
at least two microbial products are required to stimulate a strong immune response upon 
encounter with a pathogen [94]. Such synergistic effects would result in robust immune 
responses and lead to better protection against infection. For example, using double 
gene knockout mice (TLR2-/- TLR9-/-), it was shown that TLR2 and TLR9 cooperate 
in the control of pathogen replication following Mycobacterium tuberculosis and 
Trypanosoma cruzi infections [257, 258]. Detailed information regarding combined 
TLR stimulation may have implication in the development of more effective vaccines. 
In this regard, it was recently reported that attenuated live yellow fever vaccine, 
one of the most successful vaccines, simultaneously and potently activates TLR2, 
TLR7, TLR8 and TLR9 on different DC subsets [259]. This may explain why single 
TLR agonist have not been as successful adjuvants or immunotherapeutics in large 
animals and humans as previously expected [260]. While cooperation among TLR 
during infection may result in more robust immune responses and protection, these 
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responses must be downregulated to maintain tissue homeostasis, thereby avoiding 
immunopathology. In this regard, inhibitory effects at the appropriate time would be 
necessary to prevent uncontrolled responses which would otherwise lead to tissue 
injury. Therefore, TLR7/8 signals on top of TLR9 signaling activate down-regulatory 
mechanisms to avoid potential pathological consequences of overstimulation of immune 
responses as suggested by others [261, 262].  
It is not fully understood what exactly determines synergy or inhibition/tolerance 
between TLR agonist combinations. Bagchi et al [95] have recently suggested that the 
outcome may be influenced by the differential requirements of the MyD88-dependent 
(D) and MyD88-independent (I) intracellular signaling pathways. By studying agonists 
in various categories, these investigators found that simultaneous or sequential 
activation of both D and I pathways causes synergistic or complementary responses, 
while tolerance or inhibition is caused by agonists that act through the same pathways 
[95].  Our results are consistent with this pattern, since TLR7/8 and TLR9 all utilize the 
D pathway. 
 
4.6 Conclusion 
 
We have shown that PP respond poorly to TLR agonists despite expressing high 
levels of TLR mRNA. Simultaneous stimulation of TLR agonists was not sufficient to 
elicit innate responses in PP tissues. Moreover we have shown in this study that 
synthetic and natural TLR7/8 agonists activate innate immune responses in sheep which 
was not reported previously. Furthermore, we show that simultaneous stimulation of 
sheep cells with CpG and the TLR7/8 agonists resulted in suppression of responses in 
blood mononuclear cells including purified B cells. 
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CHAPTER 5: A NOVEL REGULATORY B CELL POPULATION IN SHEEP 
PEYER’S PATCHES SPONTANEOUSLY SECRETES IL-10 AND 
DOWNREGULATES TLR-9-INDUCED IFNα RESPONSES. 
 
5.1 Abstract 
Peyer's patches (PP) play an important role in the induction of immune 
responses in the intestine, but regulation of TLR-induced innate immune responses in 
PP is not well understood. We investigated the responses of PP and other immune cells 
to the TLR9 agonist, CpG ODN. PBMC and LN cells secreted significant amounts of 
interferon (IFNα, IFNγ), and interleukin (IL)-12 following stimulation with CpG ODN. 
In contrast, PP cells exhibited poor cytokine responses, despite abundant expression of 
TLR9 mRNA. PP cells spontaneously secreted high levels of IL-10, and the primary 
source of the IL-10 was CD5-CD11c-CD21+ B cells. Neutralization of the IL-10 or 
depletion of CD21+ B cells resulted in a significant increase in CpG-induced IFNα 
response in PP, suggesting that IL-10 from CD21+ B cells regulate innate responses in 
PP. These IL-10-secreting PP CD21+ B cells may represent a novel subset of the 
recently proposed regulatory B cells (Bregs) in the intestine. 
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5.2 Introduction 
 
The innate immune system has an intricate system of receptors called pattern 
recognition receptors (PRR) which have the ability to recognize pathogen-associated 
molecular patterns (PAMPs) as danger signals [4, 18]. On recognition of their 
respective ligands, PRR are capable of inducing a variety of innate immune responses. 
The TLR constitute one such family of PRR and are evolutionarily conserved 
transmembrane glycoproteins molecules [167, 170]. At least thirteen TLR have been 
identified in mammals and they appear to detect distinct microbial components. For 
example, TLR3, TLR4, TLR7/8 and TLR9 recognize double-stranded RNA, 
lipopolysaccharides (LPS), single strand RNA/imidazoquinolines and CpG motifs in 
bacterial DNA, respectively [41, 171-174]. In bacterial DNA, CpG dinucleotides occur 
in the expected frequency (1/16) while in vertebrate DNA, this frequency is reduced 
(1/64). The cytosine in CpG dinucleotides is often methylated in vertebrate DNA [175]. 
Thus, the vertebrate immune system has evolved to specifically recognize CpG 
dinucleotides as a way of detecting the presence of microbial organisms.  
Both in vitro and in vivo studies have demonstrated that CpG ODN are potent 
activators of the innate immune system in numerous species including humans, non-
human primates, mice, cattle, sheep, pigs, horses, dogs, cats, chickens and fish [53, 56, 
176-181]. However, CpG-specific responses differ from species to species and the 
differences in responses seem to be related to TLR9 expression in different cell types. 
For example, in resting human cells, B cells and plasmacytoid dendritic cells (pDC) are 
the two cell types that predominantly express TLR9 and are directly activated by CpG 
ODN [43, 92]. In contrast, in mice, a wide variety of cell types express TLR9 and are 
activated directly by CpG ODN including B lymphocytes, monocytes, macrophages, 
myeloid dendritic cells, NK cells, T-regulatory cells, intestinal and pulmonary epithelia 
and even mast cells [62, 103, 263-265]. All of these cell types express functional TLR9 
and this explains why CpG ODN are so potent in mice. TLR9 expression in ruminants 
has been recently reported [93, 251] and appears to have an expression pattern similar to 
that of humans [93]. We recently reported that sheep lymph node cells respond well to 
all three classes of CpG ODN and with higher magnitude than PBMC [203, 238]. 
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However, responses in gut-associated lymphoid tissues (GALT) to TLR9 ligand 
stimulation have not been explored in detail. 
The intestinal tract is constantly exposed to microbial flora and must have 
mechanisms in place to prevent unnecessary and potentially damaging immune 
responses to harmless commensal flora and dietary antigens. Several mechanisms have 
been proposed including downregulation of TLR receptor expression in lamina propria 
macrophages [126], lack of innate receptor expression (CD14, Fcα, Fcγ, CR3 and CR4) 
in intestinal macrophages [127], restricted distribution of TLR expression in intestinal 
epithelial cells [86, 266, 267] and modulation of intestinal epithelia cells by commensal 
microflora [268]. However whether such regulation of immune responses occurs in PP 
is not fully understood. 
PP are the primary site where adaptive immune responses are induced in the 
intestine of ruminants [110]. Given the role of this tissue in the initiation of immune 
responses and the importance of TLR in the initiation and development of innate and 
adaptive immune responses, a detailed understanding of how PP cells respond to TLR 
agonists would provide insights into the regulation of immune responses in intestine. 
Contractor et al recently reported that murine PP pDCs, unlike splenic pDCs, 
were incapable of producing interferon (IFNα) following stimulation with CpG ODN, 
presumably due to the suppressive effects of interleukin (IL)-10 in the PP environment 
[143]. Recently, IL-10-secreting B cells with a regulatory role have been described in 
murine models of chronic intestinal inflammation [152]. We report that PP CD21+B 
cells isolated from normal intestinal tissue spontaneously secrete IL-10, which in turn 
suppresses CpG-induced innate responses. 
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5.3 Materials and methods 
 
5.3.1 Oligodeoxynucleotides 
 
A-class (2216), B-class (2007) and C-class (2429) CpG ODN have previously 
been shown to be biologically active in sheep PBMC and LN in vitro and in vivo [210, 
211, 238]. Table 3.1 shows the sequences of the six ODNs used in these studies (See 
section 3.3.1). CpG ODN sequences 2007, 2216 and 2336 were obtained from Merial 
Limited (Lyon, France), while CpG ODN sequence 2429 were provided by Coley 
Pharmaceutical group (Wellesley, MA, USA) and control non-CpG ODNs 2007GC and 
2216GC were purchased from Operon (Alameda, CA, USA).  
 
5.3.2 Animals  
 
Suffolk sheep of either sex (3 to 4 months of age) were obtained from the 
Department of Animal and Poultry Science (University of Saskatchewan, Saskatoon, 
SK, Canada). The animals were housed at the Vaccine and Infectious Disease 
Organization (VIDO) animal facility and fed ad libitum on a ration of rolled barley and 
alfalfa hay. All experiments were carried out according to the Guide to the Care and 
Use of Experimental Animals, provided by the Canadian Council on Animal Care. 
Experimental protocols were approved by the University of Saskatchewan Animal Care 
Committee and animals were housed in the same pen throughout each experiment. 
 
5.3.3 Isolation of PBMC, JPP, IPP and LN cells 
 
Blood was collected from the jugular vein of sheep in ethylene diamine 
tetraacetic acid (EDTA)-treated vacutainer tubes (BD Biosciences, Mountain View, CA, 
USA) and PBMC were isolated using 54% isotonic PercollTM (Pharmacia Biotech AB, 
Uppsala, Sweden), as described previously [201, 212]. Cells were counted using a cell 
counter (Dual Diluter III, Coulter electronics Ltd, Luton, England) and resuspended in 
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Aim-V medium (GibcoBRL, Burlington, ON, Canada) containing 2% fetal bovine 
serum (FBS; GibcoBRL). 
Sheep were euthanised and scLN and mLN were removed and placed in ice-cold 
minimum essential medium (MEM, GibcoBRL) containing the antibiotics 100 IU/mL 
Penicillin, 100 µg/mL Streptomycin sulfate and 0.25 µg/mL Amphotericin B (Sigma-
Aldrich, St Louis, Missouri, USA). Cells were isolated from LN by finely mincing 
tissue with a scalpel, filtering the cell suspension through a 40-µm nylon cell strainer 
(Becton Dickinson Labware, Franklin Lakes, NJ, USA) and washing cells with 
Dulbecco’s Phosphate Buffered Saline (PBSA) (pH 7.2), as described previously [213]. 
JPP and IPP tissues were also removed and placed in MEM (GibcoBRL) containing 
antibiotics (100 IU/mL Penicillin, 100 µg/mL Streptomycin sulfate, 0.25 µg/mL 
Amphotericin B) (Sigma-Aldrich). The PP cells were also isolated from the same sheep 
as described previously [110, 245]. The number of viable cells in all tissues was 
determined by trypan blue dye exclusion and counting with a hemocytometer under a 
light microscope. Cells were resuspended in AIM V medium containing 2% FBS. 
 
5.3.4 Tissue culture conditions 
 
Stimulation of PBMC, JPP, IPP and LN cells was performed in 96-well, round 
bottom plates (Nunc, Naperville, IL, USA) using AIM V medium supplemented with 
2% FBS, 100 IU/mL Penicillin, 100 µg/mL Streptomycin sulfate, 0.25 µg/mL 
Amphotericin B, 2mM L-glutamine, 50µM 2-Mercaptoethanol and 10µg/mL 
Polymyxin B Sulfate (Sigma-Aldrich). For the dose titration experiment, PBMC and 
LN were incubated with either 0.66, 2.0, 6.0 or 18.0 µg/mL of each type of CpG ODN 
(2336, 2007, 2429, 2007GC) for 48 hrs at 37°C in an atmosphere of 5% CO2 and 95% 
humidity. Forty eight hours was previously shown to be optimal time for detection of 
cytokine secretion in ovine PBMC stimulated with CpG ODN [200]. For each 
treatment, 5x105 cells were cultured in triplicate wells in 200 µL total volume. Culture 
supernatants were harvested and stored at –20oC until assayed for IFNα, IFNγ. 
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5.3.5 Enzyme-linked immunosorbent assay (ELISA) for IFNα, IFNγ, IL-10 and IL-12 
 
The IFNα, IFNγ, IL-10 and IL-12 ELISA assays used during this study were 
previously shown to detect ovine and bovine IFNα, IFNγ and IL-12 cytokines as 
described elsewhere [210, 213, 214, 249]. Briefly, polystyrene microtiter plates 
(Immulon 2; Dynex Technology Inc, Chantilly, USA) were coated with capture 
antibody. For IFNγ ELISA, mouse anti-bovine IFNγ antibody (clone 2-2-1) [213] and 
for IFNα ELISA, two mouse anti-bovine IFNα antibodies (clones IFN-1C6 and IFN-
1D10) were diluted in coating buffer [215]. For IL-12, mouse anti-recombinant bovine 
IL-12 antibodies (Serotec MCA 1782EL, NC, USA) were diluted to 8 µg/mL in coating 
buffer. For IL-10, mouse anti-bovine IL-10 antibodies (Serotec MCA 2110, NC, USA) 
were diluted to 0.5 µg/mL in coating buffer and applied to Maxisorp 96U plates (Dynex 
Technology Inc, Chantilly, USA).  Plates were washed with Tris buffer saline/0.05 % 
Tween 20 (Sigma-Aldrich) (TBST) at all steps. Recombinant bovine IFNγ (bIFN-γ), 
bovine IFNα (bIFN-α) (Ciba Giegy) and recombinant human IL-12 (rHuIL-12) (Serotec 
PHP 100) and recombinant bovine IL-10 (Kindly donated by J.C. Hope, Institute for 
Animal Health, Compton, UK) were used as standards. Standards and samples were 
diluted in TBST/0.5% gelatin (Sigma-Aldrich) (TBST-g) and added to the wells. For 
IFNγ and IFNα ELISA, the captured cyokines were detected in two steps, first by 
addition of rabbit anti-bovine IFNγ antisera 92-131 [203] or rabbit anti-bovine IFNα 
antisera 92-133 [211] followed by addition of biotinylated goat-anti rabbit IgG (Zymed, 
California, USA).  For IL-12 and IL-10 ELISA, the captured cytokines were detected in 
one step by using biotinylated mouse anti-bovine IL-12 clone CC326 (Serotec MCA 
2173B) or biotinylated mouse anti-bovine IL-10 clone CC320 (Serotec MCA 2111B). 
Strepavidin-alkaline phosphatase (Jackson ImmunoResearch, Westgrove, PA) were 
used for detection. The assay was developed by using p-nitrophenyl phosphate (Sigma-
Aldrich) substrate in 1 % diethanolamine (Sigma-Aldrich) and 0.5 mg/mL magnesium 
chloride. The reaction was stopped by adding 0.3M EDTA to each well. Optical density 
of the reaction product was measured at 405 nm using a 490 nm reference on a 
Benchmark microplate reader (Bio-Rad Laboratories, Hercules, CA, USA). Sample 
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concentrations were calculated using Microplate Manager 5.0.1 version software (Bio-
Rad). 
 
5.3.6 IFNα  ELISPOT Assay and neutralization of IL-10 
 
IFNα-secreting cells (ISC) were detected using an ELISPOT assay. Microtiter 
nitrocellulose filtration plates (Whatman, Clifton, NJ) were coated overnight with two 
monoclonal mouse anti-bovine IFNα antibodies (clones IFN-1C6 and IFN-1D10) and 
were both diluted to 1:1000. Wells were washed with RPMI complete media to remove 
free protein before adding 1×106 cells/well to triplicate wells, in a final volume of 
200 μl culture medium. Cultures were incubated for 24 h at 37 °C in a humidified 
atmosphere with 5% CO2 before removing the cells. Total ISC were detected by first 
adding biotinylated goat anti-rabbit IgG (H+L chain specific; 1:5000 dilution; Zymed, 
South San Fransisco, CA, USA), followed by AP–conjugated streptavidin (1:1000 
dilution; Jackson Immunoresearch Lab., Westgrove, PA), and finally ISC were 
visualized with 5-bromo-4-chloro-3-indolyl phosphate/nitroblue tetrazolium 
(BCIP/NBT) insoluble alkaline-phosphatase (AP) substrate (Sigma–Aldrich). The 
frequency of CpG-specific ISC per 1×106 cells was calculated by subtracting the 
number of spots present in wells stimulated with GpC controls and media from the 
number of spots present in CpG-ODN stimulated wells. An inverted light microscope 
was used to count three replicate wells for each cell population and data presented are 
mean values for replicate samples. To inhibit the action of IL-10, neutralizing mouse 
anti-bovine IL-10 antibody (Serotec, MCA 2111EL) was added at 1/200 dilution with 
CpG ODN to cell cultures. 
 
5.3.7 Magnetic activated cell sorting (MACS) 
 
The CD21+ B cell fraction was isolated as described previously [246]. Briefly 
JPP and PBMC were stained with mouse anti-bovine antibody (IgG1, AbD Serotec, 
UK) for 15 min at 40C. The cells were then washed twice with MACS buffer (PBSA, 
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0.5M EDTA and 10% BSA) and followed by centrifugation for 8 min at 440 x g. The 
cells were then stained with goat anti-mouse IgG1 phycoerythrin (PE) conjugate 
(Southern Biotech, A1, USA) for 15 min at 40C and wash again as above. The cells 
were then labeled with anti-PE magnetic beads for 15 min at 40C and eluted through the 
LC MACS column (Miltenyi Biotec, Bergish Gladbach, Germany) according to 
manufacturer’s instruction. The CD21+ B cell fraction was eluted, washed in PBSA and 
re-suspended in AIM V media containing 2% FBS. The purity of the cells was above 
94% as assessed by flow cytometry. 
 
5.3.8 Quantitative RT-PCR 
 
RT-PCR was used to quantify TLR9 mRNA in IPP, JPP, mLN, jejunum (small 
intestine between PP), duodenum, and colon. TLR9 mRNA was also assessed in single 
cell suspensions prepared from these tissues [IPP, JPP, mLN, and PBMC]. 
 
5.3.8.1   mRNA isolation and cDNA synthesis 
 
Total RNA was isolated from either homogenized tissues (IPP, JPP, mLN) or 
from isolated cell suspensions (PBMC, IPP, JPP, mLN) using Trizol reagent 
(Invitrogen, Carlsbad, CA) and RNA samples were treated with DNAse I Amp Grade 
(Invitrogen) (1 U/μg of RNA). The absence of genomic DNA contamination was 
validated by use of treated RNA as template directly in PCR. No amplified product was 
present. RNAs were quantified by determining optical density at 260 nm (OD260) and 
the OD260/OD280 ratio was calculated to assess purity. Further, RNA quality was 
assessed by capillary electrophoresis (Agilent 2100 Bioanalyzer). For complementary 
DNA (cDNA), RNA (1 μg) was incubated in a final volume of 15 μl with dNTP 
(0.5 mM final each) (Invitrogen), 0.5 μg oligo dT (Invitrogen), RNAse out inhibitor 
(20 U) (Invitrogen), Superscript TM reverse transcriptase (RT) (8 U) (Invitrogen), and 1× 
buffer RT (Invitrogen). The reaction was allowed to proceed for 40 mins at 42 °C and 
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then heat inactivated at 93 °C for 5 min. The cDNA generated was either used 
immediately for qPCR or stored at −80 °C.  
 
5.3.8.2. Real-time RT-PCR 
 
The cDNA generated as above were used in the Real-time PCR. cDNA was 
combined with primer/probe sets and IQ SYBR Green Supermix (Bio-Rad, Hercules, 
CA) according to the manufacturer's recommendations. All primers were designed 
using Clone Manager (Scientific and Educational Software, Cary, NC). TLR9 forward 
primer 5’ CGTGAGCAGCAACAGCATC 3’ and reverse primer 5’ 
TAAGCGACCGAACCAGAAGG 3’ were purchased from Sigma–Aldrich. The PCR 
conditions were 95 °C for 3 min, followed by 45 cycles with denaturation at 95 °C for 
15 s, annealing temperature at 59°C for 30 s, and elongation at 72 °C for 30 s. Real-time 
assays were run on a Bio-Rad iCycler iQ system (Bio-Rad, Hercules, CA). The 
specificity of the PCR reactions was assessed by the analysis of the melting curves of 
the products and size verification and sequencing of the amplicons. To normalize the 
amount of cDNA, we sampled equal tissue sizes, quantitated RNA, assessed its quality 
prior to reverse transcription, and used a reference gene. Samples were normalized 
internally using the average cycle threshold (Ct) of glyceraldehyde-3-phosphate 
dehydrogenase (GAPDH) as a reference in each tissue. To quantify the numbers of 
copies, plasmid containing sheep TLR9 cDNA were linearized with XhoI (New England 
Biolabs) and 10 two-fold dilutions of the plasmid were used to create a standard curve 
for quantification of the RNA-generated cDNA. Values were expressed as transcript 
copy number per 1µg of total input RNA, which were determined in each sample by 
interpolation with the respective standard curves. The correlation coefficient of TLR9 
standard curve was 0.996. The concentration of the test samples were calculated from 
the standard curves, according to the formula y = −MCt + B, where M is the slope of the 
curve, Ct the point during the exponential phase of amplification in which the 
fluorescent signal is first recorded as being statistically significant above background, 
and B is the y-axis intercept. Only Ct values <40 were used for calculation of the PCR 
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efficiency from the given slope according to the equation: PCR 
efficiency = (10[−1/M] − 1) × 100. All PCRs displayed efficiency between 94% and 
100%.  
 
5.3.9 Statistical analysis 
Data were analyzed using the statistical software program GraphPad Prism 5 
(Graphpad, San Diego, CA, USA).  One way ANOVA (Kruskal-Wallis) and Dunn’s 
multiple comparison tests were performed on each treatment and tissue. Differences 
were considered significant when p<0.05.  
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 5.4. Results 
 
5.4.1 IFNα  and ΙFNγ  secretion is reduced in Peyer’s patch cells stimulated with CpG 
ODN 
 
We determined IFN responses of IPP and JPP cells stimulated with 2 µg/mL of 
CpG ODN and compared responses to those of LN cells. Both scLN and mLN exhibited 
IFNα responses that were significantly greater (p<0.05) than both JPP and IPP cells 
(Fig. 5.1 A). The IFNα responses of JPP cells were not significantly different from IPP.  
Stimulation of scLN and mLN cells with CpG ODN resulted in a significantly higher 
production (5-10 fold) of IFNγ than cells from either ileal of jejunal PP (Fig. 5.1 B). 
However, JPP cells produced significantly more IFNγ when compared to IPP cells (Fig. 
5.1 B).  Thus CpG-induced IFNα and IFNγ secretion by Peyer’s patches cells was 
significantly reduced when compared to LN cells.  
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Fig. 5.1 A-B: IFNα and IFNγ secretion by ovine IPP, JPP and LN cells following stimulation with 2.0 
µg/mL of CpG ODN (2429). Data represent individual values for 12 animals (n=12). Horizontal bar 
represents mean value for each tissue and significant difference (p<0.05) relative to ileal Peyer’s patches 
are represented by boxed *. 
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5.4.2 Reduced cytokine responses of PP cells are not due to suboptimal CpG ODN 
concentration.  
 
In the experiment described above, the concentration of CpG ODN used was 2 
µg/mL as this was reported to be optimal for induction of immune responses in LN and 
PBMC [203, 238]. We reasoned that PP cells may require a higher dose of CpG ODN 
for optimal response. For this reason, we performed a dose titration experiment using 
CpG ODN concentrations of 0 .66, 2.0, 6.0 and 18.0 µg/mL. 
As shown in Fig. 5.2 A, IPP cells did not secrete detectable IFNα when 
stimulated with increasing concentrations of any of the three classes of CpG ODN. 
Although with JPP cells both 2 and 6 µg/mL of CpG ODN induced production of IFNα, 
there was no significant difference between the two ODN concentrations (Fig. 5.2 B). 
All three classes of CpG ODN induced IFNα secretion by mLN cells (Fig. 5.2 
C). The optimal dose of CpG ODN was 2 µg/mL and increasing the concentration of 
ODN did not significantly enhance the response. Similarly, with PBMC, 2 µg/mL of 
CpG ODN induced an optimal IFNα response and increasing concentration of ODN did 
not significantly increase the response (Fig. 5.2 D).  
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Fig. 5.2 A-D: IFNα secretion by ovine IPP, JPP, mLN cells and PBMC following stimulation with 
varying concentrations of all three classes of CpG ODN (A: 2336, B: 2007 and C: 2429). Data represent 
median values for cells isolated from 8 animals and assayed with each concentration of CpG ODN. 
 
IFNγ secretion in response to various concentrations of CpG ODN followed a 
pattern similar to that seen for IFNα. IPP cells did not produce detectable levels of IFNγ 
regardless of the type and concentration of CpG ODN used for stimulation (Fig. 5.3 A). 
Concavalin A (Con A) stimulation confirmed that the cells were viable and capable of 
secreting IFNγ (Fig. 5.3 A-D). Con A induced IFNγ but not IFNα (Fig. 5.3 A-D) from 
all tissues tested. JPP cells did secrete detectable levels of IFNγ when stimulated with 2, 
6 and 18 µg/mL of CpG ODN but the responses were not significantly different with 
each concentration (Fig. 5.3 B).  A- and C-class CpG ODN induced JPP to secrete 
higher levels of IFNγ higher than B-class (Fig. 5.3 B) and all three classes of CpG ODN 
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induced similar IFNγ responses in mLN cells (Fig. 5.3 C). The optimal CpG ODN dose 
was between 2-6 µg/mL of ODN for mLN cells.  
 PBMC showed low IFNγ responses when stimulated by A- and C-class of 
CpG ODN (Fig. 5.3 D) as previously reported [238]. Therefore regardless of the 
concentration or class of CpG ODN, interferon secretion (IFNα and IFNγ) by PP cells 
was significantly lower when compared to cells isolated from LN.  
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Fig. 5.3 A-D: IFNγ secretion responses by ovine IPP, JPP, mLN cells and PBMC following stimulation 
with varying concentrations of all three classes of CpG ODN (A: 2336, B: 2007 and C: 2429). Data 
represent the median value for cells isolated from 8 animals and assayed at each concentration of CpG 
ODN. 
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5.4.3 IL-12 secretion is also reduced in PP stimulated with CpG ODN 
 
 It has been recently reported that pDC in mouse Peyer’s patches stimulated 
with CpG ODN do not produce IFNα but secrete significant amount of IL-12 [143]. 
Therefore we investigated whether CpG ODN could induce detectable IL-12 secretion 
by sheep PP cells.  
 As shown in Fig. 5.4 A, IPP cells did not secrete significant levels of IL-12 
when stimulated with B- and C-class CpG ODN, but these ODNs induced significant 
IL-12 production by JPP cells (Fig. 5.4 B). This response was CpG-specific as the GpC 
control did not induce any IL-12 (Fig. 5.4 B).  
 When comparing IL-12 secretion among tissues stimulated by B- and C-
class CpG ODN (Fig. 5.4 C-D), secretion of IL-12 was significantly lower with IPP 
cells than the other three tissues. Following stimulation by CpG ODN, mLN secreted 
significantly higher levels of IL-12 than PBMC and JPP (Fig. 5.4 C-D).  In turn, PBMC 
secreted higher levels of IL-12 than JPP when stimulated with CpG ODN (Fig. 5.4 C-
D). Therefore, IL-12 secretion by PP cells was lower than cells isolated from other 
tissues and followed a trend similar to the IFNα and IFNγ responses.  
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Fig. 5.4 A-D: IL-12 secretion by ovine IPP, JPP, mLN cells and PBMC following stimulation with B- 
and C-class CpG ODN (B: 2007 and C: 2429) at 2 µg/mL. Data represent the mean value for cells 
isolated from 8 animals. Significant difference (p<0.05) relative to (i) GpC ODN in Fig. 5.4 A-B and (ii) 
ileal Peyer’s patches in Fig. 5.4 C-D are represented by boxed *.  ** Significant difference relative to 
both PP. 
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5.4.4 Peyer’s patches have a lower frequency of IFNα producing cells 
  
We hypothesized that the reduced IFNα response in PP is a consequence of 
either a lower frequency or a lack of IFNα-secreting cells in the tissue. Therefore we 
assessed the number of IFNα producing cells in the various tissues using an ELISPOT 
assay. 
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Fig. 5.5 A-D: Frequency of IFNα producing cell in ovine IPP, JPP, PBMC, and mLN following 
stimulation with either 2 µg/mL of CpG ODN (A: 2336; C: 2429), 2216GpC or medium alone. Values 
for cells from individual animals are presented with mean value indicated by horizontal bar for each 
treatment group (n=6).  Significant difference in IFNα producing cells per million cells relative to GpC 
controls are indicated by boxed * (P<0.05). 
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 A significant number of IFNα−secreting cells were detected in IPP following 
stimulation with CpG ODN versus medium alone (Fig. 5.5 A). This response was CpG 
specific as the GpC control did not induce any detectable responses (Fig. 5.5 A). 
Similarly, significant numbers of IFNα-secreting cells were detected in JPP, PBMC and 
mLN stimulated with CpG ODN (Fig. 5.5 B-D).  
 When comparing among tissues, following CpG ODN stimulation (Fig. 5.6), 
it was found that the frequency of IFNα-secreting cells was significantly lower in IPP 
than all the other tissues. mLN contained significantly higher IFNα−secreting cells than 
PBMC and JPP. In turn, PBMC had a significantly higher frequency of IFNα-secreting 
cells than JPP following stimulation with CpG ODN (Fig. 5.6). ELISPOT analysis of 
ISC frequency was consistent with data for ELISA analysis of cytokines (Fig. 5.1 A). 
 
 
 
 
 
 
 
 
Fig. 27 
 
 
 
 
 
 
5.4.5 Peyer’s Patches express high levels of TLR9 mRNA. 
 
All the data so far (Fig. 5.1-5.6) clearly indicated that IPP and JPP responses to 
CpG ODN stimulation were significantly lower when compared to cells isolated from 
LN regardless of CpG ODN concentration or class. We reasoned that IPP and JPP cells 
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Fig. 5.6: Frequency of IFNα producing cells in ovine IPP, JPP, PBMC, and mLN following stimulation 
with 2 µg/mL of CpG ODN (2429). Data for individual animals are presented with mean value 
indicated by horizontal bar for each group (n=6).  Significant differences in IFNα producing cells 
relative to IPP are indicated by * (P<0.05). ** represent significant difference between PBMC and both 
PP whereas *** represent significant difference between mLN and all other tissues. 
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may lack sufficient TLR9 expression to respond effectively to CpG ODN stimulation.  
Therefore, we evaluated TLR9 mRNA expression in cells isolated from different 
tissues. RNA isolated from IPP, JPP, blood and mLN tissue all expressed significantly 
higher copy numbers (p<0.05) of TLR9 than duodenum, jejunum and colon (Fig. 5.7 
A). Interestingly, IPP and JPP tissue expressed similar levels of TLR9 mRNA as mLN 
and PBMC.  
 Since the CpG stimulation experiments were done with cells suspensions 
isolated from tissues, we wondered whether TLR9 expression in those cell suspensions 
differed from that in intact tissues.  
 As shown in Fig. 5.7 B, cell suspensions had significantly higher expression 
of TLR9 mRNA than intact tissues but the overall pattern of expression was similar. 
Thus these data confirmed that the cell populations used expressed TLR9. Therefore, 
poor CpG-induced interferon responses in PP were unlikely due to lack of TLR9 
receptor expression (Fig. 5.7 A-B).   
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Fig. 5.7 A-B: TLR9 mRNA expression in ovine IPP, JPP, PBMC, mLN, duodenum, jejunum and colon. 
Data for individual animals are presented with mean value indicated by horizontal bar for each treatment 
group (n=6). Significant TLR9 mRNA expression relative to duodenum and colon is indicated by a boxed 
* (P<0.05). B: TLR9 mRNA expression in ovine IPP, JPP, mLN and their respective cells suspension. 
Data for individual animals are presented with mean value indicated by horizontal bar for each treatment 
group (n=6). Significant TLR9 mRNA expression in the cells suspension relative to their respective tissue 
is indicated by a boxed * (P<0.05). 
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5.4.6 Role of IL-10 in regulation of CpG-induced responses in Peyer’s Patches 
 
5.4.6.1 Kinetics of IL-10 production in PP 
 
 One factor which could contribute to the reduced CpG ODN induced 
cytokine responses by PP cells could be the presence of immunoregulatory cytokines 
such as IL-10.  Therefore we evaluated the kinetics of IL-10 secretion in cultures of IPP, 
JPP, mLN cells and PBMC at different time points (6, 16, 24 and 48 hrs) following 
stimulation with CpG ODN. In PBMC and mLN cultures, significant IL-10 was not 
detected until after 48 hrs (Fig. 5.8 C-D) whereas with JPP and IPP cells, significant IL-
10 was detected as early as 16 hrs of culture (Fig. 5.8 A-B) when stimulated with CpG 
ODN. In fact, IPP cells had detectable levels of IL-10 as early as 6 hrs of culture (Fig. 
5.8 A) and the level of IL-10 production was higher than all other tissues at all time 
points (Fig. 5.8 A-D). 
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Fig. 5.8 A-D: Kinetics of IL-10 secretion by IPP, JPP, mLN and PBMC stimulated with CpG ODN 
(2429). Data for individual animals are presented with mean value indicated by horizontal bar for each 
treatment group (n=8). Significant difference in IL-10 secretion relative to 6 hrs time point is indicated by 
* p<0.1 and ** p<0.05. U/mL for IL-10 was previously defined by Kwong et al [249], as the biological 
activity of IL-10 which is represented by one unit being the reciprocal of the dilution that inhibited IFNγ 
by 50%. 
  
 Surprisingly, we observed that unstimulated PP cells produced detectable 
levels of IL-10 whereas with PBMC detectable IL-10 production occurred only after 
CpG ODN stimulation (Fig. 5.9). Therefore, PP cells spontaneously secreted IL-10 as 
early as 6 hrs in cultured cells. 
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Fig. 5.9: Kinetics of IL-10 secretion by IPP, JPP, mLN and PBMC cultured in medium. 
 
5.4.6.2 IL-10 inhibits IFNα production in PP 
 
 The kinetics of IL-10 production indicated that this cytokine was secreted 
very early in PP cell cultures. Therefore, we hypothesized that IL-10 may suppress the 
induction of IFNα. We evaluated the effect of neutralizing IL-10 on CpG-induced IFNα 
response. The optimal concentration of neutralizing IL-10 antibody was evaluated by a 
titration experiment and 1/200 dilution of the antibody was found to be optimal (Data 
not shown). As previously observed, CpG ODN (2429) alone induced IFNα-producing 
cells (IPC) in IPP, JPP and PBMC (Fig. 5.10 A-C). Neutralization of IL-10 resulted in a 
significant increase in CpG-induced INFα producing cells in IPP, JPP (Fig. 5.10 A-B) 
but not PBMC (Fig. 5.10 C). Therefore IL-10 appeared to play a direct role in inhibiting 
IFNα secretion by PP cells. 
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Fig. 5.10 A-C: IFNα producing cells responses in ovine IPP, JPP and PBMC following stimulation with 
2 µg/mL of CpG ODN (C: 2429) and/or anti-IL-10 antibody (1/200) or isotype control antibody (IC) or 
media alone. Data for individual animals are presented with mean value indicated by horizontal bar for 
each treatment group (n=7).  Significant differences in IFNα producing cells per million cells relative to 
2429CpG + IC are indicated by boxed * (P<0.05).  
 
5.4.7 Peyer’s patch CD21+ B cells are the major source of the IL-10 
 
 We then investigated what was the predominant cell type in PP responsible 
for IL-10 production.  As shown before, JPP cells secreted IL-10 regardless of CpG 
ODN stimulation (Fig. 5.11 A) whereas PBMC secreted IL-10 only after CpG 
stimulation (Fig. 5.11 D). When MACs purified CD21+ B cells from both tissues were 
stimulated with CpG ODN, we observed that unstimulated JPP CD21+ B cells secreted 
IL-10 (Fig. 5.11 B) whereas PBMC CD21+ B cells did not secrete IL-10, even after 
CpG ODN stimulation (Fig. 5.11 E). Induction of IL-10 in PBMC may require 
involvement of more than one cell type since neither of the fractionated PBMC 
populations produced IL-10 (Fig. 5.11 D-F). 
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Fig.  
 
 
5.4.8 CD21+ Peyer’s patch B cells inhibit CpG-induced IFNα, IFNγ  and IL-12 
responses in JPP. 
 
 We depleted CD21+ PP B cells from JPP cells and using equivalent cell 
numbers, we tested whether CD21+ cells had any effect on the CpG-induced responses 
in JPP. As shown in Fig. 5.12 A, IFNα responses in JPP CD21- cells were significantly 
higher than in JPP upon stimulation with CpG ODN 2429 whereas no IFNα was 
secreted by CD21+ cells. Similar results were obtained when CpG-induced IFNγ and IL-
12 responses were assessed in CD21- cells compared to JPP (Fig. 5.12 B and 5.12 C). 
CD21- cells secreted significantly higher level of IFNγ and IL-12. These results suggest 
strongly that CD21+ B cells play a regulatory role in this tissue.  
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Fig. 5.11 A-F: Using MACs isolation, purified CD21+ B cells from JPP and PBMC were obtained. JPP 
CD21+ B cells secrete IL-10 spontaneously whereas PBMC CD21+ B cells do not. Data represent the mean 
of 7 animals for IL-10. 
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Fig. 5.12 A-C: Using MACs isolation, CD21+ B cells were depleted from JPP. JPP, JPP-CD21+ B cell, 
JPP-CD21- cell fractions were assessed for IFNα, IFNγ and IL-12 following 5μg/ml of CpG ODN (2429). 
Data represent the mean of 6 animals. Boxed * represent significant difference (p<0.05) between CD21- 
fraction and whole JPP cells.  
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5.4.9 Characterization of CD21+ B cells from JPP and PBMC by FACs analysis 
 
 Phenotypic characterization of JPP B cells by flow cytometry revealed that 
the IL-10-secreting B cells were CD21+ CD72+MHCII+ (Fig. 5.13).  
 
 
 
 
 
 
 
95.1 
  97.2 
29.5 
Fig. 5.13: Isolated JPP CD21+ B cells with purity of 97.2% co-labelled with anti-CD11c, MHCII, sIgM 
and CD72 FITC. 
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Further phenotypic characterization of PBMC CD21+ B cells by flow cytometry 
revealed that the B cells were CD21+ CD72+CD11c+MHCII+sIgM+ (Fig. 5.14). 
 
 
 
 
Fig. 5.14: Isolated PBMC CD21+ B cells with purity of 90.2% co-labelled with anti-CD11c, MHCII, 
sIgM and CD72 FITC. 
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5.5 Discussion 
 
Our investigations revealed that JPP CD21+ B cells secrete IL-10 which plays a 
direct role in the suppression on IFNα secretion by JPP cells. Moreover, this B cell 
population spontaneously secretes IL-10 in the absence of TLR stimulation. 
In sheep, CD21+ B cells are representative of naïve B cell population and are 
mainly CD5- , CD11b-, CD11c-, sIgMlo and CD62L+ [269]. They localize in the B cell 
follicles of Peyer’s patches, lymph nodes and spleen and are actively recirculating in 
blood and lymphatic system [112, 270, 271]. In this study, we found that unstimulated 
CD21+ B cells from PP cells secrete high amount of IL-10 whereas unstimulated CD21+ 
B cells from blood do not secrete IL-10. The IL-10-secreting CD21+ B cells in Peyer’s 
patches may represent a novel population of B cells analogous to the recently proposed 
regulatory B cells (Bregs) [140, 152, 154]. Typically B cells are known mainly for 
producing antibodies but they have the ability to produce cytokines and function as 
antigen presenting cells. It is now known that like T cells, the B cell population consists 
of distinct subsets capable of performing pathogenic and regulatory functions [152]. 
Bregs have been observed in several murine models of chronic inflammation including 
inflammatory bowel disease, but not in normal intestinal tissue [152]. One of the 
mechanism by which Bregs mediate their regulatory functions is via production of the 
regulatory cytokines IL-10 and TGFβ which dampen inflammation [272-275]. Here, we 
propose a novel B cell population capable of secreting IL-10 in the steady state and 
which may perform regulatory functions similar to murine Bregs. However, there appears 
to be a major difference between the two: sheep PP Bregs constitutively occur in normal 
intestinal tissues in the absence of any known pathology and spontaneously secrete IL-
10 in the absence of TLR9 stimulation. In contrast, murine Bregs are associated with 
chronically inflamed intestinal tissue and are not present in steady state [272]. Further 
investigation is required to characterize the function of these sheep PP Bregs. 
  Our investigation revealed that IL-10 directly suppressed IFNα responses in PP. 
IL-10 is an immunoregulatory and anti-inflammatory cytokine. The major known 
sources of IL-10 are dendritic cells, regulatory T cells and macrophages [116, 276, 277]. 
IL-10 can affect a variety of cell types including monocytes, macrophages, dendritic, 
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neutrophils. It potently inhibits production of a variety of cytokines (IL-1, IL-6, IL-12, 
IL-18, TNF) [278-281] and chemokines (IL-8, IP-10, Mip3α, Rantes) [282-284], 
thereby affecting recruitment of neutrophils, DC, and monocytes. IL-10 induces the 
generation of regulatory T cells that can suppress antigen specific responses in vivo and 
in vitro [285-287].  IL-10 also plays an important role in regulating mucosal responses 
as indicated by numerous studies with IL-10 deficient (IL-10-/-) mice which develop 
spontaneous intestinal inflammation [139, 288, 289]. Our observation that IL-10 
inhibited IFNα responses is consistent with Contractor et al (2007) who showed that IL-
10 inhibited IFNα production spleen pDCs, and also implicated IL-10 in the inability of 
pDCs from PP to produce IFNα although they did not evaluate the direct effect of IL-10 
on PP pDCs. Recently Monteleone et al., 2008 showed that  lamina propria DC failed to 
secrete IL-12 in response to CpG and this was attributed to inhibitory IL-10 secreted by 
these cells and the authors also showed that unlike spleen or LN, mucosal DC expressed 
high levels of TLR2, 3, 4, 5 and 9 but responded poorly to agonists for these TLR [267].  
However this study did not investigate the effect of IL-10 on IFNα in DC or other cells 
in PP.  
IFNα, a type I interferon, is known for its role in antiviral defences, but can also 
activate innate and adaptive immune responses [290]. IFNα, together with IL-12 can 
induce NK cell cytotoxicity and also augment Th1-mediated immunity through innate 
production of IFNγ by NK cells and CD8+ cells. IFNα can also act independently of IL-
12 to activate cDC maturation and cross-presentation and to enhance CD8+ T cell 
responses. Therefore, inhibition of IFNα in the PP may skew the balance of immune 
responses from potentially damaging Th1 type responses.  
JPP but not IPP are the primary sites where immune responses are initiated in 
the gut [110]. We would therefore expect that cells from PP would respond to a potent 
activator like CpG ODN in a manner similar to other secondary lymphoid tissues like 
LN. In this study we show that CpG-induced responses (IFNα, IFNγ, and IL-12) in PP 
are reduced compared to the LN. Our observations are in line with others who have 
reported that dendritic cells from lamina propria do not respond to TLR ligands unlike 
spleen DC [143, 168]. These results are not surprising as the intestine is constantly 
exposed to bacterial DNA and other MAMPs present in microbial flora and must have 
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mechanisms for preventing unnecessary responses to microbial stimuli. Our findings 
that PP respond poorly to CpG ODN in terms of IFNα and IFNγ despite expressing high 
levels of TLR9 is consistent with observations by Pedersen and colleagues who reported 
that primary epithelial cells isolated from normal human colon expressed TLR9 mRNA, 
but were completely unresponsive to CpG-ODN stimulation in vitro [291]. One of the 
mechanisms that have been proposed for this tolerance is the downregulation of TLR 
receptors on mucosal immune cells, for example TLR4 in lamina propria macrophages 
[126]. However, we observed that TLR9 mRNA expression in both the IPP and JPP 
were abundant and comparable to expression in immune cells from LN and blood. The 
similar TLR9 expression profiles in both IPP and JPP and mLN in our studies are 
consistent with the TLR profiles reported recently in sheep [251] and in pigs [252]. 
Taken together, data from our studies and those from others suggest that the low 
responses of PP cells to CpG ODN were not due to downregulation of TLR9 receptor. 
Rather, other mechanisms are involved in downregulating CpG-induced responses.  
In sheep and many other species including humans, two distinct PP are found in 
the small intestine namely JPP and IPP, each with their own characteristic development, 
structure and function described by Landsverk et al [235]. IPP consist of a continuous 
patch in ovine species which involutes at a young age and is thought to be responsible 
for the primary generation of B cells, similar to the bursa of Fabricus in avian species. 
In contrast, JPP persist in the adult animal and contain M cells with clusters of B cells in 
the follicle-associated epithelium [100, 235, 292].  The cell compositions of the PP are 
quite different from LN and PBMC. Unlike peripheral lymph nodes, B cells comprise a 
large proportion of lymphoid cells in the PP (up to 80% in JPP and even higher in IPP) 
of sheep [100, 114] whereas the B cells frequency in PBMC or LN is around 30-40% 
[238]. Although the responses in PP were lower than other lymphoid compartments, we 
showed that JPP is the primary site for initiation of immune responses (IFNα, IFNγ and 
IL-12) in response to CpG ODN whereas IPP does not secrete these cytokines in 
respond to CpG ODN. This correlates with previous findings that JPP but not IPP are 
inductive sites for immune responses in the intestine [110]. Therefore implying that IPP 
is more of a primary lymphoid tissue in sheep. Moreover, we observed significantly 
higher levels of IL-10 secretion earlier in IPP cell cultures than JPP cell cultures. This 
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may be due to the higher frequency of B cells in IPP than JPP. The role of IL-10 in IPP 
is unknown.  
We demonstrated that the frequency of IFNα producing cells is lower in PP 
compared to LN and PBMC. The major source of IFNα upon stimulation with CpG 
ODN is plasmacytoid dendritic cell (pDC) in humans [92] and in sheep ([293]. The 
reasons why PP contain fewer IFNα producing cells (presumably pDC) that retain their 
capacity to respond to MAMPs remains unknown.  
Interestingly, our results also showed that IL-12 was produced in similar fashion 
as IFNα in the tested immune compartments (IPP, JPP, mLN and PBMC) when 
stimulated with CpG ODN. This observation suggests that IL-12 secretion is also 
dependent on the frequency of responder cells (probably pDC) in the tissues tested. 
Thus, the CpG-responder cells (presumably “pDC”) in the Peyer’s patches have the 
ability to produce both significant levels of IFNα and IL-12 similar to previous studies 
[67, 294] but different to a recent study [143].   
One current explanation for immune homeostasis in the gut involves the ability 
of intestinal epithelial cells (IEC) to play a fundamental role involving different 
mechanisms (reviewed by [295]. For example, certain luminal bacterial products 
support colonic homeostasis via activation of epithelial surface TLRs in colonic 
epithelium [103, 134, 296]. The main distinction from our report is that these studies 
focus on the intestinal epithelial cell and TLR expression. Instead our report deals with 
immune cells that are present in PP. We clearly demonstrated that these PP immune 
cells were less responsive than their counterpart in other immune compartments. These 
results suggest that the immune cells in PP may have regulatory mechanisms to PAMPs 
independently of IEC.  However, we are not excluding the effect of IEC as 
demonstrated by many studies. 
While IL-10 downregulates IFNα responses, several other factors could also 
regulate PP cells responses to CpG ODN including; (i) additional anti-inflammatory 
cytokines such as transforming growth factor beta (TGFβ) and thymic stromal 
lymphopoietin (TSLP) contributing to the anti-inflammatory environment; (ii) Multiple 
signals may be required to induce optimal innate immune responses (e.g multiple TLR, 
BCR engagement, T cell and myeloid DC cooperation); (iii) regulatory T cell working 
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in concert with regulatory B cells in the intestine to modulate immune responses. 
However, further investigations are required to determine the mechanisms by which PP 
disregard PAMPs from commensal microorganisms but induce an immune response to 
pathogens. 
 
5.6 Conclusion 
 
The current analysis demonstrated that PP B cells spontaneously secrete IL-10 
which “conditions” an anti-inflammatory environment in this tissue leading to poor 
cytokine responses to TLR9 agonist, CpG ODN. This may represent a strategy by which 
PP dampen innate responses to PAMPs in intestinal immune tissues to maintain 
intestinal homeostasis. 
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CHAPTER 6: TLR9 SIGNALING FAILURE RENDERS PEYER’S PATCH 
REGULATORY B CELLS UNRESPONSIVE TO CpG ODN STIMULATION 
 
6.1 Abstract 
 
Jejunal Peyer’s patch (PP) regulatory CD21+ B cells (Bregs) suppress TLR9-
induced innate immune responses. However, TLR9 activation in Bregs has not been 
studied.  Here, we investigated the responses of Bregs to stimulation with the TLR9 
agonist, CpG ODN.  Bregs express high levels of TLR9 mRNA, but fail to proliferate 
when stimulated with CpG. Furthermore, unlike CD21+ B cells isolated from blood, 
Bregs do not secrete IgM or IL-12 following CpG stimulation. We hypothesized that the 
unresponsiveness of Bregs to CpG stimulation was due to an inability of the TLR9 
receptor to activate the TLR signaling pathway. This was confirmed through kinome 
analysis which demonstrated dynamic patterns of phosphorylation of peptides 
representing TLR adaptor proteins such as IRAK1, TAK1, IKK, and NFκB-p65 in 
CD21+ B cells from blood B cells but not Bregs. Therefore, a dysfunctional TLR9 
signaling pathway may be an important mechanism by which mucosal Bregs fail to 
respond to TLR9 agonists. 
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6.2 Introduction 
 
Toll-like receptors (TLRs) are the most studied family of pattern recognition 
receptors (PRR) and have been found to be important in the detection of microbial 
threats and play an essential role in the induction of immune responses [4, 18]. TLRs 
are expressed by cells of innate and adaptive immune system and recognize an array of 
pathogen-associated molecular patterns (PAMPs) such as double stranded RNA, LPS, 
single stranded RNA and bacterial DNA [41, 171-174]. TLR9 detects bacterial DNA or 
synthetic CpG ODN [41]. Activation of TLR9 by CpG ODN leads to recruitment of 
downstream adaptor molecules including MyD88, TRAF6, IRAK1, TAK1, IKKα, 
IKKγ, p-38, JNK and Fos, which subsequently trigger NFκB and/or AP-1. This leads to 
up-regulation of innate immune response genes resulting in production of 
proinflammatory cytokines, type I interferons and cell proliferation. In humans [92] and 
in ruminants [93], the main cell populations that express TLR9 and directly activated by 
CpG ODN are B cells and plasmacytoid dendritic cells (pDC).  
Interestingly, several studies have found that B cells, which are adaptive 
immune cells, constitutively express TLRs mainly TLR1 and TLR6-10 [74, 297] . 
These TLRs are subsequently up-regulated when the B cells are activated by either 
CD40 ligation or BCR stimulation. B cell activation by the TLR9 agonist, CpG ODN, 
was first reported by Krieg and colleagues who found that in vitro and in vivo 
stimulation of murine B cells with CpG ODN induced cell proliferation and secretion of 
immunoglobulins [54]. Subsequently, CpG ODN has been shown to directly stimulate B 
cells to preferentially secrete ‘Th1-like’ immunoglobulins IgG2a, IgG2b and IgG3 in mice 
[298] and also to secrete cytokines such as IL-6, IL-12 and IL-10 [197]. In humans, 
CpG ODN can induce class switching to IgG1, IgG2 and IgG3 but significant secretion 
of immunoglobulins requires additional signals such as BCR cross-linking, CD40 
ligation and dendritic cell-derived B cell activating factors such as BAFF and APRIL 
[74, 299]. Additionally, CpG ODN seems to require cooperative stimulation from 
CD40L or signals from pDC to induce cytokines such as IL-6 and IL-10. However CpG 
ODN alone can induce costimulatory molecules and chemokine receptors on human B 
cells [78, 300]. There seems to be substantial species-specific differences with respect to 
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stimulation of B cells with CpG ODN. In mice, all sub-types of B cells seem to be 
directly activated by CpG ODN whereas in humans, direct activation occurs mainly in 
activated and memory B cells from blood.  
We recently reported a novel B cell (Bregs) population with regulatory functions 
in sheep Peyer’s patches (PP). These PP Bregs suppress IFNα, IFNγ , and IL-12 through 
IL-10 and possibly other mechanisms [301]. However, how TLR responses are 
regulated in these Bregs have not been explored. The objective of the present 
investigation was to determine whether PP Bregs can be activated by CpG ODN. 
Investigations at the level of both biological responses and phosphorylation-mediated 
signal transduction indicate that Bregs do not respond to stimulation with the TLR9 
agonist, CpG ODN. The absence of apparent TLR9 signaling events immediately 
following stimulation indicates that signaling is blocked close to the receptor. 
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6.3 Materials and methods 
 
6.3.1 Oligonucleotides and Animals 
 
The sequences of the three oligodeoxynucleotides (ODNs) used in this study 
have been published (Table 3.1) [301]. B-class (2007) CpG ODN was obtained from 
Merial Limited (Lyon, France), C-class (2429) from Coley Pharmaceutical Group 
(Wellesley, MA) and control non-CpG ODN 2007GC was purchased from Operon 
(Alameda, CA). Synthetic single stranded RNA oligoribonucleotide (ORN) 1075 was 
obtained from Coley Pharmaceutical Group (Ottawa, ON, Canada). 
Suffolk sheep of either sex (3 to 4 months of age) were obtained from the 
Department of Animal and Poultry Science (University of Saskatchewan, Saskatoon, 
SK, Canada) and were housed at the Vaccine and Infectious Disease Organization 
(VIDO) animal facility. All experiments were carried out according to the Guide to the 
Care and Use of Experimental Animals, provided by the Canadian Council on Animal 
Care. Experimental protocols were approved by the University of Saskatchewan Animal 
Care Committee. 
  
6.3.2 Isolation of PBMC, JPP, and lymph node cells (LN) and tissue culture conditions 
 
Blood was collected from the jugular vein of sheep in ethylene di-amine tetra-
acetic acid (EDTA)-treated vacutainer tubes (BD Biosciences, Mountain View, CA, 
USA) and PBMC were isolated using 54% isotonic PercollTM (Pharmacia Biotech AB, 
Uppsala, Sweden), as described previously [201, 212].  
Sheep were euthanised and mesenteric lymph node (mLN) and jejuna Peyer’s 
patches (JPP) were collected and cells isolated as described before [110, 245]. The 
number of viable cells was determined by trypan blue dye exclusion and counting in a 
hemocytometer under a light microscope. Cells were resuspended in AIM V medium 
containing 2% fetal bovine serum (FBS). For magnetic activated cell sorting (MACS) 
isolation, cells were resuspended in MACS buffer (PBSA, 0.5M EDTA and 10% BSA). 
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Stimulation of PBMC, JPP, and mLN cells was performed in 96-well, round 
bottom plates (Nunc, Naperville, IL, USA) using AIM V medium supplemented with 
2% FBS, 100 IU/mL Penicillin, 100 µg/mL Streptomycin sulfate, 0.25 µg/mL 
Amphotericin B, 2 mM L-glutamine, 50 µM 2-Mercaptoethanol and 10 µg/mL 
Polymyxin B Sulfate (Sigma-Aldrich) as described before [301]. For each treatment, 
5x105 cells were cultured in triplicate wells in 200 µL total volume. Culture 
supernatants were harvested and stored at –20oC until assayed for IL-10, IL-12 and 
IgM. 
 
6.3.3 Enzyme-linked immunosorbent assay (ELISA) for IL-10, IL-12 and IgM 
 
ELISA for quantifying cytokines in cell culture supernatants were performed as 
previously reported for IL-12 [214] and IL-10 [249]. For IgM ELISA, serum was 
diluted using PBS with 0.05% Tween 20 (PBST) and positive control (sheep pre-bleed 
serum) was serially diluted (1/10, 1/100, 1/1000, to 1/1000,000) while supernatants 
were serially diluted by 3-fold. Diluted samples were incubated for 2 hours and then 
washed. The captured IgM antibodies were detected in one step by using alkaline 
phosphatase labelled rabbit anti-sheep IgM antibody (KPL, MD, USA; Cat: 052303) 
and visualized by using p-nitrophenyl phosphate (PNPP). 
 
6.3.4 Cell purification using magnetic activated cell sorting (MACS) 
The B cell population was obtained by enriching for CD21+ B cells. Routinely, 
purified cells were >94% pure for CD21+ cell population.   The CD21+ B cells fraction of 
PBMC and JPP was isolated as previously described [246, 302].  
 
 
6.3.5 Caspase assay 
Caspase-3/7 enzyme activity was determined using Caspase-Glo 3/7 assay (Promega, 
Madison, USA) according to manufacturer’s instructions. Briefly CD21+ B cells were 
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isolated as described above and stimulated with media, CpG ODN (5 ug/ml), or GpC (5 
ug/ml). After 48 hr of incubation, 100 µl of Caspase-Glo® 3/7 Reagent (Promega 
Corporation, USA) was added to each well of 96-well plate.  Luminescence in each sample 
was measured using the plate-reading Luminometer (Victor3V, PerkinElmer, Inc., CA, 
USA).   
 
6.3.6 Lymphocyte Proliferative responses (LPR) 
 
Cells were re-suspended in culture medium at 2.5 x 105 cells per well in a final 
volume of 200 µL. Triplicate cultures were stimulated and incubated as already 
described above. During the final 6 hrs of 72 hrs incubation, cells were pulsed with 0.4 
µCi 3H-Thymidine (Amersham Pharmacia, Piscataway, NJ). Cells were harvested using 
standard liquid scintillation protocols and uptake of 3H-Thymidine was assessed in a 
beta counter (Topcount, Packard Instrument Company, Meriden, CT). Cell proliferation 
was calculated as the mean counts per minute (c.p.m.) of triplicate cultures and 
expressed as a stimulation index (c.p.m. in the presence of stimulus/c.p.m. in the 
absence of stimulus). For the LPR assay, a γ-irradiated cell line expressing murine 
CD40-ligand (CD154), a known ovine B cells mitogen [303, 304] was added at a 1:10 
ratio to confirm that B cells in enriched cultures were capable of a proliferative 
response. 
 
6.3.7 Quantitative RT-PCR 
RT-PCR was used to quantify TLR9 mRNA in the JPP (CD21+ and CD21-) and PBMC 
(CD21+ and CD21-) population as described previously [251]. Samples were normalized 
internally using the average cycle threshold (Ct) of beta-actin (β actin) as a reference. 
Values were expressed as delta Ct value per 500 ng total input RNA. 
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6.3.8 Kinome Analysis 
 
A description of the rationale and process of construction of the bovine specific 
peptide arrays for kinome analysis has been presented elsewhere [305]. Briefly, peptides 
were selected to represent phosphorylation events associated with a spectrum of cellular 
events but with emphasis on responses associated with innate immunity. Bovine 
consensus sequences of the human and mouse peptides selected from Phosphosite were 
obtained by employing the Blastp program from NCBI to compare collected human 
peptides against the NCBI bovine protein database. Blastp was set to retrieve short exact 
matches. Parsed BlastpSM results revealed that the majority of the hit sequences had 
100% identity to their query sequences and a comparison of the protein descriptions for 
the query and hit sequences confirmed that they referred to the same protein. Similarly, 
we used BlastpSM to determine whether the array was also ovine specific.  Analysis of 
the 16 peptide sequences (described in table 6.1) by BlastpSM revealed that they are the 
same protein in sheep.  
Isolated purified CD21+ B cells (25 X 106) from JPP and PBMC  were 
stimulated with medium alone or 5 μg/ml of 2429 CpG ODN for 4 hrs at 370C and 5% 
CO2 and 95% humidity. Cells were pelleted and stored at -80 °C before use with the 
peptide arrays. Cell lysate was prepared and incubated with the arrays as reported 
previously with the exception that lysates from 25 x 106 CD21+ B cells were incubated 
with each chip (10). Briefly, cell pellets were lysed with 100 µl lysis buffer (20 mM 
Tris-HCL pH 7.5, 150 mM NaCl, 1 mM EDTA, 1 mM ethylene glycol tetraacetic acid 
(EGTA), 1% Triton, 2.5 mM sodium pyrophosphate, 1 mM Na3VO4, 1 mM NaF, 1 
µg/mL leupeptin, 1 g/mL aprotinin, 1 mM phenylmethylsulphonyl fluoride (PMSF)), 
incubated on ice for 10 minutes and then spun in a microcentrifuge for 10 minutes at 4 
ºC. A 70 µl aliquot of this supernatant was mixed with 10 µl of the activation mix (50% 
Glycerol, 50 uM ATP, 60 mM MgCl2, 0.05% v/v Brij-35 and 0.25 mg/mL BSA) and 
incubated on the chip for 2 hours at 37 ºC. Finally, slides were washed once with Tris-
buffered saline (PBS) (1 x solution; pH 7.3) containing 1 % TRITON® X-100, twice 
with 2 M NaCl containing 1% TRITON X-100 and in demineralized H2O. Phospho-
protein specific stain peptide arrays were performed. Following incubation, slides were 
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washed once in PBS-Triton then submerged in stain (PRO-Q® Diamond Phosphoprotein 
Stain, Invitrogen) with agitation for 1 hour. Arrays were then washed in tubes 
containing destain [20% acetonitrile (EMD Biosciences, VWR distributor, Mississauga, 
ON) and 50 mM sodium acetate (Sigma) at pH 4.0] for 10 minutes three times with the 
addition of destain each time. A final wash was done with distilled water. Arrays were 
dryed and read using a GENEPIX®   professional 4200A microarray scanner (MDS 
Analytical Technologies, Toronto, ON) at 532-560 nm with a 580 nm filter to detect dye 
fluorescence. Images were collected using the GENEPIX 6.0 software (MDS). Images 
were then loaded on ARRAYVISION® (Image Research Inc). Intensity values for the 
spots and background were obtained and normalization (80th percentile per chip) and 
statistical analyses were performed with GENESPRING® (Agilent Technologies) 
software.  We used four biological replicates and each slide contains triplicate array. 
The results were shown as fold change in phosphorylation and measured relative to the 
respective unstimulated CD21+ B cells. 
 
6.3.9 Statistical analysis 
 
Data were analyzed using the statistical software GraphPad Prism 5 (Graphpad, 
San Diego, CA, USA).  Statistical differences in median values between two groups 
were determined using the Kruskal-Wallis test and comparisons were done between 
groups using Dunn’s multiple comparison test.  Values of p<0.05 were considered 
significant.  
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6.4. Results 
 
6.4.1 Peyer’s patch cells proliferate poorly in response to CpG ODN stimulation.  
 
We evaluated lymphocyte proliferative responses in JPP stimulated with CpG 
ODN and these responses were compared to those of mLN and PBMC. Both PBMC and 
mLN exhibited significantly higher proliferative responses (p<0.05) compared to JPP 
(Fig. 6.1). However, of note, the proliferative responses in PBMC were significantly 
higher than in mLN.  
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Fig. 6.1: Lymphocyte proliferative responses in jejunal Peyer’s patches (JPP), mesenteric lymph node 
(mLN) and peripheral blood mononuclear cells (PBMC) stimulated with 2 µg/mL of CpG ODN 2429. 
*Significantly (P<0.05) higher than JPP.** Significantly higher than the other tissues. 
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Furthermore, we performed a dose titration experiment using CpG ODN doses 
of 0.66, 2.0, 6.0 and 18.0 µg/mL to test responses of PP over a wider dose range. 
As shown in Fig. 6.2 A, in JPP, C-class (ODN 2429) induced significant 
proliferation of JPP cells at 6 and 18 µg/mL (Fig. 6.2 A). No significant proliferation 
was observed with the other ODN and regardless of the concentration of ODN used 
(Fig. 6.2 A). 
In mLN, the optimal dose of CpG ODN was 2 µg/mL and increasing the 
concentration of ODN did not result in any additional response (Fig. 6.2 B). Similarly, 
in PBMC, 2 µg/mL of CpG ODN induced an optimal proliferative response and 
increasing the concentration of ODN did not result in any additional response (Fig. 6.2 
C) with the exception of ODN 2336 (A-class). Therefore, the poor proliferative 
responses in PP following stimulation with CpG ODN are not due to suboptimal 
concentrations of the ODN.  
In humans, purified blood B cells have been reported to respond to direct CpG 
ODN stimulation [92]. In this study, we wondered whether purified B cells from JPP 
would respond directly to CpG ODN stimulation in a similar fashion as blood B cells in 
sheep.  Therefore we isolated CD72+ cells (all B cells express CD72) using MACs from 
both PBMC and JPP and assessed their responses to CpG ODN. As previously 
demonstrated, PBMC proliferated significantly to CpG ODN (Fig. 6.3 A-B). Similarly 
purified blood CD72+ B cells proliferated significantly to CpG ODN stimulation 
whereas blood CD72- cell fraction did not respond to either class of CpG ODN (Fig. 6.3 
A-B). 
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Fig. 6.2 A-C: Lymphocyte proliferative responses by ovine JPP, mLN and PBMC following stimulation 
with varying concentration of all 3 classes of CpG ODN. Data represent median value for cells isolated 
from 8 animals and assayed with each concentration of CpG ODN. 
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  This observation suggested that CpG-induced proliferation in PBMC is a 
result of B cells proliferation.  In contrast, JPP cells did not proliferate upon stimulation 
with CpG ODN and neither did the CD72+ or CD72- B cell fractions (Fig. 6.3 A-B) 
following stimulation with both B- and C-class ODN.  
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Fig. 6.3 A-B: Lymphocyte proliferative responses in JPP, PBMC, isolated CD72+ and CD72- fractions 
from both tissues. A: Stimulated with 5 µg/mL of CpG ODN 2007.B: Stimulated with 5 µg/mL of CpG 
ODN 2429.   
 
 Sub-populations of B cells (naïve, activated and memory) have been 
reported to respond differentially to TLR activation in blood [51, 74, 75]. In the present 
study, blood CD21+ B cells isolated from sheep were highly proliferative when 
stimulated with both classes of CpG ODN (Fig. 6.4 A-B) but the CD21- population had 
a much lower proliferation response (Fig. 6.4 C). In contrast, CpG ODN did not induce 
any significant proliferative responses in purified CD21+ B cells from PP (Fig. 6.4 E). 
Therefore, CD21+ B cells from blood and PP behave quite differently with respect to 
their proliferative responses to CpG stimulation. However, CD154 induced significant 
proliferation on PP CD21+ B cells, indicating that these cells were viable and have a 
proliferative capacity when appropriately stimulated.  Interestingly, the CD21- 
population in PP had a higher proliferative response upon stimulation by CpG ODN 
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(Fig. 6.4 F). This observation suggests that CD21+ B cells downregulate CpG-induced 
proliferation in PP cells.  
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Fig.   
 
6.4.2 Peyer’s patches CD21+ B cells fail to secrete significant IgM upon stimulation 
with CpG ODN. 
 
 B cells produce polyclonal IgM antibody following stimulation with CpG 
ODN [54]. We therefore assessed whether PP CD21+ B cells secreted IgM in response 
to CpG ODN stimulation, and compared these responses to CD21+ B cells from blood. 
As expected, PBMC secrete significant levels of IgM when stimulated with CpG ODN 
(Fig. 6.5 A). Purified blood CD21+ B cells secreted high levels of IgM in response to 
CpG ODN stimulation but no significant IgM production was observed in the CD21- 
cell fraction (Fig. 6.5 A) in PBMC stimulated with CpG ODN. In contrast, the mixed 
Fig. 6.4 A-F: Lymphocyte proliferative responses in JPP, PBMC, purified CD21+ and CD21- cell 
fractions from both tissues stimulated with either medium alone, CpG 2007, GpC 2007,  CpG 2429 or 
CD154.  
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population of PP cells did not produce any significant IgM upon stimulation with CpG 
ODN (Fig. 6.5 B). Neither CD21+ nor the CD21- cell fractions from the PP produced 
significant IgM responses following stimulation with CpG ODN (Fig. 6.5 B). Thus 
unlike CD21+ B cells isolated from blood, CD21+ B cells isolated from JPP did not 
produce IgM when stimulated with CpG ODN.   
 
 
 
 
 
 
 
 
 
 
 
 
6.4.3 PP CD21+ B cells express TLR9  
  
 One of the requirements for CpG ODN induction is the presence of its 
receptor, TLR9. We wondered whether the poor responsiveness of PP CD21+ B cells to 
the CpG stimulation was due to a lack of TLR9 expression. Therefore we evaluated the 
expression of TLR9 in both PP and PBMC CD21+ B cells using qPCR. 
 As shown in Fig. 6.6, both PP CD21+ and blood CD21+ B cells express 
similar levels of TLR9 mRNA. As expected both CD21+ fraction expressed higher 
TLR9 mRNA compared to that of CD21- fraction. Thus the poor responses of PP 
CD21+ B cells to CpG ODN stimulation may not be due to the lack of TLR9 receptor. 
Fig. 6.5 A-B: IgM responses in JPP, PBMC, isolated CD21+ and CD21- cell fractions from both tissues 
upon stimulation with 5 µg/mL of 2429 CpG ODN.  
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Fig. 6.6: TLR9 expression in JPP, PBMC, isolated CD21+ and CD21- cell fractions from both tissues as 
assessed by qPCR. Results are normalized to beta-actin and total RNA used per sample was 500 ng.  
 
6.4.4 PP and blood CD21+ B cells express similar levels of apoptotic markers 
 
 One of the possible outcomes of CpG ODN stimulation in B cells can induce 
programmed cell death (apoptosis). Thus we evaluated whether stimulation of JPP 
CD21+ B cells with CpG ODN induced apoptosis. Therefore we evaluated expression 
levels of apoptotic marker Caspase 3/7. We found that PP CD21+ B cells had levels of 
Caspase 3/7 similar to those in CD21+ B cells isolated from blood following stimulation 
with CpG ODN (Fig. 6.7). Therefore programmed cell death is unlikely to be the cause 
of the poor response in PP CD21+ B cells stimulated with CpG ODN.   
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Fig. 6.7: Caspase 3/7 expression was assessed in JPP-CD21+ and PBMC-CD21+ cell fractions stimulated 
with 5 µg/mL 2429 CpG ODN or medium alone for 48 hrs. Results is expressed relative to medium alone 
treatment. Data represent the mean for 4 animals.  
 
 
 
6.4.5 PBMC CD21+ B cells but not PP CD21+ B cells secrete IL-12 
 
 B cells are known mainly for the production of antibodies but they can also 
secrete a variety of cytokines including IL-12 when stimulated with TLR agonists [156]. 
Recently, it was shown that human and murine B cells secrete high levels of IL-12 
when stimulated with CpG ODN and CD154 [160, 306]. Thus we tested whether CD21+ 
B cells from blood and PP were capable of secreting IL-12 upon either CpG ODN 
stimulation or CD154. As shown by Fig. 6.8 A, purified PP CD21+ B cells did not 
secrete IL-12 upon stimulation with either CpG ODN (C and B-class) or CD154.  
However, purified blood CD21+ B cells secreted high levels of IL-12 in response to 
stimulation by both CpG ODN and CD154 (Fig. 6.8 B). 
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Fig. 6.8 A-B: IL-12 secretion in CD21+ cell fractions from PBMC and JPP stimulated with 5 µg/mL 2429 
CpG ODN, 2007CpG, CD154 or medium alone. Data represent the mean for 6 animals.  
 
6.4.7 Unresponsiveness of PP CD21+ B cells to CpG ODN is not due to IL-10. 
 
 Another potential cause of PP B cell failure to respond to CpG stimulation 
may be the influence of anti-inflammatory cytokines such as IL-10 and TGF-β  [307]. 
IL-10 is known to have pleiotropic effects on B cells proliferation [136]. We assessed 
whether IL-10 had any effect on the responsiveness of these cells to CpG ODN. As 
reported previously (Chapter 5) [301], unstimulated purified CD21+ B cells from PP 
spontaneously secrete IL-10.  Therefore we tested whether neutralization of IL-10 had 
any effect on CpG-induced responses in PP CD21+ B cells. Neutralization of IL-10 in 
PP CD21+ B cell cultures did not result in any significant increase in proliferation 
following stimulation with CpG ODN (Fig. 6.9 A-B). Inhibition of IL-10 was also done 
using a P38 inhibitor (SB203580, a known inhibitor of IL-10 [308]) and similar results 
were obtained (data not shown). Thus IL-10 does not seem to play a role in the 
unresponsiveness of PP CD21+ B cells to CpG ODN.   
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Fig. 6.9 A-B: Neutralization of IL-10 in PP CD21+ B regulatory cells. Lymphocyte proliferative 
responses in PP CD21+ B cells were assessed following addition of various concentrations of anti-IL-10 
antibody and stimulation with 5 µg/mL 2007CpG (A), CpG2429 (B), isotype control (IC) or medium 
alone. Data represent the mean for 5 animals. 
                     
6.4.8 Failure of TLR9 signaling in PP CD21+ B cells  
 Although CD21+ B cells from blood and JPP express similar levels of TLR9 
mRNA, there was a marked difference in B cell responses to CpG ODN stimulation. 
The seeming presence of the TLR9 receptor on both cell types suggests that the 
differential responses of these two cell types to CpG stimulation reflects unique patterns 
of signal transduction.  To investigate this potential mechanism, kinome analysis was 
utilized to quantify levels of activity of kinases known to be activated in the TLR9 
pathway. Both blood and PP CD21+ B cells, with and without stimulation by CpG ODN 
were examined.  PP and blood CD21+ B cells showed marked differences in their 
overall signal patterns as well as numerous differences specific to TLR signaling. As 
shown in Table 6.1, sixteen out of the 300 peptides on the array revealed contrasting 
fold changes in phosphorylation when PP CD21+ B cells were compared to blood 
CD21+ B cells.  
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Table 6.1: Specific peptides on the array representing TLR9 adaptor molecules that are in stark contrast 
in CD21+ B cells from JPP and PBMC in terms of their phosphorylation state. 
 
TLR 
adaptor 
proteins 
Target amino 
acid on the 
protein 
JPP‐CD21+ CpG 
fold change 
PBMC‐CD21+ 
CpG fold change 
Effect of 
phosphorylation on 
target peptide [ref] 
IKK-alpha T23 ‐4.43  46  Activation  [309] 
Fos T232 ‐113.6  2.13  Activation [310] 
IKK-beta Y199 54.2  1  Activation [311] 
TAK1 S192 ‐67.37  72.2  Activation [312] 
p38-alpha Y323 ‐136.47  100.2  Activation [313] 
JNK1 S377 ‐26.9  88.23  Activation [314] 
TRAF6 T186 35.97  ‐13.1  Unknown 
NFkB-p65 S276 1.02 5.25 Activation [315] 
NFkB-p65 S311 -1.28 3.31 Activation [316] 
NFkB-p65 S536 1.09 3.61 Activation [317] 
IRAK1 T100 3.51 1.03 Inhibition [318] 
IRAK1 T387 -3.82 9.11 Activation [319] 
FADD S194 -29.23 -1.36 Activation [320] 
FADD S194 -22.74 -1.25 Activation [320] 
Casp8 S347 -6.18 4.34 Inhibition [321] 
PKACa T195/7 -7.76 3.62 Activation [314] 
PKACa S338 -6.27 1.12  Activation [322] 
 
 Activation of TAK1 depends on the phosphorylation of a series of C-
terminal sites including Ser192 [323, 324]. This kinase target underwent 70 fold 
increase in phosphorylation in CD21+ B cells from PBMC upon CpG ODN stimulation. 
In contrast, CpG stimulation of PP CD21+ B cells induced a decrease (-50 fold) in 
phosphorylation of the same kinase target (Table 6.1). Activation of IKK-α also 
depends on phosphorylation of the amino acid Thr23 [309]. We found that upon CpG 
stimulation of blood CD21+ B cells, this IKK-α target site had increased 
phosphorylation (46 fold) but stimulation of PP CD21+B cells with CpG resulted in a 
decreased phosphorylation (-4.4 fold) of this peptide. Activation of p-38-alpha kinase 
depends on phosphorylation of target sites including Tyr323 [313]. Upon CpG 
stimulation of blood CD21+ B cells, this target underwent 100-fold increase in 
phosphorylation, whereas PP CD21+ B cells underwent a decrease in phosphorylation (-
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136 fold) upon CpG stimulation. Similarly, JNK1 (S377), NFκB-p65 (S311, S276, and 
S536), FADD (S194), Casp8 (S347), PKACa (T195/7) and Fos (Thr232) have been 
shown to be activated when their respective targets are phosphorylated [314, 320-322, 
325, 326]. We found that in blood CD21+ B cells, all these targets displayed increased 
phosphorylation following stimulation with CpG ODN while in PP CD21+ B cells, all 
those targets displayed decreased fold changes in phosphorylation (Table 6.1). The 
enzymatic activities of IRAK1 have been shown to be regulated differentially, that is 
phosphorylation of the T387 target site resulted in activation of the enzyme [319] while 
phosphorylation of the T100 target site resulted in inhibition of IRAK1 [318]. In blood 
CD21+ B cells, we observed that IRAK1 (T387) was phosphorylated (9 fold higher) 
while in PP CD21+ B cells, we found decreased (-3.8 fold) phosphorylation of IRAK1 
(T387) following CpG stimulation. Interestingly, we observed in blood CD21+ B cells, 
that the inhibitory IRAK1 target site T100 was unchanged in phosphorylation fold 
change (1.0) while in PP CD21+ B cells, IRAK1 (T100) displayed increased 
phosphorylation (3.5 fold) upon stimulation with CpG ODN.   
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Fig. 6.10 A-B: Phosphorylation state of adaptor molecules in the TLR9 signaling pathway in CD21+ B 
cells isolated from (A) blood and (B) JPP. Color patterns indicate the fold change in phosphorylation. 
 
 As summarized in Fig 6.10 A-B, all of the above adaptor molecules are involved 
in the TLR9 pathway but they display differential phosphorylation fold changes in PP 
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compared to blood CD21+ B cells upon stimulation by CpG ODN.  These results 
demonstrate that the key adaptor molecules for TLR9 signaling transduction leading to 
NFκB, AP-1 and MAPK pathway activation are dysfunctional in PP CD21+ B cells 
compared to blood CD21+ B cells following stimulation with CpG ODN. Thus, the 
kinome data indicate that following CpG stimulation, PP CD21+ B cells decrease 
phosphorylation of key adaptor molecules in the TLR9 signaling pathway.   
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6.5 Discussion 
 
 We previously observed that JPP Bregs have regulatory activity and down-
regulate TLR9-induced IFNα, IFNγ and IL-12 responses, and this suppression is 
mediated at least in part through IL-10 [301]. In the present study, we demonstrated that 
JPP Bregs failed to proliferate, secrete IgM and produce IL-12 following CpG ODN 
stimulation.    
We investigated the mechanisms for JPP CD21+ B cells (Bregs) unresponsiveness 
to CpG ODN.  The failure of Bregs to respond to CpG ODN was not due to a lack of 
TLR9 expression, CpG activation induced apoptosis or autocrine IL-10 regulation. 
However, CpG ODN unresponsiveness was not due to a lack of proliferative capacity in 
JPP Bregs, since vigorous proliferation was observed when these cells were stimulated 
with CD154 (a T cell signal). Thus, Bregs have the capacity to proliferate when 
appropriately stimulated.  
PP Bregs demonstrated the hallmarks of the described B regulatory cells [152] as 
they exclusively produced IL-10 but not IL-12 even when stimulated with CpG ODN, 
ORN or CD154.  Moreover, we demonstrated another regulatory aspect of Bregs as they 
suppress proliferation responses in other B cells. In this regard, depletion of CD21+ B 
cells resulted in a significant increase in the proliferative responses of CD21- cell 
populations, presumably CD21- B cells. This result suggests that PP Bregs may regulate 
other B cells but the mechanisms by which they mediate this regulation are not known.  
TLR9 is a requisite for CpG-induced responses [41]. We have shown that Bregs 
express similar levels of TLR9 mRNA as blood CD21+ B cells, suggesting that an 
absence of TLR9 was not the cause of the unresponsiveness of PP Bregs to CpG 
stimulation. We then hypothesized that the failure of PP Bregs to respond to TLR 
agonists may be due to differential regulation of phosphorylation events downstream of 
the TLR9 signaling pathway. Therefore we used kinome analysis to characterize TLR9 
signaling in PP CD21+ B (Bregs) cells and blood CD21+ B cells.  Interestingly, in blood 
CD21+ B cells which is highly responsive to TLR9 agonists, CpG ODN stimulation 
activates kinases such as IRAK1, TAK1, IKKα, p38-alpha, JNK1, FOS, NFκB-p65, 
FADD, Casp8 and PKACa which are associated with TLR9 mediated signal 
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transduction.  In contrast, the above TLR adaptor molecules displayed a net decrease in 
phosphorylation in PP Bregs following CpG stimulation leading to inactivation of these 
kinases associated with TLR9 mediated signal transduction.  
It seems that stimulation of PP Bregs cells by CpG ODN results in decreased 
phosphorylation of adaptor molecules early in the TLR9 pathway and causes 
inactivation of key adaptor molecules. Therefore, there may be regulatory mechanism in 
PP Bregs by which adaptor molecules are inactivated following ligand interaction with 
TLR9. Some key possible negative regulatory mechanisms in the TLR9 pathway that 
could be involved including: (i) factors that cause degradation of signal transduction 
molecules such as Triad3A (degrade specifically TLR4 and TLR9 receptor) [327], (ii) 
Inhibition of adaptor molecules such as SH2 homology 2 domain-containing protein 
tyrosine phosphatase (SHP)-1 (Inhibit IRAK1) [328], (iii)  deubiquitination of adaptor 
molecules by factors such as A20 and deubiquitinating enzyme A (DUBA) [329],and 
(iv) non-functional TLR9 receptor. However, we have evidence that the TLR9 receptor 
is functional in PP Bregs under certain condition.  When co-stimulated with CD154 and 
CpG ODN, Bregs proliferate significantly compared to stimulation with CD154 alone 
(Data not shown). This suggests that upon appropriate co-signaling, the TLR9 pathway 
can become active in PP Bregs.  This may represent a novel way by which PP Bregs fail to 
respond to TLR agonists which are abundantly present in the gut.  
 
6.6 Conclusion: 
 
In conclusion, PP Bregs do not display biological responses to direct TLR 
stimulations despite expressing TLR9. However, kinome analysis confirmed TLR9 
signaling did occur following CpG ODN stimulation. This response entailed differential 
signaling activity close to the receptor suggesting attenuation of both the primary and 
secondary TLR-induced signal transduction in PP Bregs.  This raises important questions 
regarding the physiological role of the TLR9 receptor expression on this cell type. 
 
 
 
 137
 
  
CHAPTER 7: GENERAL DISCUSSION 
 
7.1 Intestinal homeostasis 
 
The intestinal tract represents the largest body surface that is in contact with the 
external environment. While the gut is an essential organ for the uptake of nutrients and 
fluids, most human pathogens enter the body through its mucosal surface. Normally, the 
intestine is continuously exposed to a large and diverse microbiota. In order to shape the 
intestinal environment, the mucosal immune system actively interacts with the 
microbiota, thereby limiting its level of penetration and growth in the gut lumen. 
However, when the intestine is exposed to dangerous pathogens, it elicits strong 
immune responses to confer protection to the host. Thus there is a very dynamic balance 
between the host protective immunity and regulatory mechanisms thereby establishing 
intestinal homeostasis.  
The innate immune system (IIS) provides various mechanisms of defense that 
prevents microbes from gaining access to the apical surface of the IEC. For example, 
the apical side of the IEC is covered by a layer of mucus and glycocalyx which are 
produced by goblet cells present in the crypt and villus epithelium throughout the 
intestine [330]. The mucins trapped and allowed the elimination of commensals and 
pathogenic microbes by intestinal peristalsis [331]. Moreover, the IIS can produce a 
wide spectrum of antimicrobial agents that maintain the mucosal epithelial integrity 
[332].  
In this thesis, we attempt to understand how the intestine regulates immune 
responses. We explored this issue by determining the responses of PP cells to PAMPs 
such as TLR agonists [CpG ODN, ORN, poly(I:C) and LPS].  In chapter four of this 
thesis, we demonstrated that the PP cells responded poorly to TLR agonists compared to 
other tissues (PBMC and LN). This hyporesponsiveness of PP cells could not be 
overcome by stimulation with combinations of TLR agonists, contrary to published 
reports with cells from blood. These results suggested that TLR responses are highly 
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regulated in PP cells. Therefore, this regulation in the PP must be achieved through 
regulatory mechanisms directed towards TLR agonists.  
Peyer’s patches are the primary sites for induction of antigen-specific immune 
responses. The intestine also expresses PRR including TLR receptors which detects 
PAMPs from microbes. We reasoned that understanding how TLR responses are 
regulated in PP may improve our understanding of how innate immune responses are 
regulated in the intestine. We therefore investigated the mechanisms which mediate the 
unresponsiveness of PP cells to TLR agonists. One of the mechanisms by which the 
intestine regulates innate responses is through the downregulation of innate receptors 
including TLR.  Surprisingly, PP cells expressed similar levels of TLR7/8/9 as cells 
isolated from blood and LN.  Thus PP cells respond poorly to TLR9 stimulation despite 
expressing TLR9 receptor.  
The immunoregulatory cytokine IL-10 can modulate many different 
inflammatory pathways [136]. The involvement of IL-10 in the intestine has been 
shown through IL-10-knockout mice which tend to develop colitis in the presence of 
commensals [139]. Therefore, we explored whether IL-10 contributed to the 
unresponsiveness of PP to TLR agonists. As shown in chapter five, PP cells 
spontaneously secreted IL-10 which downregulated CpG-induced IFNα, IFNγ and IL-
12 responses. In this regard, IL-10 was directly involved in the poor responses of PP 
cells to TLR9 stimulation. Moreover, cells that expressed the TLR9 receptor were able 
to respond to CpG ODN stimulation following neutralization of IL-10, suggesting that 
TLR9 receptors are functional in these PP cells. Subsequently, the IL-10-producing 
cells in PP were identified as CD21+ B cells.  Depletion of PP CD21+ B cells resulted in 
significantly increased CpG-induced responses (IFNα, IFNγ and IL-12). These results 
demonstrate that PP CD21+ B cells (Bregs) play a regulatory role in dampening TLR9-
induced responses at least in part through the action(s) of IL-10. This finding has 
important implications in our current understanding of how immune responses are 
regulated in the intestine. B cells may develop a specialized regulatory role in the PP in 
order to actively lower immune responses to TLR agonists that are constantly present in 
the environment. Numerous studies have shown that DC and macrophages and even the 
epithelial cells have specialized functions in the intestinal environment [116, 127, 134]. 
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Thus we report a novel B cell population capable of secreting IL-10 in the steady state, 
which may perform regulatory functions similar to the recently described murine Bregs.   
 
7.2 Bregs : Characteristic and regulation of TLR9 signaling pathway 
 
Usually, B cells are characterized by their ability to produce antibody. However, 
B cells have the ability to perform additional immune functions namely production of 
cytokines and to function as APC by taking antigen via their BCRs. Moreover, like T 
cells, there is a B cell population that can perform regulatory functions. Bregs were 
shown to develop in several murine models of chronic inflammation, including IBD, 
RA and EAE and they mediate their effects through the production of regulatory 
cytokines such as IL-10 and TGFβ [152].  In chapter 6, we showed that PP Bregs 
demonstrated the hallmarks of such described B regulatory cells [152] in much as they 
exclusively produced IL-10 but not IL-12 even when stimulated with CpG ODN, ORN 
or CD154. Further, the responses of the Bregs to CpG stimulation were tested. PP Bregs 
do not proliferate or secrete IgM following TLR stimulation alone. Whether Bregs secrete 
or regulate the production of IgA by other cells is unknown. However, we have an 
initial indication that Bregs may regulate the production of IgA in the PP. IgA has been 
reported however to play some roles in immune regulation in mucosal compartments 
[333]. 
Given that IL-10 plays a role in dampening innate responses, we explored the 
role of IL-10 in the seeming hyporesponsiveness of Bregs. Neutralization of IL-10 
followed by CpG stimulation did not lead to Bregs proliferation but stimulation with 
CD154 led to the proliferation of these Bregs. These results suggest that Bregs are strictly 
regulated but may be activated under certain conditions.  
    Upon encountering their respective PAMPs, the TLR receptor is activated and 
initiates signal transduction pathways that culminate in potent transcriptional responses 
via NFκB. This is important in situations where immune responses are needed to rescue 
the host. However, inappropriate activation of the pathway may lead to constant 
inflammation. The intestine is constantly exposed to commensals expressing PAMPs. 
Thus there must be mechanisms by which the TLR signaling pathway is regulated. The 
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mechanism(s) by which cells from PP prevent overstimulation by PAMPs is unknown. 
There are several proposals on how the cells of the intestine could downregulate 
immune responses (reviewed in Honda and Takeda, 2009 [334]). Given the differences 
in TLR-induced responses between CD21+ B cells isolated from PP and blood, we 
explored whether the TLR signaling pathway is functional in PP Bregs as compared to 
CD21+ B cells from blood. In chapter six, we showed that there were major differences 
in the phosphorylation states of key adaptor molecules in the TLR9 pathway in PP Bregs 
compared to blood CD21+ B cells. For example, adaptor molecules such as IRAK1, 
TAK1, FOS, IKK-α, JNK are not phosphorylated in PP Bregs. Thus the TLR9 pathway 
leading to activation of NFκB and AP-1 is dysfunctional in PP Bregs. These results 
suggest that there are negative regulators that keep adaptor molecules unphosphorylated 
in this cell type following CpG stimulation.  The actual mechanism(s) that cause(s) 
negative phosphorylation in all these adaptor molecules remain unknown at this time 
and further investigations are required. 
 
7.3 Bregs: Differentiating between commensals and pathogens 
 
One of the fundamental questions in mucosal immunology is how the intestine 
differentiates between harmless commensal bacteria and pathogens. Numerous studies 
have revealed some of the regulatory mechanisms that maintain intestinal homeostasis 
(See chapter 1). For example, Lee et al, demonstrated that the IEC can distinguished 
between apical and basal TLR9 stimulation. Apical TLR9 stimulation led to 
unresponsiveness of the NFκB pathway whereas basal TLR9 stimulation resulted in 
hyperresponsiveness of the NFκB pathway leading to upregulation of cytokines [134]. 
Similarly, TLR5 which is the receptor for flagellin is located at the basolateral surface 
of the epithelium, thereby allowing it to recognize invading flagellated pathogens [335]. 
For example, commensal E. coli strains colonizing the apical surface of polarized model 
of intestinal epithelia do not activate pro-inflammatory gene expression whereas 
Salmonella typhimurium highly activate immune responses in these cells upon 
colonization. Therefore the compartmentalization of TLR has allowed the host to 
differentiate between pathogens and commensals.  Similar mechanism could be used at 
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the cell level in Bregs where TLR9 may be expressed intracellularly in the endosome, 
lysosome and endoplasmic reticulum (ER). Thus the TLR9 agonist needs to be 
endocytosed and presented in the appropriate subcellular compartment for activation 
and signal transduction to occur. It has recently been reported that a 12-membrane 
spanning protein that resides in the ER, UNC93B1, is required for TLR7 and TLR9 
trafficking [336]. In most cells, including CD21+ B cells, the cellular location of TLR9 
and requirement of trafficking proteins such as UNC93B1 for TLR9 function is 
unknown. Therefore regulation of TLR9 through subcellular compartmentalization may 
be one of the mechanisms involved in the gut.   
It has been estimated that there are approximately 1014 bacteria in the gut. The 
microbiota is very diverse, comprising of about 500 species [337]. Therefore, 
commensals probably express most PAMPs, including TLR agonists, and therefore are 
similar to pathogens in this regard. However, pathogens differ from commensal bacteria 
by the presence of specific pathogenicity genes. These genes usually express virulence 
factors such as adherent molecules, invasion systems, enzymes and toxins. These 
virulence factors more importantly allow for pathogens to enter epithelial cells, invade 
and colonize the tissue, damage the host intestine and create a local or systemic 
infection. Therefore, not only TLR agonists will be present but also antigens and 
virulence factors from the pathogen would be available to trigger the host immune 
responses. Our observations that Bregs are not responsive to TLR stimulation indicate 
that there are regulatory mechanisms involved in the activation of these B cells. How 
mucosal Bregs differentiate between pathogens and commensals is still unknown. Below, 
we propose a model by which these cells could differentiate between pathogens and 
commensals.   
 
7.3.1 Model 
 
In the steady state,  TLR agonists (from commensals) fail to induce robust 
immune responses in PP cells including DC, Mφ, NK cells in the SED and B cells in the 
follicles. This is at least in part due to the IL-10 produced by CD21+ B cells (Bregs) 
which subsequently downregulates other immune cells (presumably pDC, cDC and NK 
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cells) as suggested by our results. Furthermore, TGFβ is known to be produced in the 
intestine and contribute to regulation of inflammatory responses [338].  Thus, under the 
influence of mainly IL-10 and TGFβ, the PP maintain an “anti-inflammatory” state 
which allows for active regulation of immune responses to PAMPs including TLR 
agonists, and hence homeostasis.  Moreover, the microenvironment around the follicles 
may be favorable for the generation of inducible iTregs from CD4+CD25- T cells since 
both TGFβ and IL-10 are present in the environment [307]. Tregs have already been 
proposed to contribute to the intestinal homeostasis. Therefore Bregs and Tregs together 
may contribute significantly to intestinal homeostasis in PP.  
However, upon infection, the epithelial cells are breached and replicating 
pathogens invade the SED of the PP. The epithelial cells have been shown to respond to 
the breach by secreting cytokines and chemokines including IL-8 which will allow for 
the recruitment of cells from the systemic system. Therefore, high level of pathogenic 
molecules and TLR agonists are exposed to immune cells including DC in the PP. 
Resident and incoming DC can then be activated by both TLR and antigen and secrete 
pro-inflammatory cytokines such as IFNα and IL-12. Those DC would mature and 
migrate to the regional lymph nodes to present their cargo in terms of MHCII-antigen to 
local cognate T cells, thereby activating these cells, which would then migrate back to 
the gut and trigger cognate B cells. Bregs may also act as APC and sample the antigen 
and TLR agonists. It is not known whether these two signals are sufficient to activate 
Bregs. However, when they interact with cognate T cell help, Bregs are rapidly induced to 
proliferate as shown in the thesis. Together with the recognition of antigen through its 
BCR and by cognate T cell help and TLR activation, Bregs could produce specific 
antibodies against pathogenic antigens and could secrete proinflammatory cytokines 
such as IL-6, IL-12. Therefore, the microenvironment of the PP would thereby switch 
from an ‘anti-inflammatory state into a pro-inflammatory condition. The strict 
requirement of T helper cells seems to be crucial for activation of PP Bregs. This may 
represent one of the mechanisms by which the intestine maintains homeostasis. 
Moreover, Bregs may only play a regulatory role without being activated to secrete 
antibody or other pro-inflammatory cytokines. However, this model is far from 
complete and many questions remain unanswered. 
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Fig. 7.1: Model demonstrating the potential role of PP Bregs in regulating TLR responses to commensal 
bacteria.  
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7.4 Significance of Bregs in Peyer’s patches 
 
In sheep, there are two distinct PP, namely the IPP and JPP. The IPP is a 
primary lymphoid organ that supplies the peripheral B cell pool in a manner similar to 
the way that the Bursa of Fabricus does in birds [100]. JPP are secondary lymphoid 
tissues that function in mucosal immune reactions similar to lymph nodes [110]. These 
two types of PP differ significantly in histology, ontogeny and lymphocyte trafficking 
[100].  In this thesis, we demonstrated that the JPP cells were significantly more 
responsive compared to the IPP cells following TLR stimulation. These results are 
consistent with the fact that JPP are primary sites for immune induction. It would make 
sense that downregulating TLR responses in JPP would be an effective way of avoiding 
unnecessary responses to commensals. We noted that in IPP cells, the levels of IL-10 
expression were significantly higher than in the JPP and since IPP is not an immune 
induction site, we speculate that IPP may be a site for tolerance induction.  However, 
the role(s) of IL-10 in the IPP is unknown at this time.  
 
 
.  
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CHAPTER 8: CONCLUSION 
 
8.1 Overall Conclusion 
 
In summary, we have shown that Peyer’s patches respond poorly to TLR 
agonists despite expressing high levels of TLR mRNA. We clearly demonstrated that 
IL-10 plays a role in the reduced PP CpG-induced responses and that PP CD21+ B cells 
(Bregs) spontaneously secrete IL-10 which “conditions” an anti-inflammatory 
environment in this tissue leading to poor cytokine responses to CpG ODN and 
presumably to other TLR agonists. This may represent a strategy by which PP dampen 
innate responses to PAMPs in intestinal immune tissues to maintain intestinal immune 
homeostasis. The regulation of TLR9 pathway in PP B cells seems to be achieved 
through the inactivation of multiple adaptor molecules in the pathway. 
 
8.2 Future work 
 
There are several directions that the work from this thesis can take. Of particular 
interest is the effect of Bregs on other B cells (CD21-) including memory B cells that can 
be activated directly with TLR agonists. It would also be interesting to determine 
whether Bregs can have any role in the generation of Tregs or other regulatory cells. 
Several important questions remain unanswered. Do these Bregs exist in vivo? Are they 
restricted to PP or are they located in effector sites (e.g lamina propria) as well? Do they 
occur in other species or is this a phenomenon of sheep? Further investigations may 
elucidate how these Bregs work in the intestine. 
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